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INTRODUCTION 
1. DISSERTATION REQUIREMENTS 
This work is being submitted in accordance with the revised dissertation requirements for the 
degree of Master of Medicine (MMed) in Public Health Medicine as adopted by the University 
of Cape Town in 2009 (Dean’s Circular MED12//09).  These require that when submitting an 
MMed dissertation in the form of a published or publishable manuscript, the dissertation 
comprise the following components: 
• Part A: Study protocol. 
• Part B: Structured literature review. 
• Part C: Study results in the form of a manuscript of an article for a named peer 
reviewed journal. 
• Part D: Supporting documents including data capture instruments, consent forms, 
ethics approval letter and technical appendices. 
 
2. HISTORY OF DISSERTATION AND ROLE OF CANDIDATE 
This study was conceived in 2002, when I was registered for individual courses for the degree of 
Master of Public Health.  I was responsible for the design of the study including development of 
data collection tools for adherence monitoring and a database for storage of adherence 
information under the supervision of B. Eley.  This study formed part of a larger cohort study of 
antiretroviral therapy for the treatment of HIV-infected children and their infected parents at Red 
Cross Children’s Hospital, for which ethical approval was obtained. (Annexures A and B).  
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Hence there was no separate proposal for the adherence study, and no separate ethical approval 
was needed.  I participated in patient enrolment and data collection which occurred between July 
2002 and February 2005.  In 2006 I registered for the full degree of Master of Public Health and 
in 2007 revised this registration to that for the MMed (Public Health Medicine).  Under the 
supervision of B. Eley and A. Boulle, I conducted the main analysis work in 2007 and wrote the 
final manuscript which was submitted to BMC Pediatrics in February 2008.  The paper was 
accepted and published in September 2008.  As I still had to complete a further 2 years of 
registrar training, the dissertation is being submitted in April 2010 as a requirement for 
admission to the Public Health Medicine examination of the College of Medicine of South 
Africa. 
 
3. CONTENTS OF THE DISSERTATION 
In accordance with the regulations for the MMed (Public Health Medicine) dissertation, this 
work contains the following sections: 
Part A: Study protocol: This was prepared in 2007 to cover the analysis of the adherence data 
which had already been collected as part of the broader research study described above.  The 
literature review and study justification contained in the protocol therefore apply to early 2007, 
the data collection procedures describe how the data to be analysed had already been collected at 
that time, and the proposed analysis is described prospectively.  Footnotes have been inserted 
into the original protocol to indicate where any deviations from the protocol have been made 
during the course of the analysis.   
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Part B: Structured literature review of paediatric antiretroviral adherence studies from lower and 
middle income countries.  The literature review is presented in two parts: 
• Part B (i): Main literature review covering studies published prior to submission of 
this paper for publication in February 2008. 
• Part B (ii): Post-script literature review covering studies published from 1 February 
2008 to 31 Januray 2010.  This has been included as the dissertation is being 
submitted after publication of the manuscript in order to update the literature review 
and contextualize the findings of this study within current paediatric antiretroviral 
adherence research. 
Part C: Manuscript as published in BMC Pediatrics.  The tables and figures that comprise the 
article are numbered as they appeared in the article and thus do not appear in the list of tables 
and figures for the dissertation as a whole. 
Part D: Supporting documents as follows: 
• Protocol for study of antiretroviral therapy for children at Red Cross Children’s 
Hospital South Africa of which this study is one component.  This has been abridged 
by omitting sections not relevant to this study, but includes consent forms, and data 
collection instruments.   
• Official ethics approval letter from the University of Cape Town Faculty of Health 
Sciences Research Ethics Committee. 
• Instructions to authors for the target journal, BMC Pediatrics. 
• Technical appendix explaining choice of adherence measure used in study.
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PART A: PROTOCOL 
 
1. SYNOPSIS 
Title: Assessment of adherence to antiretroviral therapy in young children in Cape Town, 
South Africa measured by medication return and caregiver self-report: a prospective cohort 
study. 
Background and Rationale: Excellent adherence to antiretroviral therapy (ART) is necessary 
if HIV-infected children are to experience the dramatically improved outcomes that this 
treatment affords.  However, there is very limited data on adherence to antiretroviral therapy in 
Africa, with few studies that examine the predictive value of low technology measures of 
adherence in terms of viral and immune outcomes.  In addition there are no long terms studies 
of adherence in young children in Africa. 
Objectives: To determine the association between adherence to ART in young children 
throughout the first year of therapy measured by medication returned as well as caregiver self-
report, and subsequent virologic and immunologic outcomes, and to identify predictors of good 
long-term adherence. 
Study design, population and sampling: This is a prospective cohort study, analyzing existing 
data collected on 122 HIV-infected children who commenced ART at Red Cross Children’s 
Hospital in Cape Town.  During the first year of treatment, adherence was measured monthly at 
the clinic by medication returned, with viral and immune response assessed at the end of the 
year.  After 3 months of treatment, a questionnaire was administered to assess experience with 
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giving medication and self-reported adherence.  The association between measured adherence 
and immune and viral response will be determined using logistic regression models to adjust for 
other predictors of these outcomes.  Similarly, multivariate logistic regression will be used to 
identify predictors of good adherence. 
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2. BACKGROUND AND SIGNIFICANCE 
In 2006, UNAIDS estimated that there were 2.3 million HIV-infected children under 15 years 
worldwide, with 85% of these living in sub-Saharan Africa.[1]  South Africa was estimated to 
have 294 000 HIV-infected children <15 years of age at mid-2006.[2]  Antiretroviral treatment 
(ART) of children in Africa has resulted in dramatically improved survival, clinical, 
immunologic and virologic status in the few reported cohorts with treatment access.[3-9]  
Excellent adherence is the most important factor in determining treatment success and 
preventing viral resistance, and the need for near-perfect adherence to lifelong therapy from an 
early age has been identified as a major challenge in the administration of ART to HIV-infected 
children.[10-14]  There is concern about the extent to which such adherence is achievable for 
children in resource-limited settings, particularly in the context of the rapid scale-up of 
paediatric treatment programmes required to address the HIV burden on children in Africa 
where <15% of children needing ART on the continent currently receive it.[10, 12, 15-16] 
 
Research from rich countries suggests that adherence may be more complex in children 
compared to adults due to many factors including reliance on caregivers who may themselves 
be ill or may not be the child’s parent, complex dosing regimens, lack of availability of 
paediatric fixed-dose combinations (FDC), poor drug palatability, difficulty with taking 
tablets/capsules and interference with daily routines such as schooling, mealtimes and 
sleep.[13, 17-22]  These studies report adherence estimates of between 50 and 75%, well below 
the required 90 to 95% to achieve optimal viral suppression.[11, 13, 17-22]  Interpretation of 
studies on paediatric adherence is furthermore complicated by the lack of consistency in 
 15 
 
methods of assessing adherence and discrepant definitions of adherence.[22]  In addition, 
although it has been suggested that multiple measures of adherence should be used to assess 
adherence, the majority of studies make use of a single measure, caregiver self-report, which is 
known to over-estimate actual adherence.[22] 
 
While African adult studies show that good adherence is possible despite poor social 
circumstances, there are limited studies in children.[15, 23]  Health service challenges as well 
as individual factors such as poor socio-economic circumstances, poor literacy and the 
prohibitive cost of liquid drug formulations necessitating tablet administration to very young 
children may be further barriers to good adherence in African children.[10, 12]  Muller et 
al.[24] used the electronic Medication Event Monitoring System (MEMS) to measure 
adherence for a 3 month period in young children in South Africa (median age 48 months) and 
found median adherence of 87.5% (IQR: 69 – 97).  However, only 36% of patients achieved 
excellent (≥95%) adherence.  In contrast, 91% of caregivers reported excellent adherence on a 
visual analogue scale (VAS).[24]  MEMS adherence correlated significantly with attaining 
virologic suppression, while VAS adherence was less predictive.[24]  In Kampala, Uganda, 
similarly discrepant results are reported using different adherence measures.[25]  Among 
children aged 2-18 years 72% had adherence ≥95% measured with home-based unannounced 
pill counts, compared to 89% using 3-day self-reported adherence and 94% using clinic-based 
pill counts.[25]  This underpins the need to use multiple measures of adherence to obtain 
accurate estimates.  The only other dedicated ART adherence studies of African children only 
measured self-reported adherence and included only older children, with approximately one 
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third of caregiver-child pairs reporting missing doses in studies in both Côte d’Ivoire[26] and 
Uganda[27]. 
 
African studies thus concur with international literature that more objective measures of 
adherence (e.g. unannounced pill counts and MEMS) tend to be more sensitive to lapses in 
adherence.[22, 28]  However, apart from the single South African study, the association 
between each of these measures of adherence and treatment outcomes has not been determined.  
In addition, measures such as MEMS and unannounced pill counts are not feasible in resource-
limited settings with large-scale programs, and there is a need to determine the utility of simpler 
measures of adherence such as clinic-based pill-counts and self-report in predicting virologic 
response in the African context.  Furthermore, all published African studies have been 
conducted over short periods (≤3 months), mostly in older children and may not reflect longer 
term adherence patterns in very young children. 
 
There is thus a need for further studies on adherence to ART in children in Africa, particularly 
longer term studies on very young children, using more than one measure of adherence, in order 
to determine both levels and determinants of adherence, and the relationship between measured 
adherence and treatment outcomes.  In particular, it would be useful to be able to identify 
children at greatest risk of sub-optimal long-term adherence in the context of busy clinics 
carrying out rapid scale-up ART roll-out programmes, so that adherence support can be 
appropriately directed.   
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3. AIM 
To determine the association between adherence to ART in children throughout the first year of 
therapy measured by medication return (as measured at the clinic) (MR) as well as caregiver 
self-report and subsequent virologic and immunologic outcomes, and to identify predictors of 
good long-term adherence. 
 
4. OBJECTIVES 
1. To describe clinical and socio-demographic characteristics of children commencing 
ART at Red Cross Children’s Hospital. 
2. To describe the level of adherence to ART in children throughout the first year of 
treatment using medication return (MR), as well as after 3 months of treatment using 
caregiver self-report. 
3. To assess the extent of agreement between self-reported adherence and measured MR 
adherence for the same period. 
4. To determine the association between each of the above measures of adherence and 
virologic and immunologic outcomes. 
5. To identify factors associated with good adherence during the first year on ART. 
6. To describe caregiver experience with administering ART to infants and young 
children.   
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5. METHODS 
This study will make use of data collected prospectively by the Red Cross Children’s Hospital 
ART programme.  The data was collected as part of clinical care of children commenced on 
donor-funded ART prior to the Western Cape provincial government roll-out of ART.  The 
principal objectives of this programme were to extend access to ART to as many children and 
their parents as possible, and to evaluate ART effectiveness and adherence locally. 
 
5.1 Study design 
Prospective cohort study 
 
5.2 Population and sampling  
All HIV infected children (n=122) commenced on antiretroviral triple therapy between July 
2002 and January 2004 will be included in the study.  Selection criteria for commencement of 
ART are detailed in the original programme protocol and published research (Annexure A).[4]  
Briefly, clinical and immunological criteria as recommended by the 2001 European treatment 
guidelines were followed, in addition to selective social criteria that assessed treatment 
readiness and caregiver willingness to comply with monitoring.[29]  These included having an 
identifiable caregiver to administer medication and attend clinic appointments; being resident in 
Cape Town for at least 3 months and caregiver compliance with the last 3 clinic appointments.  
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The majority of children were commenced on stavudine (d4T), lamivudine (3TC) and efavirenz 
(EFV - children >10kg or >3 years) or ritonavir (RTV - children <10kg or <3 years). 
 
5.3 Sample size 
At the time of data collection, there were no studies from resource limited settings that 
examined the association between adherence and virologic or immunologic outcomes on which 
to base a sample size calculation.  It was anticipated that more than 100 children would 
commence ART and be included in the study, which would make it the largest dedicated 
pediatric ART adherence study to date from either a developed or developing country.[22]*
 
   
5.4 Measurements 
Analysis of the following existing measurements that were taken as part of the ART 
programme will be done: 
 
                                                 
*The change from donor-funded ART to the government ART programme necessitated ending the study as the 
government programme did not fund adherence monitoring.  We therefore made use of all existing data on 
children who initiated ART during the study period.  The accumulated sample size comprised 88 children who 
remained alive and in care at 1 year when viral load measurement was performed, all of whom had adherence 
assessments done.  This was sufficient to detect a 50% reduction in the proportion with viral suppression in those 
with adherence below the selected threshold for “good adherence”, compared to those with adherence above this 
threshold with 90% power, assuming that 75% of children would have adherence above the threshold and 80% of 
these children would be virologically suppressed. 
  
 20 
 
5.4.1 Clinical and socio-demographic characteristics 
Clinical and demographic characteristics at commencement of ART were recorded by the 
clinician treating each child using standardized data collection forms (Appendix 5 of Annexure 
A).  As the Center for Disease Control (CDC) clinical staging system was used in data 
collection (Appendix 1 of Annexure A), for this analysis children will be retrospectively re-
staged according to primary medical record information using the WHO 4-stage clinical 
classification.[30]  Weight-for-age, height-for-age and weight-for-height z-scores will be 
calculated using EpiInfo 2000, version 1.0 (Division of Surveillance and Epidemiology, CDC, 
Atlanta, Georgia). 
 
5.4.2 Laboratory measurements 
Viral load, CD4 cell count and percentage were determined using standard laboratory methods 
at commencement of ART and after 1 year of treatment (Appendices 5 and 12 of Annexure A).  
Viral suppression will be defined as <400 copies/ml. 
 
5.4.3 Measurements of Adherence 
A. Medication return (MR) 
At every monthly visit for 1 year, caregivers were requested to return all empty medicine 
containers together with unused medication.  A dedicated programme pharmacist measured the 
amount of unused medication volumetrically for syrups/solutions and by pill count for 
tablets/capsules.  The percentage adherence for each antiretroviral medication was calculated by 
dividing actual use (determined from returned containers and unused medication) by expected 
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use (determined from the previous month’s script), and entered on a standard form. (Appendix 
7 of Annexure A)  These measures have been entered into a Microsoft Excel spreadsheet as a 
monthly percentage adherence for each individual drug.  
 
B. Questionnaire 
A standardized interview (Appendix 8 of Annexure A) was administered by the treating 
clinician to each caregiver after the child had completed 3 months of ART.  The interview 
script was based on Pediatric AIDS Clinical Trials Group (PACTG) adherence questionnaires 
modules 1 and 2.[31-32]  The interview assessed the caregiver’s ability to accurately describe 
the ART regimen, recall of missed doses in the past 3 days, difficulties associated with giving 
medication and beliefs about ART.  Interpreters were used so that interviews were conducted in 
the language of the caregiver’s choice.  Caregiver responses were recorded on a standardized 
data collection form (Appendix 8 of Annexure A) and anonymously entered into a password 
protected Microsoft Access Database. 
 
5.5 Data Management 
Clinical and socio-demographic characteristics as well as laboratory measurements have been 
entered into a Microsoft Excel spreadsheet.  MR measurements have been stored in a separate 
Microsoft Excel spreadsheet, while adherence questionnaire responses have been entered into a 
Microsoft Access database.  These 3 sources of data are all anonymized and will be merged 
using the anonymization key into a single password-protected Microsoft Access database.  Hard 
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copies of completed data collection forms will remain stored in locked steel filing cabinets in 
locked offices.   
 
6. ANALYSIS: 
All statistical analysis will be carried out using Stata (version 9) (Stata Corporation, College 
Station, Texas, USA).†
 
  
Continuous variables will be summarized using means and standard deviations (SD) for 
normally distributed data and medians and IQRs for non-normally distributed data.  Categorical 
variables will be described using proportions.   
 
Medication return (MR) adherence data will be examined to determine the best way of 
developing a composite measure of adherence for all three drugs over the year.  The correlation 
between viral suppression at one year and both the monthly mean adherence for all 3 drugs and 
the lowest monthly adherence of any drug will be calculated using longitudinal logistic 
regression analysis methods.  In addition, the relationship between viral suppression and a 
simple overall mean annual adherence for all 3 drugs will be determined using logistic 
regression to adjust for other factors that might determine viral suppression.  A small amount of 
extra medication (in excess of what was prescribed) was issued at each visit so that patients 
                                                 
† Stata (version 10) became available before the analysis was commenced and was thus used. 
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would not be without medication if drugs were spilled or additional doses required due to 
vomiting or spitting out.  For a number of medication returns, therefore, more drug was used 
than prescribed (i.e. adherence >100% is recorded).  For these visits, adherence will be capped 
at a maximum of 100% per return when calculating monthly and annual mean adherence.  
Factors associated with adherence >100% will also be examined.  
 
The best composite measure of MR adherence will be selected based on prediction of viral 
suppression, clinical interpretability and simplicity.  Using this composite measure, the cut-off 
level of adherence that best predicts viral failure will be determined.  Adherence above this 
threshold will be called “good adherence”. 
 
Univariate and multivariate analysis of the association between demographic, social and clinical 
factors, as well as experiencing problems with giving medication, and having “good adherence” 
will be examined.  For univariate analysis, Wilcoxon rank sum (Mann-Whitney) and Student’s 
t-tests will be used for non-normally and normally distributed variables respectively and chi2 or 
Fisher’s exact tests for categorical variables according to the expected number of observations 
within each cell.  Logistic regression models will be used for multivariate analysis. 
 
Based on interview responses to doses missed in the last 3 days, children will be classified as 
either fully adherent (FA) (no doses missed) or not fully adherent (NFA) (≥1 dose missed).  
Correlation between FA and viral suppression will be determined using logistic regression.  
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Agreement between MR adherence for the third month of treatment below the cut-off required 
for viral suppression, and caregiver reported NFA will be measured using the kappa statistic. 
 
All multivariate models will be built by sequentially adding the next most significant predictor 
variable from the univariate analysis, and variables with a p-value <0.1 after adjustment for 
those already included in the model, or that change the OR for variables included in the model 
by more than 10%, will be retained.‡
 
  P-values for all statistical analyses will be reported 
exactly with no particular cut-off used to define significance.[34] 
7. ETHICS, REPORTING AND IMPLEMENTATION 
7.1 Ethics 
This study has already been approved by the University of Cape Town research Ethics 
Committee as part of the larger study of ART in children (REC REF: 261/2002) (Annexure B).  
The latter study protocol specifically included collection of serial adherence data on children 
and use of this data for research.  Voluntary written informed consent was obtained prior to 
study enrolment from each caregiver, together with verbal assent from the child if he/she was 
old enough to provide this.  Consent forms (Appendix 3 of Annexure A) were translated into 
English, Afrikaans and Xhosa, with interpreters being used so that the study could be fully 
                                                 
‡This approach has been superceded by work on causal inference that was published subsequent to completion of 
our analysis.[33] 
 25 
 
explained to the caregiver and child in a language that they understood and all questions 
addressed.  
 
Since the data to be analysed were collected as part of the routine clinical care of the children, 
there is no anticipated harm to the children.  Every effort will be made to ensure patient 
confidentiality through the use of anonymization keys and password protection in the database 
to be analyzed, and the secure storage of all source documents. 
 
Benefits to the children and their caregivers during the study period were enhanced adherence 
monitoring through the regular medication measurements and questionnaires, which may have 
improved clinical outcomes.  As adherence monitoring was provided to all children in the same 
way, this possible benefit would have been afforded equally to all children in the study. 
 
Results of this study could benefit all children commenced on ART as it may assist in 
development of clinical practice to prevent poor adherence as well as to identify children likely 
to be non-adherent and requiring adherence interventions, in the context of busy roll-out clinics 
where detailed adherence assessment and intervention is not practical for all children. As the 
children in the study group are representative of those for whom the research outcomes are 
intended, justice is maintained. 
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The study will be conducted in accordance with the 1996 Declaration of Helsinki and local 
rules and ethical regulations of South Africa.  
 
7.2 Reporting and implementation 
The results of this study will be submitted for publication in a peer reviewed journal and 
presented at local conferences and meetings so that they can be maximally accessed by those 
involved in providing ART for children.  The clinicians and pharmacist who participated in the 
project and all clinicians involved in ART provision at Red Cross Children’s Hospital will be 
informed of the results.  Since these clinicians support outreach programmes to a number of 
paediatric ART sites in the Western Cape and are involved in developing provincial, national 
and international paediatric ART guidelines, there should be ample opportunity for the results 
to influence general paediatric ART policy and practice.  
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8. LOGISTICS 
8.1 Timetable 
Task Duration 
Merge, clean and check data sets February – April 2007 
Analysis May – September 2007 
Prepare draft manuscript October – December 2007 
Prepare final manuscript and submit for publication January – February 2008 
 
8.2 Budget 
As the data has already been collected, no further costs will be incurred. Mary-Ann Davies will 
be responsible for data management and analysis of the merged database as part of her M.Med 
studies, and so does not require any payment. 
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PART B (i): STRUCTURED LITERATURE REVIEW 
 
1. INTRODUCTION 
Paediatric ART guidelines universally recommend adherence monitoring and support, as near 
perfect adherence is required for optimal viral suppression and prevention of resistance.[1-9]  
Access to ART for children in low- and middle-income countries (LMIC) has expanded 
enormously in recent years with nearly 275,000 children on treatment by the end of 2008.[10]  
Adherence for children in developing countries with extremely limited access to second-line 
regimens, viral load measurement or resistance testing is critical.[11]  In this context, the 
accurate measurement of adherence and identification of its determinants is important to 
maintain first-line regimens and develop appropriate adherence support.[12-14] 
 
WHO defines adherence as the “extent to which a person’s behaviour corresponds with agreed 
recommendations from a health care provider”.[15]  For young children, however, the role of the 
caregiver is important with adherence being a triadic partnership between medical team, 
caregiver and child.[16-17]  The caregiver of an HIV-infected child may not be the biological 
parent, and may change over time. 
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This literature review will comprise two parts with the same objectives and search strategy. 
• A main literature review that includes studies published before February 2008, when 
our study was submitted for publication. 
• A post-script covering the period during and after submission of our paper (February 
2008 – January 2010).  This aims to update the review as well as contextualize and 
interpret our findings. 
 
2. OBJECTIVES 
This literature review aims to appraise all published observational studies of ART for HIV-
infected children from LMIC that report a quantitative measure of adherence.  The main review 
will include studies published prior to 31 January 2008, while the post script covers the 
remaining period to January 2010. 
 
The objectives of the review are to report the following items as well as identify needs for further 
research: 
• Methods used to measure adherence. 
• Measurements of adherence in children. 
• Agreement between measured adherence and immune or viral response to ART. 
• Factors influencing adherence. 
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Adherence is context-specific.  Challenges faced by a caregiver from an informal settlement in a 
developing country administering syrup to an infant may be very different from those of an 
adolescent responsible for their own adherence to pills in a wealthy country.  The review 
therefore aims to be relevant to the context of adherence among very young children in Cape 
Town, South Africa.  For this review, children will be defined as <14 years of age.  This is 
consistent with National Treatment Guidelines[18], and adherence in adolescence is different to 
that in young children.[14, 19]  Health service factors and access to treatment may influence 
adherence, hence limiting the review to LMIC.[17]  Nevertheless, some challenges to adherence 
cut across settings and ages.  Hence the review will draw selectively on quantitative paediatric 
adherence studies from high income settings, qualitative paediatric adherence studies and adult 
ART adherence literature.  
 
3. SEARCH STRATEGY 
A search of the Medline bibliographic database using the PubMed interface (National Library of 
Medicine, Bethesda, MD) was performed using the following strategy: “antiretroviral AND 
(child* OR pediatric OR paediatric) AND (adherence OR compliance)”.  A key word search was 
used as this yielded more studies than that of Medical Subject Headings.  In addition, the 
bibliographies of reviews of paediatric adherence (identified through Medline as well as a search 
of International AIDS Society (IAS) conference abstracts between 2001 and 2007) were 
reviewed to identify additional studies.[17, 20-23]  Articles from LMIC (as classified by the 
World Bank)[24] that reported at least one measure of adherence to ART in vertically HIV-
infected children taking ≥3 ART drugs were included.  Exclusion criteria were studies from high 
 33 
 
income countries, inclusion of mostly adolescents, studies where most children were treated with 
<3 antiretrovirals, and studies of interventions to improve ART adherence, unless these included 
a measure of adherence in a non-intervention group.  Published abstracts were reviewed to 
determine whether studies met the inclusion criteria. 
 
4. ARTICLES PUBLISHED PRIOR TO FEBRUARY 2008 
The search yielded 234 articles published prior to February 2008, of which only 16 met the 
inclusion criteria.  An additional 2 studies were identified by searching the bibliographies of 
reviews.[21-22, 25-26]  As there were only 18 studies that met the inclusion criteria (Table 1), no 
quality criteria were applied for inclusion, however study quality was appraised. 
 
5. QUALITY AND COMPARABILITY OF STUDIES 
Tables 1 and 2 summarize key features reflecting study quality and comparability.  Quality 
criteria include whether the study primarily aimed to assess adherence, study design, sample size 
and selection criteria as well as the number and validity of measures of adherence. 
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Table 1: Characteristics of studies reviewed 
a) Studies from Africa 
 
Reference 
Year of 
publication 
Location & time Design 
Dedicated 
observational 
adherence study 
sample 
size 
Median (IQR) duration in 
months on ART at time of 
enrolment 
Median (IQR) age in 
years at study 
enrolment 
Regimens used 
         
Fassinou[27] 2004 Côte d'Ivoire; 
2000 - 2002 
prospective cohort No 78 79% enrolled at ART initiation 6.5 (0.7 - 15.2)a 2 NRTI + Nelfinavir (78%) or EFV (22%);                     
17% received drug as syrups 
Eley[28] 2004 South Africa; 
2002 - 2003 
prospective cohort No 80 All enrolled at ART initiation 50.5b (41.8 - 59.2)c 
months 
D4T + 3TC+RTV or EFV 
Arrivé[29] 2005 Côte d'Ivoire; 
2004 
cross sectional Yes 112 NR 7.1 (4.7 - 10.9)  
(interruptions);                                             
5.8  (2.4 - 7.9)                                  
(no interruptions) 
2NRTI + Nelfinavir or EFV 
Nyandiko[30] 2006 Kenya; 
2002 - 2005 
prospective cohort No 279 All enrolled at ART initiation 6.0 (4.8  - 13.7)c AZT + 3TC + NVP (<10kg) or 
D4T + 3TC + NVP (>10kg) 
Bikaako-
Kajura[31] 
2006 Uganda; 
2002 - 2003 
cross-sectional Yes 42     18 12 AZT + 3TC + EFV 
Mukhtar-
Yola[25] 
2006 Nigeria; 
2005 
cross-sectional Yes 40 NR 1-5 yrs: 57%                                                
6-10 yrs: 33%                                            
11-15 yrs: 10% 
AZT or D4T+ 3TC+NVP 
Reddi[32] 2007 South Africa; 
2003 - 2005 
retrospective cohort No 151 All enrolled at ART initiation 5.7 (0.3 - 15.4)a D4T + 3TC + EFV (over 3 years);                                           
D4T + 3TC + LPV/r or unboosetd RTV (under 3 yrs) 
Wamalwa[33] 2007 Kenya; 
2004 - 2005 
prospective cohort No 67 All enrolled at ART initiation 4.4 (1.5  - 12)a AZT or D4T + 3TC + NVP (69%) or EFV (25%);  
some FDC use 
Ellis[34] 2007 Malawi; 
2004 - 2005 
prospective cohort No 238 All enrolled at ART initiation 87 (7 - 212)a months Adult FDC only: D4T + 3TC + NVP 
Nabukeera-
Barungi[35] 
2007 Uganda; 
2004 - 2005 
cross sectional Yes 170 83% on ART for ≥ 1 year 10 FDC of D4T + 3TC + NVP (81%);                                             
FDC of AZT + 3TC + NVP (9%) ;                                                
FDC of AZT + 3TC with separate EFV (6%) 
Muller[36] 2008 South Africa; 
2006 
prospective cohort 
over 3 months 
Yes 73 28 (12 - 38) 48 (34 -65) months 2 NRTI + LPV/r (59%);                                                                   
2 NRTI + NVP or EFV (32%)                                                                        
2 NRTI + unboosted RTV (9%) 
        
arange  NR: Not reported  yr: year    
bmean  FDC: Fixed-dose combination      
c95% confidence interval NRTI: nucleoside reverse transcriptase inhibitor     
dstandard deviation NNRTI: non-nucleoside reverse transcriptase inhibitor     
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b) Studies from LMIC outside Africa 
Reference 
Year of 
publication 
Location & time Design 
Dedicated 
observational 
adherence study 
sample 
size 
Median (IQR) duration in 
months on ART at time of 
enrolment 
Median (IQR) age in 
years at study 
enrolment 
Regimens used 
         
Bunupura-
dah[37] 
2006 Thailand; 
2005 
before and after trial 
of use of flavouring 
No 30 NR 5.2b; 1.9d 2 NRTI + EFV or NVP or LPV/r;                                                                 
opened capsule, crushed tablet or liquid 
Natu[38] 2007 India; 
NR 
prospective cohort No 25 All enrolled at ART initiation 6 Adult FDC only: D4T + 3TC + NVP 
Safreed-
Harmon[39] 
2007 Thailand; 
2004 
cross-sectional Yes 29 NR 6.1 NR 
Myung[40] 2007 Cambodia; 
2002 - 2004 
retrospective record 
review 
No 95 All enrolled at ART initiation 5.5b; 2.5d D4T + 3TC + NVP or EFV 
Pensi[26] 2007 India; 
NR 
prospective cohort No 21 All enrolled at ART initiation <1yr: 1                                                               
1-5 yrs: 11                                                             
≥6 yrs: 8 
D4T + 3TC + NVP 
Plipat[41] 2007 Thailand; 
2003 - 2005 
prospective cohort Yes 162 on ART (62%) or                   
starting ART (38%) 
<7 yrs: 64%;                                                    
7-10 yrs: 22%                                              
11-14 yrs: 14% 
Dual NRTI (28%);                                                          
2 NRTI + NNRTI (65%)                                                              
2 NRTI + PI (7%) 
Wachholz[42] 2007 Brazil; 
2002 
cross-sectional Yes 194 40.2 6b (0.9 - 12)a ≥3 drugs (67%); 2 drugs (33%) 
         
arange  NR: Not reported  yr: year    
bmean  FDC: Fixed-dose combination      
c95% confidence interval NRTI: nucleoside reverse transcriptase inhibitor     
dstandard deviation NNRTI: non-nucleoside reverse transcriptase inhibitor     
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Table 2: Methods of measuring adherence and estimates of adherence 
a) Studies from Africa 
Reference 
Number of 
methods of 
adherence 
measurement 
Self report definition 
Self report 
proportion 
with 
adherence 
above 
threshold 
MR definition 
MR proportion 
with adherence 
above threshold 
Other definition 
Other 
proportion 
with 
adherence 
above 
threshold 
Correlation with clinical outcome 
         
Fassinou[27]  1 Subjective caregiver 
experience of not having 
difficulty with adherence 
79%     NR 
Eley[28]   1   >85% pills/syrup 
used 
"Most"   NR 
Arrivé[29]  1 CGSR of no doses missed 
in previous month 
67%     55% of adherent patient undetectable vs 0% non-
adherent children (p=0.098); n=24 
Nyandiko[30]  1 CGSR of no doses missed 
in previous month or 7 
days 
75%     No correlation with improvement in CD4% 
Bikaako-
Kajura[31]  
1 Child and CGSR of never 
missing a dose 
71%     NR 
Mukhtar-
Yola[25]   
1 CGSR of taking >95% of 
doses 
80%     NR 
Reddi[32]  1 Monthly child or CGSR of 
missing no doses 
60%     NR 
Wamalwa[33]  1 CGSR of no doses missed 
in previous 2 weeks 
64%     No correlation with virologic response 
Ellis[34] 1 CGSR of >95% doses taken 
in previous month 
90%     NR 
Nabukeera-
Barungi[35]  
3 Child (if >12 years) or 
CGSR of ≥95% doses taken 
in previous 7 days 
89% ≥95% pills used home-based: 
72%; 
clinic-based: 94% 
  NR 
Muller[36]  2 CG VAS estimate of 
adherence over previous 
month 
   MEMS: >80% of 
doses taken 
65% 74% of those with MEMS adherence >80% vs 43% of 
those with <80% adherence had viral load <50 
copies/ml; (p=0.017);                                                                                    
No correlation between VAS adherence and virologic 
response 
NR: Not reported        
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b) Studies from LMIC outside Africa 
Reference 
Number of 
methods of 
adherence 
measurement 
Self report definition 
Self report 
proportion 
with 
adherence 
above 
threshold 
MR definition 
MR proportion 
with adherence 
above threshold 
Other definition 
Other 
proportion 
with 
adherence 
above 
threshold 
Correlation with clinical outcome 
         
Bunupuradah 
[37] 
2 CGSR of no doses missed 
in previous 3 days 
100%   Drug trough level in 
10 children - 
repeated 
1/20 trough 
levels low 
NR 
Natu[38] 1     % actual follow-up 
visits /expected 
  95% 
attendance 
NR 
Safreed-
Harmon[39] 
3 combined 
into single 
estimate 
CGSR of no missed doses 
in previous month 
100% Average of pills 
used/pills 
prescribed 
98 - 99% Medical charts 
reviewed 
NR NR 
Myung[40] 1 Report of no missed doses 
by child-care workers that 
administered DOT 
99%     NR 
Pensi[26] 1 CGSR of >95% adherence 
(no duration specified) 
100%     NR 
Plipat[41] 
 
5 CGSR of ≥95% of doses 
taken in previous month; 
questionnaire of no doses 
missed in previous 3 days. 
CGSR:                    
95% - 96%       
Questionnaire: 
99% 
≥95% pills used 84% Physician 
assessment on VAS 
scale 
55% Mean log viral load decrease greater in those with ≥95% 
adherence by MR compared to those with lower 
adherence (p= 0.05);                                                                             
No correlation between CGSR adherence and virologic 
response; 
Wachholz[42] 1 ≥80% of doses taken in 
previous 24 hours 
50.5%     NR 
NR: Not reported        
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5.1 Primary aim of the study 
Only 5 of 11 studies from Africa [25, 29, 31, 35-36] and 3 of 7 from other countries [39, 41-42] 
have the primary aim of assessing adherence.  Most of the remaining studies report overall 
outcomes of a paediatric ART programme, with adherence being one of the outcomes reported.  
A single measure of adherence is used and methods of adherence assessment only briefly 
described.  Studies by Bunupuradah et al.[37] and Myung et al.[40] report on adherence in the 
context of interventions, namely adherence before and after addition of a flavouring product to 
medication, and the use of directly observed therapy (DOT), with limited information on how 
adherence measurement was performed. 
 
5.2 Study design 
Adherence may fluctuate with duration on treatment and child’s developmental stage, so cross-
sectional and short term cohort studies have limited value unless children with a range of 
durations on ART are included.[17, 23]  Apart from the study by Plipat et al.[41], however, the 
only long term cohort studies are those of paediatric ART outcomes, rather than of adherence per 
se.  The latter studies follow children from ART initiation and adherence is assessed for up to a 
year or two after starting ART, and may be very different from that after longer durations of 
treatment.  Furthermore, the very fact of routinely measuring adherence may impact on 
adherence itself, reducing the validity of measurements from later periods.  In this respect, cross-
sectional studies can actually “catch” patients at a range of treatment durations without affecting 
adherence by repeated measurement.  However only 4 of 7 cross-sectional or short term cohort 
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studies report on treatment duration, with a mean/median between 18 and 40 months [31, 36, 42] 
or 83% of children on ART for ≥1 year [35].  Plipat et al.[41] uniquely included both children on 
ART (62%) and initiating ART (38%) in a 1 year follow-up cohort study, however adherence is 
not reported separately for long-term and new ART patients. 
 
5.3 Sample size 
The sample sizes range from 21 – 279, but are <100 in most studies. Only one study provided a 
sample size calculation.[42] 
 
5.4 Methods of adherence assessment and definitions of “good/high” adherence 
There is no gold standard for measuring adherence.  Methods used can be direct such as 
therapeutic drug monitoring (TDM), or indirect.  Indirect methods include child or caregiver 
self-report (CGSR) of doses missed, quantifying medication not used as a percentage of that 
prescribed, or electronically monitoring number and timing of instances of medication containers 
being opened.  Proxies for indirect assessment of medication use are pharmacy refill records and 
clinic attendance.  The anticipated biological effect of adherence in terms of viral or immune 
response can also be a measure of adherence, however the criteria for an immune response 
indicative of adequate adherence have not been defined in paediatric practice.  A brief 
description of the threats to validity of the most commonly used measures will be provided. 
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Child or Caregiver self-report 
This is commonly used in adult and paediatric studies as it is simple and cheap.[21, 43-44]  
Precisely for these reasons, it is the tool most feasible for measuring adherence in clinical 
practice in resource-limited settings, hence the importance of determining its validity.  A meta-
analysis of adult studies demonstrated that self-reported adherence is associated with virologic 
suppression and some paediatric studies from developed countries have shown similar 
associations.[45-48]  Nevertheless CGSR may over-estimate adherence and is subject to recall 
and social desirability bias.[23]  Most assessments ask about adherence in the last 1 to 7 days to 
limit recall bias, but this may miss patterns of non-adherence that are intermittent, for example 
over weekends or when the child and/or caregiver is away from home or ill.  The impact of 
social desirability bias may depend on who administers adherence questionnaires as well as who 
provides the report, as a caregiver would not want to appear negligent, especially to the health 
care worker providing ART for her/his child.  Van Dyke et al.[45] for example found that 
children themselves reported the lowest adherence, non-biological caregivers the highest, and 
biological parents an intermediate level. 
 
Of the LMIC paediatric studies, 10 measure adherence using child or CGSR alone, with a further 
5 employing this together with another method.  Caregivers are the respondents for almost all 
studies and no studies report adherence separately for child respondents.[31-32, 35]  Reporting 
period is mostly short but varies from the last 24 hours to the last month. 
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Medication return (MR) 
This involves counting (pills) and measuring/weighing (syrups) medication not used, assuming 
that the remaining medication has been taken as prescribed.  Medication return implies that 
assessments are done at the clinic.  However home-based assessments, although resource-
intensive, may be more accurate as they can be unannounced and don’t rely on caregiver 
returns.[35]  Children taking syrups may vomit or spit out medication, or syrup may be spilled so 
that MR may not accurately reflect actual drug ingested.  In developed countries, there are few 
paediatric studies using MR and none in children taking syrups [21, 49]. 
 
Among studies in LMIC, adherence was assessed by MR in 4 studies.[28, 35, 39, 41]  Only one 
study performed home-based measurements[35] and one assessed adherence to syrups.[28] 
 
Electronic measurement of medication adherence 
Electronic monitoring of opening of medicine containers by means of a microchip in the lid, is 
often considered the best of the indirect methods of measuring adherence.[43]  However cost and 
technology requirements limit its use.[21, 23, 43, 50]  Not surprisingly it was only used in 1 
LMIC study.[36]  Although it should provide a less exaggerated measure of adherence in 
comparison to other methods, the electronic monitoring device (usually in the form of the 
Medication Event Monitoring System (MEMS) cap of the container) is typically only used with 
one of the drugs and adherence for the others must be inferred.  This may not be valid in children 
where poor palatability of a drug may affect adherence for that medication alone.  In addition, 
Muller et al.[36] encountered a number of practical difficulties assessing the use of syrups with 
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MEMS caps designed for pill containers.  The bottles tended to leak and with longer duration 
use, increasing amounts of syrup crystallized on the bottle neck and cap making opening and 
closing of bottles difficult.[36]  Together with expense, these difficulties limit use for monitoring 
long term adherence in clinical practice.  
 
Other indirect measures of adherence 
Clinic attendance and physician assessment were each used in one study, with no study assessing 
adherence to pharmacy refills.[38, 41]  These are all very indirect measures and have been 
infrequently used in adult studies as well as paediatric studies from developed countries.[21, 43, 
51] 
 
Therapeutic drug monitoring  
This is the only direct measure of adherence but only assesses whether the last dose of the drug 
was taken.  Furthermore, population reference values of antiretroviral medication in children are 
frequently lacking and drug levels may be influenced by differences in absorption, distribution 
and metabolism, as well as adherence.[52]  Cost limits TDM use to small samples in research 
settings.[21]  Indeed it was used in one LMIC study in only 10 children.[37] 
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Biological effect monitoring. 
Measuring therapeutic impact in terms of viral load or CD4 response could be considered a 
method of assessing adherence itself.  Most adherence studies, however, use this to assess 
validity of other adherence measures in terms of their association with CD4/viral response. 
Among the LMIC studies, however, only 5 actually assessed the validity of adherence measures 
in this way, and in many studies this was done for only a subset of children.[29-30, 33, 36, 41]  
While this impacts on study quality, poor access to CD4 and viral load measurement is a reality 
in most resource-limited settings, highlighting the importance of identifying other tools to 
monitor adherence. 
 
Definitions of good/high adherence 
There is no agreement on the threshold to define good adherence.  While early adult studies 
suggested that adherence ≥95% was required to achieve viral suppression,[1] paediatric studies 
from high-income countries have defined good adherence using thresholds of 75% to 100% with 
an association shown between viral suppression and medication refill adherence as low as 
75%.[51]  Some studies report only mean/median adherence which has little meaning if the 
majority of patients are adherent.[39] 
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5.5 Selection of study participants and missing adherence measurement information 
Long-term cohort studies 
All long term prospective cohort studies included all children initiating or on ART in the 
respective programmes, however none report on the amount of missing adherence information, 
and only one explains how missing information for particular visits was dealt with.[30]  In these 
studies adherence measurement was contingent on clinic attendance and it is unrealistic to 
assume that no clinic visits were missed.  Furthermore children may not have been accompanied 
by a suitable caregiver to complete the CGSR or not returned their medication bottles.  Nyandiko 
et al.[30] actually indicate that children were frequently not accompanied by their primary 
caregivers impacting on reliability of the CGSR.  In this study, pill count or syrup volume 
measurement was used to supplement such possibly unreliable adherence assessments.[30]  It is 
likely that other studies would have encountered the same problem. 
 
Cross-sectional and short-term cohort studies 
Most cross-sectional and short term cohort studies recruited only a subset of children on ART in 
the program, with sequential enrolment of those attending the clinic with their caregiver and 
consenting to participate.[29, 31, 35]  The proportion of caregivers declining consent is only 
reported by Arrivé et al.[29]  This is also the only study that reports on characteristics of those 
not included.  Although Nabukeera-Barungi et al.[35] conducted both home-based and clinic-
based pill counts, only children who attended the clinic with their medication containers were 
recruited at the outset.  The Brazilian study is the only one where children were enrolled 
irrespective of clinic attendance with interviews conducted at home if the clinic visit was 
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missed.[42]  It is probable that most studies over-estimate adherence as caregivers attending 
clinic visits and participating in studies are likely to be more adherent.  Muller et al.[36] 
excluded children from orphanages, those with multiple caregivers and whose caregivers 
declined to participate.  
 
5.6 Adherence measurement in the context of limited access to ART 
As access to ART for children in LMIC has only recently expanded, all of these studies assessed 
adherence at times of very limited access.  While this may have genuinely increased motivation 
to adhere, measures of adherence reported may be influenced by selection bias whereby patients 
most likely to be adherent were able to preferentially access treatment in limited 
programmes.[28]  Furthermore, capacity for adherence counseling in early small programmes is 
far greater than scaled up programmes.  In addition, social desirability bias may have a greater 
effect in the context of restricted ART access. 
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5.7 Summary of study quality appraisal 
Ideally a good quality study should have an adequate sample size supported by a sample size 
calculation, avoid selection bias and include patients initiating as well as on ART for longer 
periods, have >1 measure of adherence and assess validity of measures through associations with 
viral load.  No studies fulfill all these criteria, however those by Arrivé et al.[29], Nabukeera-
Barungi et al.[35], Muller et al.[36], Plipat et al.[41] and Wachholz and Ferreira[42] match them 
most closely. 
 
6. RESULTS FROM STUDIES REVIEWED 
6.1 Characteristics of children studied 
Most studies examined adherence predominantly in older children taking pills with the 
median/mean age ranging from 4 to 10 years.  This mirrors the age at which children initiate 
ART in LMIC settings.[27-28, 30, 32-33, 53-56]  In addition, as WHO recommended first-line 
regimens for children were non-nucleoside transcriptase inhibitor (NNRTI) -based, there are only 
small numbers of children on protease inhibitor (PI) -based regimens.[2, 27-28, 36-37, 41]  This 
is an important concern as it is the liquid PI drugs of ritonavir (RTV) and lopinavir/ritonavir 
(LPV/r) that are notorious for their bad taste.[57] 
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6.2 Measurement of adherence 
Estimates of adherence and methods of assessment used are summarized in Table 2.  Eight of 11 
studies from Africa and 4 of 7 from other LMIC used a single method of adherence assessment, 
while two studies used >1 method[30, 39] without reporting the results of each measure 
separately. 
 
Child or caregiver self-report 
This is the only measure for 10 studies and is used in combination with other methods in 6 
studies. (Table 2) The cut-off s used to define good adherence by self report are high (95 – 
100%), except in the Brazilian study (≥80% doses taken in the last 24 hours).[42]  In African 
studies, proportions of children with good adherence range from 60 – 90%.  Estimates from 
other LMIC are 95 – 100% of children with good adherence, except in the Brazilian study[42] 
where only 51% of children have good adherence.  This is the only study that recruited patients 
irrespective of their clinic attendance and may provide a more accurate estimate of adherence.  
These estimates are similar to those from paediatric studies from developed countries which 
range from 34 – 100% “good” adherence by CGSR and 20 – 58% by child self-report using cut-
offs of 90 – 100%.[21, 45-46, 58]  They are also similar to adult studies from resource limited 
settings with proportions of patients with good adherence by self-report of 54 – 97%.[43-44] 
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Medication return 
Estimates of adherence by MR are between 72% and 98%.[28, 35, 41]  Interestingly, Nabukeera-
Barungi et al.[35] found that 94% of patients had used ≥95% of pills when assessed at the clinic 
but only 72% when assessed at home, with clinic-based pill counts estimating higher adherence 
than clinic-based child or CGSR (89% ≥95% adherent).  Both clinic-based measures had poor 
agreement with the home based measure suggesting that adherence is over-estimated with clinic-
based measures alone.[35]  While Ellis and Molyneux[34] intended to measure MR adherence in 
children taking fixed-dose combination tablets (FDC), in practice it was impossible to perform 
accurate pill counts for very young children taking fractions of tablets.  There are few paediatric 
MR studies from developed countries with similar estimates of mean adherence of 70 – 90%.[21] 
 
Electronic monitoring 
Muller et al.[36] found that 65% of children took more than 80% of doses with only 40% being 
>95% adherent using MEMS caps monitoring.  These measures suggested far lower adherence 
than the estimate of 91% of patients having ≥95% adherence obtained by CGSR using a visual 
analog scale (VAS).[36] 
 
Other methods 
Clinic visit attendance of 95% was reported by one study.[38]  Physician assessment was also 
used in a single study with a low estimate of 55% of children being >95% adherent. [41]  This 
was lower than measures obtained from other adherence tools in the same study.  Bunupuradah 
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et al.[37] measured trough drug levels on 2 occasions in 10 of 30 children, in addition to CGSR, 
and 19 of 20 measurements were within the target range. 
 
6.3 Use of multiple measures and correlation with biological effect monitoring 
Five studies used >1 measure of adherence and almost all found that more objective methods 
such as electronic monitoring or MR provided lower estimates than CGSR.[35-37, 39, 41]  More 
objective methods were also more likely to show an association with CD4 or viral load response 
in the few studies that assessed this.[29-30, 33, 36, 41]  For example, the proportion of children 
with viral suppression was nearly double in those with MEMS adherence >80% compared to 
other children (p=0.017), while there was no correlation with CGSR VAS adherence.[36]  
Similarly, Plipat et al[41] found mean viral load decrease to be greater in children with ≥95% 
adherence by MR, compared to other children, but no association with any of the CGSR 
measures and poor agreement between all measures used.[41]  Studies using CGSR alone all 
showed no association with viral load or CD4 response, however usually only a subset of 
children had viral load measurements and small sample size may have limited power.  For 
example, in 24 children (of 112 studied) with viral load measurements, Arrivé et al.[29] found 
55% of adherent children compared to 0% of non-adherent children had viral load <400 
copies/ml, but this difference was not statistically significant. 
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6.4 Factors influencing adherence 
Eight studies explored factors influencing adherence by determining a statistical association with 
adherence/non-adherence while nine listed facilitators and barriers to adherence or reasons for 
missing doses (Table 3).  For convenience, these factors are grouped as those related to the 
child/caregiver, the medication and the health care system.[17, 59]  However, factors do not 
necessarily fit into a single category.  For example, lack of money for medication 
(child/caregiver factor) is related to the cost of treatment.  In addition, many factors are 
influenced by broader issues - for example, complicated regimens and poor drug palatability 
(medication related) are the direct result of a context of limited access to child-friendly drugs 
(health care system related), while capacity for caregiver disclosure to children or other adults 
(child/caregiver related) is influenced by stigma and expected consequences of disclosure which 
are affected by the health care system as well as the broader social context.[60-61] 
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Table 3: Factors influencing adherence 
Table 3 a) Factors statistically associated with non-adherence 
   
 Studies showing positive association 
with non-adherence 
Studies showing no association with 
non-adherence 
Caregiver/child related   
Old age Arrivé[29]  
Orphanhood  Nyandiko[30], Safreed-Harmon[39], 
Wachholz[42], Nabukeera-Barungi[35] 
Non-disclosure or partial disclosure to child Bikaako-Kajura[31] Nabukeera-Barungi[35] 
Social class  Mukhtar-Yola[25] 
Caregiver responsible for only 1 child Wachholz[42]  
Caregiver not using ART themselves Wachholz[42] Nabukeera-Barungi[35] 
Non-institutionalized children Wachholz[42]  
Poor caregiver education Wachholz[42] Nabukeera-Barungi[35] 
Children sicker at ART initiation Nabukeera-Barungi[35]  
Caregiver disclosure to other people Nabukeera-Barungi[35]  
   
Medication related   
Receiving EFV Arrivé[29] Nabukeera-Barungia[35] 
Receiving LPV/r vs NNRTI  Muller[36] 
Duration of treatment Nabukeera-Barungib[35] Plipat[41] 
   
Health system related   
Distance from hospital   Nabukeera-Barungi[35] 
aNo association between any medication regimen and adherence  
bNon-significant trend to lower adherence with treatment duration >24 months  
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Table 3 b) Facilitators of and barriers to good adherence 
Barrier/facilitator of adherence Supporting studies 
Caregiver related  
Barriers  
Child refusal/parent child conflict Fassinou[27], Arrivé[29], Reddi[32], Bikaako-
Kajura[31] 
Multiple caregivers Fassinou[27], Reddi[32] 
Travelling Fassinou[27] 
Forgot Arrivé[29], Mukhtar-Yola[25], Plipat[41] 
Delay in renewing script / missed clinic visit Fassinou[27], Arrivé, Reddi[32],  
Lack of money for transport to clinic, buying medication or buying food Bikaako-Kajura, Mukhtar-Yola[25], Reddi[32] 
Sharing medication with siblings not on ART Muhktar-Yola[25] 
Incorrect dosing Reddi[32] 
Child asleep Plipat[41] 
  
Facilitators  
Use of reminders Bunupuradah[37] 
Caregiver adherence strategies Bikaako-Kajura[31] 
  
Medication related  
Barriers  
Bad taste Bunupuradah[37], Plipat[41] 
Vomiting medication Reddi[32] 
Complicated regimens Reddi[32] 
Prolonged treatment duration Fassinou[27] 
  
Facilitators  
Mix with juices, syrup or flavour-masking product Bunupuradah[37] 
Perceived benefit of drug Bikaako-Kajura[31] 
Use of fixed-dose combination drugs  Pensi[26] 
  
Health system related  
Barriers  
Drug stockout Arrivé[29] 
Stigma Bikaako-Kajura[31] 
Cost of drugs / limited access to ART Muhktar-Yola[25] 
  
Facilitators  
DOT ART Myung[40] 
Family centered model Reddi[32] 
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Caregiver/child-related 
Two major concerns for optimal paediatric adherence in Africa are whether adherence is 
adversely affected by low socio-economic status as well as caregiver changes and inconsistent 
caregiving quality exacerbated by adult illness and mortality.  No studies showed worse 
adherence among children who had lost a biological parent, however this may reflect a selection 
bias as orphans with better caregivers are likely to access ART.[30, 35, 39, 42]  Institutionalized 
children have been shown to have better adherence than those looked after by biologically 
related non-parent caregivers.[42]  In Africa, however, most orphans would be cared for by 
extended families and it is a concern that having multiple caregivers is a common reason for non-
adherence.[27, 32]  Better adherence is associated with the child’s caregiver being on ART or in 
HIV care him/herself, supporting family centered models of care.[32, 42]  Results with regard to 
socio-economic status are mixed.  Mukhtar-Yola et al.[25] found no association between social 
class and adherence, but all children were paying for ART so variation in social class may have 
been limited.  In addition, lack of money for clinic transport, medication and buying food was 
cited as a reason for non-adherence in this and other studies.[25, 31-32]  Not surprisingly, these 
were some of the few studies where at least some children included were required to pay for 
treatment.  The impact of caregiver education is inconclusive.[35, 42] 
 
Results regarding disclosure are also conflicting.  Bikaako-Kajura et al.[31] found that disclosure 
to the child was beneficial enabling children to share responsibility for their own adherence.  
These findings have not been supported by other studies from LMIC as well as high income 
countries; however the inclusion of qualitative interviews in the former study may have provided 
 54 
 
a better understanding of the impact of disclosure on adherence.[35, 47]  Caregiver disclosure to 
other adults is associated with better adherence.[35] 
 
As in developed countries, simply forgetting, child refusal of medication and interference with 
child’s sleep are common reasons for missing doses, while reminders and other adherence 
strategies facilitated adherence.[17, 21, 27, 29, 31-32, 41, 60]  
 
Medication related 
Adherence to lifelong therapy is challenging, particularly with multiple poorly palatable drugs.  
Poorer paediatric adherence with longer treatment duration has been shown in developed 
countries.[62]  Few studies from LMIC report on the influence of treatment duration with 
conflicting results, probably related to the duration on treatment of children included.  While 
Plipat et al.[41] found no change in adherence over a year, Nabukeera-Barungi et al.[35] found a 
non-significant trend to lower adherence in those on treatment for >2 years and long duration 
was a barrier to adherence for children in Cote d’Ivoire.[27]  As in developed countries, 
medication palatability was a reason for experiencing difficulty with giving medication in many 
LMIC studies.[37, 41, 46, 57] However, only Arrivé et al.[29] found a significant association 
between a particular drug and adherence.  Nevertheless, the finding of similar adherence to the 
poorly palatable LPV/r compared to NNRTI-based regimens by Muller et al.[36] is questionable 
as MEMS monitoring was not done on LPV/r but assumed to be the same as that for the 
nucleoside reverse transcriptase inhibitor (NRTI) monitored.  The overall high adherence rates 
reported by many studies may mask finding an effect of poor palatability.  For example, 
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Bunupuradah et al.[37] found 100% adherence despite caregivers expressing difficulties with 
giving medication due to its poor taste.  Almost all caregivers found it easier to give medication 
when a flavouring product was added, but the study could not show any increase in already 
perfect adherence.[37]  Complicated regimens were considered a barrier to treatment with the 
use of FDC drugs facilitating adherence.[26, 32] 
 
Health system related 
Given the enormous differences in health system constraints between developed and developing 
countries, there is a paucity of data on the impact of health system factors on adherence in both 
adult and paediatric studies.[60]  Drug stockouts were the most common reason for non-
adherence found by Arrivé et al.[29], with the cost of drugs and limited access to ART being 
cited as barriers by Mukhtar-Yola et al.[25]  Nabukeera-Barungi et al.[35] found no association 
between adherence and distance from clinic, but only children living within a 20km radius were 
included.  Fear of stigma was a major reason for non-disclosure by caregivers to children.[31]  
While the exploration of interventions is beyond the scope of this review, Myung et al.[40] 
ascribe the high adherence in their study to the DOT strategy employed. 
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7. SUMMARY, INTERPRETATION AND NEEDS FOR FUTURE RESEARCH 
This review shows that at the time of submitting our study for publication, there had been recent 
growth of LMIC paediatric ART adherence literature.  However, there remained a dearth of good 
quality long term dedicated adherence studies using multiple measures of adherence validated 
with viral load.  Studies of infants and young children taking PIs and syrups, were lacking.  As in 
developed countries, study comparability was limited by the range of different methods and 
thresholds used to assess and define adherence, as well as different populations studied in terms 
of age, socio-economic context, access to and duration on ART and regimens used.  While 
published studies indicated mostly good adherence from paediatric studies in LMIC, comparable 
with that of developed country settings, the use of predominantly self-report to measure 
adherence and the impact of a context of limited and or/early access to ART meant that these 
levels may not have reflected actual ART adherence in the long term as programmes scaled up.  
As access to viral load testing remained limited despite increasing access to paediatric ART, 
there was a need to develop practical low technology measures of adherence validated with viral 
response.  Good quality cohort studies to increase understanding of short term and long term 
adherence, patterns of change in adherence over time, as well as the factors underlying adherence 
during different phases of ART, were also needed.   
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PART B (ii) : POST-SCRIPT LITERATURE REVIEW 
 
1. INTRODUCTION 
In order to contextualize our research and ensure completeness of the literature review, studies 
published during and after the period of submission of our paper have been reviewed as a post 
script.  This includes all studies published between February 2008 and January 2010 identified 
using the same search strategy and eligibility criteria as the main literature review.  The search 
strategy yielded 124 articles of which 12 were eligible (including our own).  One of these studies 
was excluded as it is a re-analysis of a study previously reviewed.[1-2]  In addition, ongoing 
adherence research was carried out at Red Cross Children’s Hospital resulting in a Doctoral 
dissertation, which has been included.[3] 
 
2. NUMBER AND QUALITY OF STUDIES 
The number of studies published in 2008 and 2009 (Table 4) reflects both increasing access to 
ART and recognition of the importance of studying adherence in developing country settings.[4-
10]  It is encouraging that study quality appears to have improved and the range of children’s 
ages and regimens have widened.  Sample sizes are ≥90 in all but 2 studies [11-12] with 4 very 
large studies with sample sizes of up to 1500 children.[13-16]  Nine studies are dedicated 
adherence studies rather than reports of overall ART programme outcomes, with 4 of these 
including ≥6 months follow-up.  Six studies used a single measure of adherence, namely child or 
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CGSR to assess adherence, with 2 studies using >1 method but not reporting on these 
discreetly.[16-17]  In addition to our study where MR and CGSR was used to assess adherence, 
Vreeman et al.[13] supplemented CGSR with clinic attendance, while Michaels[3] used 4 
adherence measures: CGSR, MR, pharmacy refill and clinic attendance.  Nevertheless, only 3 
studies determined validity of adherence measure with viral response, indicating ongoing 
restricted access to this technology.[3, 18-19] 
 
3. RESULTS OF STUDIES REVIEWED 
3.1 Characteristics of children studied 
Most studies continue to include older children with the median/mean age ranging from 4.6 to 9 
years (Table 4).  Only the 2 studies from Red Cross Children’s Hospital focus on younger 
children with median/mean age at enrolment of 37 and 27 months respectively.[3, 18]  As 
expected, these are also the only studies where large proportions of children are on PI-based 
regimens and taking syrups.  Michaels[3] reports 81% of children taking liquid formulations of 
drugs.  
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Table 4: Characteristics of studies reviewed (February 2008 - January 2010) 
a) Studies from Africa 
Reference 
Year of 
publication 
Location & 
time 
Design 
Dedicated 
observational 
adherence 
study 
Sample 
size 
Median (IQR) duration in 
months on ART at time of 
enrolment 
Median (IQR) age in years at 
study enrolment 
Regimens used 
         
Davies[18] 2008 South Africa;  
2002 - 2004 
prospective cohort Yes 115 All enrolled at ART initiation 37 (16 - 61) months 2NRTI + RTV or EFV 
Michaels[3] 2008 South Africa; 
2004 - 2006 
prospective cohort Yes 135 All enrolled at ART initiation 27a months 2NRTI + EFV (33%) or NVP (14%) or                    
LPV/r (34%) or RTV (19%) 
Biadgilign[14] 2008 Ethiopia;    
2008 
cross-sectional Yes 390 24 (12 - 48)b 9 (1 - 14)b D4T + 3TC + NVP (30%); AZT + 3TC + NVP (27%) 
AZT + 3TC + EFV (27%); D4T + 3TC + EFV (16%) 
Vreeman[13] 2008 Kenya;  
2003 - 2007 
retrospective cohort Yes 1516 58% on ART < 1 year <1 yr: 2% 
1-2 yrs: 18% 
3-5 yrs: 29% 
6-8 yrs: 24% 
9-14 yrs: 27% 
2 NRTI + NNRTI 
Kiboneka[16] 2008 Uganda;  
2004 - 2006 
prospective cohort No 770 377 (173 - 624) days 9 (4 – 13) 2 NRTI + NNRTI (98%) 
Byakika-
Tusiime[11] 
2009 Uganda;  
2004 - 2008 
prospective cohort + 
cross sectional  
No 41 NR  NR NR  
Vreeman[15] 2009 Kenya; 
2007 - 2008 
retrospective cohort Yes 1490c NR  5a; 3.5d pre-election;                       
6a; 3.2d post election 
NR 
Wamalwa[19] 2009 Kenya; 
2004 - 2005 
Unblinded RCT Yes 90 All enrolled at ART initiation 4.7 (2.3 - 6.2) 2 NRTI + NNRTI 
Polisset[20] 2009 Togo; 
2006 
Cross-sectional Yes 74 10.5 (6.7 – 22.7) 6 (4 – 9) 2 NRTI + NNRTI (62%); 3 NRTI (32%);                   
2 NRTI + PI (6%) 
Ntanda[17] 2009 Uganda; 
2002 - 2008 
retrospective review 
of prospectively 
collected data 
No 101 All enrolled at ART initiation 6 (3 -10) 2 NRTI + NNRTI 
amean   NR: Not reported    yr: year  
brange   NRTI: nucleoside reverse transcriptase inhibitor  RCT: randomized controlled trial 
cnumber before election; 1408 after election NNRTI: non-nucleoside reverse transcriptase inhibitor   
dstandard deviation  PI: protease inhibitor   
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b) Studies from LMIC outside Africa 
Reference 
Year of 
publication 
Location & 
time 
Design 
Dedicated 
observational 
adherence 
study 
Sample 
size 
Median (IQR) duration in 
months on ART at time of 
enrolment 
Median (IQR) age in years at 
study enrolment 
Regimens used 
         
White[21] 2008 Jamaica; 
2005 
cross sectional Yes 63 18.3 (8.3 - 32.6) 7.9 (4.8 - 10.6) AZT + 3TC + NVP (81%) 
Costa[12] 2008 Brazil; 
2005 
cross-sectional Yes  54 NR 0.5 to 20b NR 
amean   NR: Not reported    yr: year  
brange   NRTI: nucleoside reverse transcriptase inhibitor  RCT: randomized controlled trial 
cnumber before election; 1408 after election NNRTI: non- nucleoside reverse transcriptase inhibitor  
dstandard deviation  PI: protease inhibitor      
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Table 5: Methods of measuring adherence and estimates of adherence (February 2008 - January 2010) 
a) Studies from Africa 
Reference 
Number of 
methods of 
adherence 
measurement 
Self report definition 
Self report 
percentage with 
adherence above 
threshold 
MR definition 
MR percentage 
with adherence 
above threshold 
Other definition 
Other 
percentage 
with 
adherence 
above 
threshold 
Correlation with clinical outcome 
 
Davies[18]  2 CGSR of no doses missed in 
previous 3 days 
86% ≥90% syrups/pills 
used 
79%   ≥90% MR adherence associated with VL <400 
copies/ml aOR: 5.5 (95%CI: 0.8 - 35.6);                                                                        
No association between CGSR adherence and  
VL <400 copies/ml 
No association between CGSR or MR adherence and 
immunologic  response                                                                         
Michaels[3]  4 CGSR of no doses missed in 
previous 3 days 
88%  Mean: 100-107% % on time 
pharmacy refills: 
% on time clinic 
visits: 
Mean: 85%           
 
Mean: 89% 
CGSR adherence correlated with VL <400 copies/ml; 
No/weak association between other adherence 
measures and VL <400 copies/ml 
Biadgilign[14]  1 CG SR of taking >95% doses 
correctly in previous 7 days 
87%     NR 
Vreeman[13]  2 Child or CGSR of taking all 
doses in previous 7 days 
71%   Never missing a 
clinic vist 
43% NR 
Kiboneka[16]  3 measures 
combined into 
single figure 
CGSR of >95% doses taken 
in previous month 
94% >95% pills used 94% >95% of 
pharmacy refills 
collected 
94% NR 
Byakika-
Tusiime[11]  
2 CGSR 100% >95% pills used 
in unannounced 
pill count 
36%   NR 
Vreeman[15]  1 CGSR of no doses missed in 
previous 7 days 
98% pre-election; 
95% after election 
    NR 
Wamalwa[19]  1 CGSR of no doses missed in 
previous 2 weeks 
85% (with diaries) 
92% (no diaries) 
    >95% adherence associated with higher proportion of 
virologic suppression after 3 months, but not after  
6 and 9 months of ART. 
Polisset[20]  1 CGSR of no doses missed in 
previous month 
42%     NR 
Ntanda[17]  2 measures 
combined into 
single figure 
CGSR of >95% of doses 
taken in previous 3 days 
93% >95% pills used 93%    
NR: Not reported VL: viral load       
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b) Studies from LMIC outside Africa 
Reference 
Number of 
methods of 
adherence 
measurement 
Self report definition 
Self report 
percentage with 
adherence above 
threshold 
MR definition 
MR percentage 
with adherence 
above threshold 
Other definition 
Other 
percentage 
with 
adherence 
above 
threshold 
Correlation with clinical outcome 
         
White[21]  1 Child or CGSR of no doses 
missed in previous 4 days 
86%     NR 
Costa[12]  1 Not mentioned 83%     NR 
NR: Not reported        
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3.2 Measurement of adherence 
Child or caregiver self-report 
Cut-offs to define good adherence were between 95 and 100% of doses taken, and adherence 
estimates using this method are at least as good as those in earlier studies (Table 5).  Barring 2 
studies, the proportion of children with good adherence is ≥85%.  Vreeman et al.[13] however 
reported a lower proportion of 71% while a worryingly low proportion of 46% was found in 
Togo.[20]  Notably this study measured adherence both in clinic attendees and using home visits 
for those that did not present at the clinic, and is thus similar to the study by Wachholz and 
Ferreira[22] which also reported low adherence.  The fact that drug stock-out was the reason for 
non-adherence for 43% of those missing doses in the Togo study nevertheless highlights the fact 
that adherence is critically dependant on a secure and reliable drug supply.[20] 
 
Medication return 
This was assessed in 5 studies, but is only reported independently of CGSR measurements in 3 
with estimates of 79% and 88 – 100% of children having adherence ≥90% and >95% 
respectively[11, 18], while mean adherence of 100 – 107% is reported at 1, 2 and 6 month 
intervals by Michaels[3]. 
 
Other methods 
Clinic attendance was assessed in 2 studies with very different results.  Michaels[3] found that 
90%, 79% and 70% of children in South Africa were on time for clinic visits at 1,2 and 6 months 
respectively, while Vreeman et al.[13] report that 57% of children missed at least one clinic visit, 
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although 76% of those missing a visit, missed less than 10% of their visits.  These results may be 
explained by the differences in follow-up duration, however, as follow-up was limited to 6 
months in the former study with a decline in adherence over time, while the latter study had a 
longer follow-up period and found the percentage of missed clinic visits increased dramatically 
after 6 months on ART.  This underpins the need to incorporate ongoing adherence assessment 
into ART programmes.  Pharmacy refill was only reported independently by one study with 
mean adherence of 85%.[3]  No further studies have used electronic monitoring or TDM to 
assess adherence reflecting the limited access to these technologies in resource-limited settings.  
 
3.3 Use of multiple measures and correlation with biological effect monitoring 
While we found that CGSR of missed doses was more common in those with <90% MR 
adherence, CGSR non-adherence was only 32% sensitive for MR non-adherence and showed no 
relation to viral response.[18]  In contrast, children with ≥90% adherence were 5.5 times more 
likely to have viral load <400 copies/ml compared to those with lower adherence after 
adjustment for disease severity.  Michaels[3] also found poor agreement between the 4 measures 
of adherence studied, except that for clinic visits and pharmacy refill, and found that CGSR was 
most closely correlated with viral suppression.  Differences between results from these 2 studies 
may be explained by the closer temporal relationship between CGSR and viral load 
measurement, different completeness of MR data and different treatment of MR adherence in 
excess of 100%, and the use of non-clinical staff to conduct CGSR interviews in the second 
study.  Although Vreeman et al.[13] used 2 methods to assess adherence, agreement between 
methods is not reported and viral load measurements were not available.  While White et al.[21] 
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only report on adherence by CGSR, they mention that better clinic attendance was associated 
with higher CGSR adherence.  Wamalwa et al.[19] found that >95% adherence by self report 
was associated with viral load suppression after 3 months, but not after 6 and 9 months of ART, 
but the numbers of children with viral load measurements for the later time points is very small. 
 
3.4 Factors influencing adherence 
Ten studies report on factors statistically associated with non-adherence while 8 identify 
facilitators and barriers to good adherence (Table 6). 
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Table 6: Factors influencing adherence (February 2008 - January 2010) 
a) Factors statistically associated with non-adherence 
 
Studies showing positive 
association with non-adherence 
Studies showing no association 
with non-adherence 
Caregiver/child related   
Female gender Polisset[20]  
Old age White[21] Davies[18] 
Orphanhood Vreeman[13] (double orphans only)  White[21], Ntanda[17] 
Non-disclosure or partial disclosure to child  Biadgiligin[14]a 
Non-institutionalized children White[21]  
More than one HIV-infected child Michaels[3]  
Poor caregiver education Davies[18]  
Not taking cotrimoxazole with ART Biadgilign[14]  
Receiving nutritional support Biadgilign[14]  
Child awareness of caregiver's health status Biadgilign[14]  
Poor socio-economic status Davies[18], Michaels[3]  
Longer caregiver hours worked White[21]  
Poor self-efficacy Costa[12]  
Poor caregiver knowledge of medication regimen  Davies[18] 
Caregiver depression Byakika-Tusiime[11], Michaels[3]  
Use of medication diaries  Wamalwa[19] 
Individual (vs compound) housing Polisset[20]  
   
Medication related   
Duration of treatment Vreeman[13], Michaels[3] Davies[18]a, Wamalwa[19] 
Receiving PI vs NNRTI-based ART Davies[18], Polisset[20]  
Nausea as a side effect White[21]  
Experiencing difficulty with giving medication  Davies[18], Polisset[20]  
≥ 6 pills/syrup spoons per day Polisset[20]  
   
Health system related   
Not paying a fee Biadgilign[14]  
Urban referral center Vreeman[13]  
Post-election conflict Vreeman[15]  
Counselling by clinician rather than counsellor Michaels[3]  
aNegative association   
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b) Facilitators of and barriers to good adherence 
Barriers/facilitators of adherence Supporting studies 
Caregiver related  
Barriers  
Child refusal / parent child conflict Polisset[20] 
Travelling White[21] 
Forgot Biadgilign[14], White[21], Polisset[20], Michaels[3] 
Delay in renewing script / missed clinic visit Biadgilign[14], White[21] 
Lack of money for transport to clinic, buying medication or buying food Biadgilign[14], Ntanda[17] 
Child asleep Biadgilign[14] 
Depression Biadgilign[14] 
Change in schedule White[21], Davies[18], Michaels[3] 
  
Facilitators  
Use of reminders Davies[18], Michaels[3] 
CG adherence strategies Davies[18] 
Seeing improved health of child Byakika-Tusiime[11] 
  
Medication related  
Barriers  
Bad taste Davies[18], Michaels[3] 
Vomiting medication Polisset[20] 
  
Health system related  
Barriers  
Drug stockout Polisset[20] 
Stigma Ntanda[17] 
Cost of drugs / limited access to ART Ntanda[17] 
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Caregiver and child related factors 
Effects of loss of one or both biological parents, socio-economic status and disclosure were 
examined by a number of studies.  While Vreeman et al.[13] found that children who had lost 
both parents had worse adherence than those with one or both parents alive, other studies 
concurred with earlier literature finding no impact of orphanhood on adherence.[17, 21]  
Vreeman et al.[13] however, are the only researchers to consider whether children had lost one 
or both parents.  Like Waccholz and Ferreira[22], White et al.[21] found children in institutions 
to have better adherence than those in family care settings.  Both studies in Cape Town found 
better socio-economic status to be associated with adherence[3, 18], with lack of money for 
transport and medication being identified as barriers in other studies.[14, 17] 
 
In contrast to the findings by Bikaako-Kajura et al.[23], non-disclosure to children and children’s 
lack of awareness of the caregiver’s illness were actually found to be associated with better 
adherence.[14]  The latter study unsurprisingly found that adherence to non-ART medication 
was associated with adherence to ART, however the authors are unable to explain the 
unexpected association between receiving nutritional support and poor adherence.[14]  It is 
however plausible that receiving nutritional support is a surrogate marker of lower socio-
economic status. 
 
Caregiver depression was associated with poor caregiver and child adherence.[3, 11]  This is 
well described in adult studies.[24]  The range of associations found with other caregiver and 
child factors such as better adherence for those living in compounds compared to those with 
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individual housing[20], variable relationships between child age and adherence[18, 21] and 
worse adherence with longer caregiver hours worked[21] highlight the need to explore context-
specific factors influencing adherence.  However, as in earlier studies, changes in schedule, 
simply forgetting and child refusal remain important barriers to adherence in all contexts 
including high income settings.[3, 6, 14, 18, 20-21] 
 
Most caregivers continue to find use of reminders and other strategies to aid adherence 
helpful.[3, 18]  Notwithstanding, Wamalwa et al.[19] specifically found that use of medication 
diaries had no impact on adherence and argue that availability of specific adherence enhancing 
interventions should not be seen as a prerequisite for successful ART.  
 
Medication related factors 
Unlike Muller et al.[2] who found no adverse effect of PI-based therapy on adherence, both our 
study[18] and that of Polisset et al.[20] found that receiving PI-based therapy was associated 
with worse adherence.  This appeared to be related to experiencing difficulty with giving 
medication, and bad taste, vomiting and difficulty with administering large numbers of pills or 
syrup spoons were the most commonly experienced problems with PI drugs.[3, 18, 20] 
 
The effect of increasing treatment duration yielded conflicting results.  Wamalwa et al.[19] 
concurred with our finding of increasing adherence over time, while others have found the 
opposite.[3, 13, 18] 
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Health system related factors 
The low adherence ascribed to drug stock-outs in Togo highlights the importance of health 
system factors in adherence.[20]  Cost of drugs continues to be reported as a barrier to 
adherence, however Biadgilign et al.[14] found that those not paying a fee for their medication 
were more likely to be non-adherent and postulate that fee paying leads to caregivers placing 
greater value on their children’s health.  It is also plausible, however, that ability to pay a fee is a 
proxy for better socio-economic status, which has been shown to be associated with good 
adherence.[3, 18]  Indeed the cost of drugs and limited access to ART were identified as barriers 
to adherence by Ntanda et al.[17]  Vreeman et al.[13] found that children treated at urban referral 
centers were more likely to be non-adherent with clinic visits, demonstrating the impact of lack 
of access to nearby services on adherence.  In a unique study by the same authors, adherence was 
shown to decrease during the conflict precipitated by the Kenyan presidential elections in 
December 2007.[15]  Although adherence was high both before and after the conflict period 
(98% and 95% of children taking all doses respectively), the study demonstrates that adherence 
can be influenced by factors beyond the health system itself.  Nevertheless, the fact that 
adherence was as high as 95% during the conflict period, and that adult studies have shown 
adherence to be maintained despite conflict, supports provision of ART despite political 
instability.[4, 25] 
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 4. OTHER PAEDIATRIC ADHERENCE RESEARCH 
 
 
Although the following studies did not strictly meet the criteria for inclusion in the post script 
literature review, their findings are pertinent to a consideration of paediatric ART adherence in 
LMIC.  Muller et al.[1] performed a secondary analysis, and found that despite similar 
proportions of children with adherence >80% by MEMS monitoring on LPV/r-based and 
NNRTI-based regimes, a much higher proportion of children in the LPV/r group (77% vs 33%; 
p=0.002) achieved viral suppression.  This concurs with adult studies that indicate that boosted 
PI regimens are more forgiving of non-adherence and high rates of viral suppression can be 
achieved with adherence as low as 80%.[26-27]  While this should not lead to complacency with 
regard to adherence support, it indicates that better drugs, as well as better adherence, are the 
means to achieve optimal ART results. 
 
 
 
A secondary analysis of a placebo-controlled trial of cotrimoxazole in the pre-ART era found 
that children with better adherence experienced lower mortality even if they were taking 
placebo.[28]  It is postulated that good adherence is a proxy for better overall caregiving and the 
mortality benefit of adherence to placebo is ascribed to a “healthy caregiver” effect.[28]  In 
terms of studies of adherence to ART, the validity of measures of adherence that demonstrate 
only small magnitude associations with clinical, viral load or CD4 response may be questionable, 
as small differences in biological effect may be due to better general caregiving by adherent 
caregivers rather than actual differences in drug exposure.  
 
 
Finally, while qualitative studies were specifically excluded from this review, the Kenyan 
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investigation of factors influencing paediatric adherence through in-depth individual interviews 
and focus groups is worth mentioning for two reasons.[29]  Firstly, while adherence was not 
actually measured in the study, admissions of non-adherence were frequent and indicate the 
likely over-estimation by routine clinic-based measures.[29]  Secondly, an ecological model of 
paediatric ART adherence is postulated which highlights the interplay of child, caregiver, 
medication, health system and broader societal factors in influencing adherence.[29] 
 
 
5. SUMMARY, INTERPRETATION AND NEEDS FOR FUTURE RESEARCH 
 
The growing literature on paediatric ART adherence has paralleled the massively increased 
access to paediatric ART in LMIC in recent years,[30] with adherence estimates remaining 
reassuringly high.  Nonetheless most studies in the current literature, even after consideration of 
those articles published recently, were conducted early on in scale-up programmes and may not 
reflect adherence as access expands, individual programmes treat increasing numbers of children 
and duration on treatment increases.  We still lack an affordable, low technology, simple and 
practical tool with which to assess adherence on an ongoing basis.  This is important as in busy 
programmes where most children are adherent, it may only be feasible to offer additional 
adherence support to those at high risk of non-adherence.  Many CGSR questionnaires are time-
consuming to administer in routine care.  Further research is therefore needed to identify the key 
questions most sensitive for non-adherence as determined by “gold standards” such as electronic 
monitoring or viral response.  The utility of a once-off MR adherence assessment as a second test 
to increase specificity in those identified as potentially non-adherent by CGSR should also be 
examined.  Nevertheless, existing research suggests that even if refined, such tools will lack both 
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sensitivity and specificity, and the role of viral load monitoring should therefore be explored.[3,
18-19, 31]  In this respect, a Thai adult study found that 30% of patients had an initial low 
detectable viral load when this technology became available within an existing ART 
programme.[32]  In 92% of those patients, a reason for incomplete viral suppression could be 
identified and was usually associated with poor adherence.[32]  With counseling, viral load 
became undetectable in 88% of patients and many resolved longstanding psychosocial 
problems.[32]  The study demonstrates the potential utility of a simple blood test to identify 
patients in need of more intensive counseling and support, and the importance of increasing 
access to viral load testing. 
 
 
There are still only a handful of studies of adherence in infants and young children taking syrups 
or PI-based therapy.  While PI-based therapy may require less fastidious adherence, there is still 
a need to examine adherence in this population particularly as revised 2008 WHO guidelines 
promote initiation of ART in all infants irrespective of clinical or immune status, and PI-based 
therapy is optimal in children previously exposed to prevention of mother to child transmission 
(PMTCT) regimens.[33-34]  Initiation and maintenance of adherence to potentially life-long 
therapy in an asymptomatic infant may pose unique challenges.  
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Abstract
Background: Antiretroviral therapy (ART) dramatically improves outcomes for children in Africa;
however excellent adherence is required for treatment success. This study describes the utility of different
measures of adherence in detecting lapses in infants and young children in Cape Town, South Africa.
Methods: In a prospective cohort of 122 HIV-infected children commenced on ART, adherence was
measured monthly during the first year of treatment by medication return (MR) for both syrups and
tablets/capsules. A questionnaire was administered to caregivers after 3 months of treatment to assess
experience with giving medication and self-reported adherence. Viral and immune response to treatment
were assessed at the end of one year and associations with measured adherence determined.
Results: Medication was returned for 115/122 (94%) children with median age (IQR) of 37 (16 – 61)
months. Ninety-one (79%) children achieved annual average MR adherence ≥ 90%. This was an important
covariate associated with viral suppression after adjustment for disease severity (OR = 5.5 [95%CI: 0.8–
35.6], p = 0.075), however was not associated with immunological response to ART. By 3 months on ART,
13 (10%) children had deceased and 11 (10%) were lost to follow-up. Questionnaires were completed by
87/98 (90%) of caregivers of those who remained in care. Sensitivity of poor reported adherence (missing
≥ 1 dose in the previous 3 days) for MR adherence <90% was only 31.8% (95% CI: 10.7% – 53.0%).
Caregivers of 33/87 (38.4%) children reported difficulties with giving medication, most commonly poor
palatability (21.8%). Independent socio-demographic predictors of MR adherence ≥ 90% were secondary
education of caregivers (OR = 4.49; 95%CI: 1.10 – 18.24) and access to water and electricity (OR = 2.65;
95%CI: 0.93 – 7.55). Taking ritonavir was negatively associated with MR adherence ≥ 90% (OR = 0.37;
95%CI: 0.13 – 1.02).
Conclusion: Excellent adherence to ART is possible in African infants and young children and the
relatively simple low technology measure of adherence by MR strongly predicts viral response. Better
socio-economic status and more palatable regimens are associated with better adherence.
Published: 4 September 2008
BMC Pediatrics 2008, 8:34 doi:10.1186/1471-2431-8-34
Received: 6 February 2008
Accepted: 4 September 2008
This article is available from: http://www.biomedcentral.com/1471-2431/8/34
© 2008 Davies et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
BMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34Background
Approximately 85% of the 2.3 million HIV-infected chil-
dren under 15 years worldwide live in sub-Saharan
Africa.[1] While antiretroviral therapy (ART) of children
in Africa has resulted in dramatically improved survival,
clinical, immunological and virological status, less than
15% of children needing ART on the continent currently
receive it. [2-11] Excellent adherence is one of the most
important factors in determining treatment success and
preventing viral resistance, and the need for near-perfect
adherence to lifelong therapy from an early age has been
identified as a major challenge in the administration of
ART to HIV-infected children.[10,12-15] There is concern
about the extent to which this is achievable for children in
resource-limited settings, particularly in the context of the
rapid scale-up of pediatric treatment programs required to
address the HIV burden on children in Africa.[14,16]
Research from rich countries suggests that adherence may
be more complex in children compared to adults due to
many factors including reliance on caregivers who may
themselves be ill or may not be the child's parent, com-
plex dosing regimens, lack of availability of pediatric
fixed-dose combinations, poor drug palatability, difficulty
with taking tablets/capsules and interference with daily
routines. [13,17-23] Adherence estimates of 50 to 75%
have been reported, well below the required 90 to 95% to
achieve optimal viral suppression.[12,13,17-23]
While African adult studies show that good adherence to
ART is possible despite poor social circumstances, there
are limited studies in African children.[16,24-27] Health
service challenges as well as individual factors such as
poor socio-economic circumstances, poor literacy and the
prohibitive cost of liquid drug formulations necessitating
tablet/capsule administration to very young children are
additional potential barriers to adherence in African chil-
dren.[10,15] In Kampala, Uganda, 72% of children aged
2–18 years had adherence ≥ 95% measured with home-
based unannounced pill counts, compared to 89% using
3-day self-reported adherence and 94% using clinic-based
pill counts.[28] Muller et al. similarly found discrepant
results using different measures of adherence in young
children (median age 38 months) in South Africa.[29]
Using electronic means (Medication Event Monitoring
System (MEMS)) to monitor adherence, only 36% of
patients achieved ≥ 95% adherence, in comparison to
91% of caregivers reporting excellent adherence on a vis-
ual analogue scale.[29] The only other published adher-
ence studies of African children include only older
children and measure self-reported adherence only, with
varying results. In Côte d'Ivoire and Uganda, approxi-
mately one third of caregiver-child pairs reported missing
doses and in South Africa, Reddi et al. describe 10% of
children missing ≥ 3 doses during the previous
month.[6,30,31] African studies thus concur with interna-
tional literature that more objective measures of adher-
ence (e.g. unannounced pill counts and MEMS) tend to be
more sensitive to lapses in adherence.[21,32] However,
such measures are not feasible in resource-limited settings
with large-scale programs, and there is a need to deter-
mine the utility of simpler measures of adherence such as
clinic-based pill-counts and self-report in predicting viro-
logical response in the African context. Furthermore, all
published African studies have been conducted over short
periods (≤ 3 months), mostly in older chidren, and may
not reflect longer term adherence patterns in very young
children.
We therefore aimed to measure the level of adherence to
ART in infants and young children during the first year of
treatment using both medication returned as measured at
the clinic and caregiver self-report, to assess the extent to
which such measured adherence predicts viral and immu-
nological outcomes and to identify factors associated with
good adherence.
Methods
Study design, setting and population
This was a prospective cohort study. All HIV infected chil-
dren commenced on antiretroviral triple therapy between
July 2002 and January 2004 (n = 122) as part of the ART
program of the Red Cross Children's Hospital, a tertiary
care institution in Cape Town, South Africa, were eligible
and agreed to participate in the study. The ART program at
the hospital began prior to the official national govern-
ment ART program and was donor funded during this
time. Selection criteria for commencement of ART have
been described elsewhere.[2] Briefly, clinical and immu-
nological criteria as recommended by the 2001 European
treatment guidelines were followed.[33] In addition, the
following limited social criteria needed to be met: having
an identifiable caregiver to administer medication and
attend clinic appointments; resident in Cape Town for at
least 3 months; caregiver compliance with last 3 clinic
appointments and caregiver willingness to comply with
ongoing regular clinic attendance and monitoring. The
majority of children were commenced on stavudine
(d4T), lamivudine (3TC) and efavirenz (EFV – children
>10 kg or >3 years) or ritonavir (RTV – children <10 kg or
<3 years) as no other protease inhibitor was readily avail-
able in suitable formulation and dosage in South Africa at
the time. Children were followed up with monthly clini-
cal visits for the first year. Viral load, CD4 cell count and
percentage were determined using standard laboratory
methods at commencement of ART and after 1 year of
treatment. The definition of undetectable viral load was
<400 copies/ml. The study was approved by the Univer-
sity of Cape Town Research Ethics Committee [Ref: 261/Page 2 of 12
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for their and their children's participation.
Measurements of adherence and associated factors
Clinical and socio-demographic characteristics at com-
mencement of ART were determined by the clinician treat-
ing each child and recorded on standardized data
collection forms. Children were retrospectively re-staged
according to medical record information using the WHO
4-stage clinical classification for the purpose of this anal-
ysis.[15] Weight-for-age, height-for-age and weight-for-
height z-scores were calculated with EpiInfo 2000, version
1.0 (Division of Surveillance and Epidemiology, CDC,
Atlanta, Georgia).
Measurement of adherence by medication return (MR)
At every monthly visit for one year, caregivers were
requested to return all empty medicine containers and
unused medication. A dedicated program pharmacist
measured the amount of unused medication volumetri-
cally for syrups/solutions and by pill count for tablets/
capsules. The percentage adherence for each antiretroviral
medication was calculated by dividing actual use (deter-
mined from returned containers and unused medication)
by expected use (determined from the previous month's
script).
A composite measure of annual average percentage adher-
ence by MR was calculated by determining the arithmetic
mean of the percentage adherence for each drug at each
monthly visit. For caregiver-child pairs who did not return
medication at every visit as requested, the annual average
percentage adherence was calculated using the number of
months for which medication was actually returned as the
denominator when determining the arithmetic mean (per
protocol analysis). Sensitivity analysis was additionally
performed assigning adherence <90% for months in
which medication was not returned and recalculating
annual average percentage adherence for children with
missing medication returns. A small amount of extra med-
ication (in excess of what was prescribed) was issued at
each visit so that patients would not be without medica-
tion if drugs were spilled or additional doses required due
to vomiting or spitting out. For a number of medication
returns, therefore, more drug was used than prescribed
(i.e. adherence >100%) so adherence was capped at 100%
per return when calculating annual average adherence. An
uncapped annual average MR adherence was also calcu-
lated for some of the analyses.
Measurement of adherence by questionnaire
A standardized interview was administered by the treating
clinician to each caregiver after the child had completed 3
months of ART. The interview script was based on Pediat-
ric Aids Clinical Trials Group (PACTG) adherence ques-
tionnaires modules 1 and 2 and assessed caregiver's
ability to accurately describe the ART regimen, recall of
missed doses in the past 3 days, difficulties experienced
with giving medication and beliefs about ART.[34,35]
Based on reported missed doses, children were classified
as not fully adherent (NFA) if ≥ 1 dose was missed in the
previous 3 days. Interpreters were used so that interviews
were conducted in the language of the caregiver's choice.
Analysis
All statistical analysis was done using Stata (version 10)
(Stata Corporation, College Station, Texas, USA). The
effects of low annual average (capped) MR adherence,
average (capped) MR adherence in the month immedi-
ately preceding viral load measurement and reported NFA
on viral load suppression and immunological response
were determined using logistic regression models
adjusted for other determinants of outcome. MR adher-
ence was dichotomized as ≥ 90% or <90% as this thresh-
old explained the largest amount of variability in the
outcome. Univariate and multivariate analysis of the asso-
ciation between demographic, social and clinical factors
as well as experiencing problems with giving medication
and annual average MR adherence ≥ 90% were examined
using Wilcoxon rank sum (Mann-Whitney), Student's t-
test, chi2 or Fisher's exact tests and logistic regression mod-
els as indicated. Agreement between MR adherence <90%
and caregiver reported NFA was calculated using the
kappa statistic.
All multivariate models were built by sequentially adding
the next most significant predictor variable from the uni-
variate analysis, and variables with a p-value <0.1 after
adjustment for those already included in the model, or
that changed the OR for variables included in the model
by more than 10%, were retained. Since variables reflect-
ing severity of illness (WHO stage, weight-for-height z-
score, CD4 percent and absolute count and log viral load)
were highly correlated with one another, only the single
most predictive variable, i.e. weight-for-height z-score,
was included in the multivariate models for virological
and immunological outcome. Similarly, only one meas-
ure of socio-economic status (formal housing, access to
water and electricity, access to a refrigerator and employ-
ment) was used at a time in each model, i.e. access to
water and electricity. Only socio-demographic factors and
regimen were included in building the multivariate model
of MR adherence ≥ 90% as the sample size did not allow
for inclusion of clinical factors as well. P-values for all sta-
tistical analyses are reported exactly with no particular cut-
off used to define significance.[36]
At the time that the study was designed, few data on pae-
diatric adherence from resource-constrained countries
were available on which to base sample size calculations.Page 3 of 12
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ART program necessitated ending of the study as the gov-
ernment program did not fund adherence monitoring. By
this stage the accumulated sample size was sufficient to
detect a 50% reduction in proportion with viral suppres-
sion in those with MR adherence <90% with 90% power,
assuming that 75% of children had MR adherence ≥ 90%.
Results
Medication was returned on at least one occasion for 115/
122 (94%) children who commenced ART with the
remaining children deceased (n = 6) or lost to follow-up
(n = 1) before their first follow-up visit (figure 1). After 1
year, 88 children were alive and remained in care on ART.
Table 1 shows the demographic and clinical characteris-
tics and ART drugs prescribed at baseline. Children were
young with a median age (IQR) of 37 (16 – 61) months.
Although overall socio-economic status was poor with
high levels of caregiver unemployment (73%) and infor-
mal housing (49%), most caregivers (88%) had at least
secondary education and the majority of children (80%)
were from households with access to water and electricity.
Annual average MR adherence
A total of 91/115 (79%) children achieved annual average
MR adherence ≥ 90% with 73% of these having adherence
≥ 95% (figure 2). Only 9 (8%) children had average
adherence for the full year below 80%. These percentages
did not change substantially if adherence <90% was
assigned for missing returns in children not returning
medication on all possible occasions. The number of chil-
dren remaining in care at each month and the proportion
returning medication as requested is shown in figure 3.
There was no change in the proportion of children return-
ing medication over time (p = 0.17). Among only those
children who remained alive and in care for the entire first
year of treatment (excluding those deceased and LFU; n =
88), the proportion with adherence <90% decreased over
time with an OR for having low adherence of 0.91 (95%
CI: 0.87 – 0.96; p = 0.000) for each additional month (fig-
ure 4). Annual average MR adherence <90% was more
likely among the 34/115 (30%) child-caregiver pairs who
failed to return empty medication containers/unused
medication at more than one follow-up visit (OR = 4.97;
95% CI:1.92 – 12.87; p = 0.001).
Relationship between MR adherence and viral/
immunological outcomes
Undetectable viral load was achieved in 62/80 (78%) chil-
dren with annual average MR adherence ≥ 90% compared
to 2/8 (25%) of children with lower adherence (OR =
10.3; 95% CI: 1.92 – 55.7; p = 0.005). In univariate anal-
ysis, other factors significantly associated with viral sup-
pression were less wasting as reflected in higher weight-
for-height z-score, less severe disease (WHO stage 2 or 3 vs
WHO stage 4) and being on a non-ritonavir containing
regimen (Table 2). Since nutritional status is an important
determinant of WHO stage, only weight-for-height z-score
and regimen were included in building an adjusted logis-
tic regression model for the relationship between adher-
ence and viral suppression. After adjustment for wasting,
regimen was no longer associated with viral load out-
come, however adherence ≥ 90% remained an important
covariate associated with viral suppression (Adjusted OR
= 5.5 [95%CI: 0.8–35.6], p = 0.075). Sensitivity analysis
was performed by recalculating average annual adherence
for caregiver-child pairs who did not return medication
for one or more months by assigning adherence <90% for
months in which medication was not returned, and there
remained a significant univariate association between MR
adherence ≥ 90% and undetectable viral load, and a
strong trend towards an association after adjustment for
baseline weight-for-height z-score. There was no associa-
tion between MR adherence in the month or 2 months
preceding viral load measurement and viral suppression
in either univariate analysis or after adjustment for base-
line weight-for-height z-score. Similarly no association
was found between the proportion of visits in which car-
egivers failed to return medication and viral suppression
in either univariate or adjusted analyses.
The median (IQR) changes in CD4 percent and absolute
count were 10.1% (5.7% – 15.2%) and 393 cells/μl (113
– 654) respectively. There was no association between
annual average MR adherence ≥ 90% and either CD4 per-
cent at 1 year, or change from baseline CD4 percent or
absolute count over 1 year in either univariate analysis or
models adjusted for other determinants of immunologi-
cal response.
Excess MR Adherence
Using the uncapped annual average MR adherence, 47/
115 (40.9%) of children had adherence >100%. This was
more common among children taking ritonavir (30/50
[60%]) compared to those on efavirenz (17/65 [26%]; p
= 0.000). Adherence >100% was also more common in
those 2 years of age or less (28/37 [75.7%]) compared to
older children (19/78 [24.4%]; p = 0.000). This age-
related difference in excess adherence was maintained
after stratifying for ritonavir-based regimen (p = 0.02 and
0.05 for those with ritonavir-based and efavirenz-based
regimens respectively).
Questionnaire responses
Of 98 children alive and in care after 3 months of ART, 87
(90%) completed adherence questionnaires (figure 1).
Annual average MR adherence ≥ 90% was more common
in those who completed questionnaires (59/87 [68%] vs
4/11 [36%]; p = 0.051).Page 4 of 12
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Table 1: Social, demographic and clinical characteristics at start of ART according to annual average MR adherence.
Variable All children (n = 122) Adherence ≥ 90% (n = 91) 
(79%)
Adherence<90% (n = 24) 
(21%)
p-value
Median age (months) (IQR) 37 (16 – 61) 37 (16 – 57) 49 (20 – 72) 0.49*
Gender
Female (%) 52 (43) 39 (43) 12 (50) 0.53†
WHO stage
4 (%) 54 (44) 34 (37) 14 (58%) 0.06†
Mean weight-for-age z-score (sd) -2.02 (1.54) -1.82 (1.55) -2.41 (1.37) 0.09‡
Mean height-for-age z-score (sd) -2.71 (1.36) -2.66 (1.36) -2.74 (1.33) 0.78‡
Mean weight-for-height z-score 
(sd)
-0.56 (1.44) -0.31 (1.34) -1.08 (1.42) 0.02‡
Median CD4 percent (IQR) 11.1 (6.9 – 15.0) 11.4 (8.0 – 15.1) 10.1 (4.2 – 14.3) 0.18*
Median CD4 count (IQR) 556 (242 – 908) 592 (273 – 938) 518 (105 – 758) 0.23*
Median Log Viral load (IQR) 5.57 (5.15 – 6.08) 5.44 (5.11 – 6.08) 5.77 (5.30 – 6.06) 0.55*
Primary caregiver
Mother (%) 107 (88) 79 (87) 21 (88) 0.72§
Not mother (%) 12 (10) 9 (10) 3 (13)
Unknown (%) 3 (2) 3 (3) 0 (0)
Median age of caregiver (IQR) 29 (26 – 32) 30 (26 – 32) 28 (25 – 35) 0.58*
Father provides financial support
Yes (%) 48 (39) 37 (41) 9 (38) 0.8†
No (%) 70 (57) 51 (56) 14 (58)
Unknown (%) 4 (3) 3 (3) 1 (4)
Caregiver has secondary education
Yes (%) 107 (88) 83 (91) 18 (75) 0.03†
No (%) 11 (9) 6 (7) 5 (21)
Unknown (%) 4 (3) 2 (2) 1 (4)
Caregiver employed
Yes (%) 27 (22) 23 (25) 4 (17) 0.37†
No (%) 89 (73) 64 (70) 19 (79)
Unknown (%) 6 (5) 4 (4) 1 (4)
Caregiver/child receives social 
grant
Yes (%) 69 (57) 55 (60) 11 (46) 0.16†
No (%) 51 (42) 34 (37) 13 (54)
Unknown (%) 2 (2) 2 (2) 0 (0)
Formal housing
Yes (%) 62 (51) 50 (55) 8 (33) 0.06†
No (%) 60 (49) 41 (45) 16 (67)
Access to water and electricity
Yes (%) 97 (80) 76 (84) 15 (63) 0.024†
No (%) 25 (20) 15 (16) 9 (38)
Access to working refrigerator
Yes (%) 85 (70) 66 (73) 12 (50) 0.036†
No (%) 37 (30) 15 (16) 12 (50)
Medication
d4T (%) 110 (90) 81 (89) 22 (92) 1.00*
AZT (%) 11 (9) 8 (9) 3 (13) 0.70*
3TC (%) 117 (96) 88 (97) 22 (92) 0.28*
ddI (%) 4 (3) 3 (3) 1 (4) 1.00*
Efavirenz (%) 67(55) 55 (60) 10 (42) 0.08†
Ritonavir (%) 55 (45) 36 (40) 14 (58) 0.10†
*Wilcoxon rank sum test
‡Student's t-test
†Chi2 test
§Fisher's exact test
BMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34Reported missed doses
NFA (missing ≥ 1 dose in the previous 3 days) was present
in 12/87 (13.8%) children, and was more common in
those whose MR adherence for that month was <90% (7/
22 [31.8%]) vs 5/62 [8.1%]; p = 0.006). Nevertheless, the
sensitivity of NFA for poor MR adherence in the preceding
month was only 31.8% (95% CI: 10.7% – 53.0%) and
agreement between the two measures was only slightly
better than that expected by chance (κ = 0.278; p = 0.003).
There was no association between NFA and viral response
at 1 year (p = 0.965). Although 38/87 (43.7%) of caregiv-
ers were unable to describe how to give their child's ART
regimen exactly, this was not associated with either NFA
or MR adherence <90% (p = 0.88 and p = 0.68 respec-
tively).
Experience with giving medication
A notable number of caregivers (33/87 [38.4%]) experi-
enced problems with giving ART medication. Poor palata-
bility of medication was the most common problem
(21.8% of caregivers), with 68% of these being attributed
to ritonavir. Change in daily routine was a problem for
12.6% of caregivers. Experiencing problems with giving
medication did not affect reported (OR = 2.13; 95%CI:
0.59 – 7.65; p = 0.32) or MR adherence (OR = 0.61;
95%CI: 0.22 – 1.65; p = 0.32) in the month in which
problems were reported, but was associated with annual
average MR adherence <90% (OR = 3.07; 95% CI: 0.91 –
10.38; p = 0.06).
Most (65/87 [74.7%]) caregivers used at least one method
to assist with remembering and giving medication. The
most commonly used aids were activities of daily living
reminders (35 [40%]) and treatment partners (23 [26%]).
While the vast majority of caregivers (81 [93%]) believed
that ART medication was improving their child's health, a
significant number (24 [28%]) were unsure or believed
that their children would not deteriorate if ART was
Profile of studyFigure 1
Profile of study.
Children commenced on ART 
(n = 122)
No medication returns for 7 children 
because deceased (n=6) or lost to 
follow-up (n=1) within first month of 
ART. 
Medication returned on at least one 
occasion for 115 children
Median (IQR) occasions of MR: 12 (9 – 12)*
Adherence questionnaires after 
3 months of ART completed by 87/98 
caregiver-child pairs alive and in care at 
3 months.
Reasons for not completing questionnaire:
Deceased or not in care: 24/122 (20%)
(13 deceased; 11 lost to follow-up)
No reason given: 10/98 (10%)
Child in institution: 1/98 (1%)
Viral load and CD4 count determined for all 88/122 (72%) 
children alive and in-care after 1 year of ART
Deceased: 19 (16%)
Lost to follow-up: 12 (10%)
Treatment stopped because of poor adherence: 2 (2%)
Transferred to another facility: 1 (1%)
*Medication was returned on all possible occasions for 50% of childrenPage 6 of 12
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any measure.
Determinants of annual average MR adherence ≥ 90%
Socio-demographic variables most strongly associated
with annual average MR adherence ≥ 90% on univariate
analysis were caregivers having secondary education and
household access to water and electricity as well as a
refrigerator (tables 1 and 3). Having secondary education
was not significantly associated with any of the indicators
of socio-economic status. Being on an efavirenz-based
regimen was less strongly associated with good adherence.
Secondary education of the caregiver and household
access to water and electricity were both independent
socio-demographic predictors of annual MR adherence ≥
90%, while taking ritonavir was negatively associated with
MR adherence ≥ 90%.
Discussion
This study extends to infants and young children the find-
ing that good adherence to ART in Africa is achievable
with nearly 80% of children obtaining average MR adher-
ence ≥ 90% over the first year of ART. [16,25,26,28] This
is at least as good as pediatric adherence in rich coun-
tries.[13,17-22] This excellent adherence occurred despite
nearly 40% of caregivers experiencing subjective difficulty
with administering medication. Secondary education,
access to water and electricity and a non-ritonavir based
regimen were all independently associated with better
adherence. This study demonstrates that although clinic-
based medication measures may not be as sensitive as
unannounced home-based measures or MEMS monitor-
ing to detect poor adherence, they are still strongly predic-
tive of virologic response. Annual average MR adherence
≥ 90% was associated with a greater than 5 fold increased
likelihood of suppressing viral load at the end of the year.
The excellent adherence seen in our study may, however,
not be representative of current pediatric adherence in
Africa as ART is scaled up. These were the first children to
receive ART at our tertiary care institution and many were
well-known to the HIV service as adherent with other
medications and clinic visits. In addition, the social crite-
ria used to determine ART eligibility may have further
selected those patients more likely to be adherent. Fur-
thermore, treatment was donor-funded in the context of
Annual average MR adherence (n = 115)Figure 2
Annual average MR adherence (n = 115).
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caregivers may have felt that ART was a privilege. Moreo-
ver, regular adherence monitoring may have enhanced
adherence. While the halving of the proportion of chil-
dren with MR adherence <90% during the year supports
this, it is a problem inherent to all adherence studies. In
addition, the actual estimate of adherence may be inflated
by use of clinic-based medication measures. The finding
by Muller et al.[29] of much lower adherence using MEMS
caps in a recent post-national ART roll-out study in a sim-
ilar setting to ours supports the likelihood of both partic-
ularly good adherence in our cohort, and of adherence
being over-estimated by our method of measurement.
Nevertheless, the strong association with viral suppres-
sion in our study indicates at least reasonable accuracy of
adherence measurement.
In contrast, reported NFA showed no relationship to viral
outcome and was only 32% sensitive for MR adherence
<90%. While the failure to find an association with viral
suppression may well be due to the fact that reported
adherence was only measured once long before viral load
measurement, the tendency for caregivers and patients to
over-estimate adherence is well estab-
lished.[15,23,28,29,32] In our study, this may have been
exacerbated by interviews being conducted by clinicians
to whom caregivers might be reluctant to admit to missing
doses, particularly in the context of limited access to ART.
This, however, reflects clinical practice.[15], and any
attempts to develop a screening tool for poor adherence in
busy roll-out clinics must take into account under-report-
ing of non-adherence to clinicians. In this study, the addi-
tional measuring of adherence by medication return
should have, at least in part, mitigated against under-
reporting.
Interestingly we found no association between MR adher-
ence in the month or 2 months immediately prior to viral
load measurement, in contrast to the strong association
with average MR adherence over the whole year. Other
studies have found strong associations between short-
term adherence and viral suppression immediately there-
after. [12,29] Having a single viral load measurement only
after a full year on treatment made it impossible to exam-
ine the effect of short-term fluctuations in adherence on
viral outcome. The small sample in this study may also
have reduced its power to show such an association par-
ticularly as a far smaller number of children than expected
had poor adherence. In addition, the sample size limited
the number of predictor variables that could be used in
Number of children in care at the end of each month on ARTFigur  3
Number of children in care at the end of each month on ART. Total number of children in care at the end of each 
month divided into those returning and not returning medication
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indicator of disease severity in the model of viral suppres-
sion and only able to include socio-demographic and reg-
imen factors as predictors of MR adherence ≥ 90%.
It is notable that nearly 40% of caregivers experienced
problems with giving ART, and that this adversely affected
adherence over the whole year. Poor palatability of medi-
cation was the most common problem reported, espe-
cially in those taking ritonavir. This problem is unique to
infants and very young children taking liquid formula-
tions of drugs, and concurs with international stud-
ies.[18,22] A limitation of our study is that drug
formulation was not recorded so its effect on adherence
Changes in proportion with MR adherence <90% during the first year on ARTFigur  4
Changes in proportion with MR adherence <90% during the first year on ART. Only children who remained alive 
and in care for entire first year of treatment (excludes children deceased or LFU; n = 88).
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Table 2: Univariate and multivariate factors associated with undetectable viral load (n = 88)
Variable Unadjusted OR 95%CI p-value Adjusted OR 95%CI p-value
Female gender 0.91 0.36 – 2.35 0.86 †
Age at treatment start (months) 1.00 0.99 – 1.01 0.81 †
WHO stage 2&3 (vs WHO stage 4) 2.80 1.07 – 7.35 0.04 *
Weight-for-age z-score 1.29 0.94 – 1.77 0.12 *
Height-for-age z-score 1.07 0.74 – 1.54 0.71 *
Weight-for-height z-score 1.94 1.27 – 2.96 0.002 1.8 1.15 – 2.80 0.01
CD4 percent 1.04 0.97 – 1.12 0.27 *
CD4 absolute (cells/l) 1.44 0.54 – 3.84 0.47 *
Log viral load 0.87 0.48 – 1.60 0.66 *
Ritonavir-containing regimen 0.33 0.13 – 0.87 0.03 †
Annual average MR adherence ≥ 90% 10.30 1.92 – 55.67 0.005 5.48 0.84 – 35.58 0.075
*Not included in building multivariate model
†Not significantly associated with viral suppression after adjustment for weight-for-height z-scorePage 9 of 12
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greater proportion of children under 2 years of age (who
would all be taking liquid formulations) had adherence
>100% suggests that repeat dosing of syrups/solutions is
frequently necessary, placing an additional burden on car-
egivers.
It is further noteworthy that MR adherence results in the
ritonavir group appear paradoxical: taking ritonavir was
both negatively associated with (capped) MR adherence ≥
90%, and positively associated with (uncapped) MR
adherence >100%. The excess adherence is explained by
frequent need for repeat dosing. However poor adherence
in the ritonavir group when measures are capped indicates
that there is not always compliance with frequent dosing
with an unpalatable drug ultimately impacting negatively
on adherence. Indeed the poor adherence in the ritonavir
group was attributable to poor adherence to ritonavir
alone, with adherence to the other two drugs in the regi-
men being acceptable (data not shown). Although ritona-
vir is no longer used as a single third agent in ART
regimens, Kaletra® (lopinavir/ritonavir) is also unpalata-
ble and is recommended in the South African national
guidelines as part of the first-line regimen in children
under 3 years of age.[37] Moreover, drugs other than
ritonavir accounted for nearly a third of palatability prob-
lems. The need for pediatric-friendly formulations of ART
cannot be over-emphasized.
While some studies have suggested that older children are
more likely to be non-adherent, we found no relationship
between age and adherence.[20,30] However, in our study
the median age was young (36 months) with few children
approaching adolescence, so its potential negative effect
could not be determined. Nevertheless, it should be noted
that the age of children commencing ART at our institu-
tion has decreased since this initial program, with the
majority of children now being less than 2 year old.[8]
Our findings may therefore not be applicable to our cur-
rent patient cohort, and there is a need for further research
into adherence in very young infants in Africa.
While previous research in Africa has found little impact
of socio-economic status on adherence, our study suggests
that better caregiver education and socio-economic status
are both strongly independently associated with better
adherence. [16,25,27,29] Caregivers with secondary edu-
cation and those with access to water and electricity are
4.5 times and 2.7 times more likely to have adherence ≥
90% respectively. The lack of association between car-
egiver education and any of the indicators of socio-eco-
nomic status emphasizes that these both impact on
adherence and one is not simply a surrogate marker of the
other. Compared to adult ART, administering medication
to children, particularly infants, is more complex and
requires exact measurement of dosages, often to a fraction
of a milliliter, and compliance with stringent storage
requirements. In addition, unlike adults where dosage
remains constant over a long period, dosages for children
change frequently due to their rapid growth. Although we
did not examine the effect of complex dosages and dosage
changes on MR adherence, the positive impact on adher-
ence in children of better education and socio-economic
status of their caregivers is not surprising. However, the
failure to find an association with caregiver's ability to
describe a regimen and adherence suggests that it is the
caregiver's overall education that impacts more on treat-
ment adherence than treatment literacy per se.
Conclusion
This study demonstrates the potential for caregivers of
African young children to achieve adherence comparable
with that of wealthier countries. The association between
MR adherence and viral response attests to the value of a
relatively simple low technology tool for measuring
adherence i.e. clinic-based medication return for detecting
lapses in adherence. Nevertheless, repeated measure-
ments of medication returned, particularly of syrups/solu-
tions, are not feasible in most large program scale-up
settings and the poor sensitivity of low reported adher-
ence for low MR adherence highlights the need to develop
practical easy-to-use reliable screening tools to detect chil-
dren in whom more intensive adherence monitoring is
indicated. [30] The negative impact of problems experi-
enced with giving ART, unpalatable drugs, poor caregiver
Table 3: Factors associated with annual average MR adherence ≥ 90%. (n = 115)
Variable Unadjusted OR 95% CI p-value Adjusted OR 95% CI p-value
Access to water and electricity 3.04 1.12 – 8.22 0.028 2.65 0.93 – 7.55 0.069
Formal housing 2.44 0.95 – 6.27 0.064 *
Access to working refrigerator 2.64 1.04 – 6.65 0.039 *
Secondary education (>Std 5/Grade 7) 3.84 1.06 – 13.98 0.041 4.49 1.10 – 18.24 0.035
Taking ritonavir 0.44 0.18 – 1.11 0.084 0.37 0.13 – 1.02 0.054
*Not included in multivariate model as only one measure of socio-economic status (access to water and electricity) used.Page 10 of 12
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BMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34education and socio-economic status on adherence in this
study underscores the need for more pediatric-friendly
drug formulations as well as the importance of supporting
caregivers in providing ART to children.
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BACKGROUND 
 
In the absence of antiretroviral therapy the median survival of HIV-infected children in Cape 
Town is 34 months. Risk for death is significantly associated with an age of less than 6 
months and CDC category C diseases at diagnosis.1 The efficacy and safety of antiretroviral 
therapy has been demonstrated in children, adolescents and adults. Current guidelines for 
treating children recommend combination therapy that includes protease inhibitors (PIs).2,3 
The benefits of PI-combination regimens include decreased risk for death, improved growth, 
better immunological reconstruction, reduction in infectious complications and significant 
reduction in the progression of the disease to AIDS.4-7  
 
The rate of immunological reconstitution differs in children and adults. In children there is 
early and progressive recovery of naïve CD4+ T-cells but only a small rise memory CD4+ 
cells. Significantly higher rates of naïve, memory and total CD4+ cells are observed in 
children less than 3 years of age. These observations suggest that the pattern of CD4+ T-cell 
regeneration during HAART is thymus-dependant.8,9 In adults the repopulation of CD4+ T-
cells is a biphasic process. Initially, memory CD4+ T-cells increase rapidly within 3 weeks of 
commencing antiretroviral therapy. This response is probably due to redistribution of CD4+ 
cells from lymphoid tissue to the peripheral bloodstream. Thereafter memory CD4+ cells 
remain relatively stable. Naïve CD4+ T-cells by contrast increase gradually but slowly.10,11     
 
Efficacy and adherence are important considerations in the management of children on 
antiretroviral therapy. A smaller proportion of children receiving PI-combination regimens 
experience suppression of plasma HIV RNA levels below the limits of detection, in 
comparison to adults. Early studies showed that only 25 to 40% of children receiving these 
regimens experience suppression of plasma HIV RNA levels below the limit of detection 
compared with 43 to 75% of adults12 More recent reports indicate improved efficacy. For 
example, a open-labelled study of 32 children treated with indinavir or nelfinavir plus 
zidovudine and lamivudine, showed that after 96 weeks of therapy 69% and 50% of children 
had achieved viral loads less than 500 and 40 copies / mL, respectively.13 Four-drug regimens 
may be superior for controlling viral replication in paediatric HIV infection.14  
 
A high level of adherence is needed for virologic success. Adherence is generally lower in 
children. In one study only 58% of HIV-infected children were able to achieve satisfactory 
adherence.15 Factors contributing to lower adherence include difficulty with drug 
administration because of the complexity of the combination regimens, lack of palatability of 
liquid formulations and high numbers of tablets/capsules and dosing frequency. Adherence 
can be improved if regimens are simplified, with ongoing education and by tailoring 
regimens to the families' schedules. Where administration of medication is particularly 
problematic, administration via a gastrostomy tube has proven to be safe and effective.12 
Experience with adult South Africans indicate that socio-economic status does not influence 
adherence.16    
 
Red Cross Children's Hospital is one of several hospitals in Cape Town, associated with the 
University of Cape's Faculty of Health Sciences. The hospital provides care for children with 
a wide range of tertiary paediatric and paediatric surgical problems, is involved in training 
undergraduate medical students, specialist paediatricians and paediatric surgeons, and has a 
number of research programmes in paediatrics and child health. HIV infection is currently the 
dominant health problem. Between 25 and 30 % of children who are admitted to the 
hospital's medical wards are HIV-infected. Approximately 23% of all deaths at the hospital 
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are currently related to HIV infection.17 A dedicate Infectious Diseases Ambulatory service 
cares for between 400 and 450 HIV-infected children and their immediate families. Five 
paediatricians, 2 medical officers (1 exclusively involved with the care of infected parents), 2 
nurses, 1 social worker, 1 oral hygienist and 2-3 volunteer counsellors staff the clinic. Care 
includes cotrimoxazole prophylaxis, treatment of minor infections, nutritional and 
micronutrient supplementation, and screening for and treatment of children with tuberculosis. 
Antiretroviral therapy is not administered routinely, but twelve children with access to private 
funding, are being managed with either dual or triple combinations. Parents receive medical 
care, and have access to individual and group counselling and educational sessions.  
 
 
ANITRETROVIRAL TREATMENT PROGRAMME 
 
The major antiretroviral treatment goals for HIV-infected children include the promotion or 
restoration of normal growth and development, prevention of complicating opportunistic 
infections and cancers, improved quality of life and prolonged survival.  
 
The principle objective of this treatment programme is to extend access to antiretroviral 
therapy, of as many children and their parents as is possible.  
 
Secondary objectives include:- 
 
- Adapting existing treatment protocols to local circumstances  
- Evaluating effectiveness and adherence locally 
- Developing an educational programme on antiretroviral therapy in children and 
their families for health care workers 
- Undertaking a cost benefit analysis of the programme 
- Developing parallel research projects around issues such as immunological 
reconstitution and psychosocial aspects of HIV-infected households. 
 
The Infectious Diseases service at Red Cross Children's Hospital has the facilities, personal 
and experience to initiate this programme and to conduct relevant operational research.  
 
 
Selection of children 
 
At present, limited resources preclude the treatment of all children in whom antiretroviral 
therapy is indicated. Therefore, children will be included in the treatment cohort on the basis 
clinical, immunological, and selective social criteria. The selection approach is modelled on 
the European treatment guidelines.2 Recent research supports delaying the introduction of 
antiretroviral therapy until advanced disease is present, as highly active antiretroviral therapy 
has the greatest effect on immune reconstitution when initiated in children with the greatest 
immunosuppression. The effect of therapy on viral load is not influenced by the 
immunological status at the time of starting HAART.18 The social guidelines will be revised 
and liberalised as circumstances improve, especially increased funding for the project. 
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Clinical and immunological criteria2 
 Clinical stage C or immunological stage 3 (Appendix 1).19 
 Consider ART if clinical stage B or CD4+ count < 20% or high viral load (>106 copies / 
mL if age < 1 year, and > 105 copies / mL if age > 1 year). 
 
 
Social criteria 
 Parent / guardian prepared to commit to long-term antiretroviral therapy 
 Parent / guardian having a permanent address in Cape Town for longer than 3 months 
 Parent / guardian prepared to complete a detailed questionnaire and serial evaluations  
 Parent / guardian prepared to comply with adherence monitoring   
 Parent with HIV infection prepared to receive antiretroviral therapy, if indicated 
 Child attending the infectious disease clinic regularly, at least the last 3 appointments 
 Child taking his / her medication regularly  
  
 
Exclusion criteria 
 Stage N or A disease, and CD4+ count > 20% 
 Child currently on antiretroviral therapy 
 Parent / guardian not prepared to commit to long-term antiretroviral therapy 
 Parent / guardian not having a permanent address in Cape Town for longer than 3 months 
 Parent / guardian not prepared to complete a detailed questionnaire and serial evaluations  
 Parent / guardian not prepared to comply with adherence monitoring   
 Parent with HIV infection not prepared to receive antiretroviral therapy, if indicated 
 Child not attending the infectious disease clinic regularly (evaluate at least the last 3 
appointments) 
 Child not taking his / her medication regularly 
 
 
Approach to selecting patients 
1. Children selected at the infectious disease clinic on the basis of their clinical staging i.e. 
clinical category C or B (Appendix 1). 
2. Caregivers informed of the programme. 
3. Caregivers complete a screening questionnaire (Appendix 2). 
4. If satisfactory, an initial CD4+ count to be done. 
5. All information including a summary of the medical history will be reviewed by a panel 
of staff members attached to the clinic. 
6. The decision of the panel will be discussed with the caregiver within 2 weeks. 
7. If a child is accepted onto the programme further information about the programme to be 
given and consent for antiretroviral therapy to be taken (Appendix 3). 
8. The instructions in Appendix 4 should be followed. These include completing a detailed 
assessment and baseline bloods (Appendix 5), and a neurodevelopmental assessment 
(Appendix 6). Further information about the programme should be given. 
9. Antiretroviral therapy commenced as soon as possible. 
10. Antiretroviral therapy will be managed according to established guidelines (see below). 
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First line therapy for children 
  
The initial regimen should achieve an undetectable viral load in many children, exert a 
sustained clinical effect and minimise the emergence of drug resistance. To ensure that the 
programme reaches many children the relative costs of individual drugs were considered. 
First-line therapy will include two nucleoside reverse transcriptase inhibitors (NRTIs) [one 
thymidine analogue and one non-thymidine analogue], and a protease inhibitor (PI). The first 
line therapy may be modified as more funding accrues.  
 
First line antiretroviral regimensd 
d4T or AZT plus 3TC or ddI plus 
Ritonavir or [Lopinavir and ritonavir 
(Kaletra)] 
Preferred regimen: AZT/3TC/Kaletra 
Current regimen based on cost 
considerations: d4T / 3TCa plus ritonavirb 
d4T plus ddI or 3TC plus EFVc Consider as alternative if > 3 years or > 
10 kg 
 
a Although AZT/3TC combination is regarded as the first line NTRI therapy, cost 
currently precludes use of this combination. It is easier to administer d4T/3TC than 
d4T/ddI in young children 
 
b Ritonavir suspension is currently the least expensive paediatric PI formulation in 
South Africa. Its major disadvantage is its taste. Palatability may be improved by 
coating the child’s mouth with peanut butter before administration, mixing the 
suspension with cold milk, juice, jelly, honey, ice cream, yogurt or chocolate 
milkshake, or eating salty food (e.g. potato chips or pickles) or chewing gum after 
taking a dose of the suspension. Some of these measures have been used successfully 
in South Africa. Unpredictable drug levels in children under the age of 2 years20 can 
be somewhat overcome by employing a higher therapeutic dose of 450 mg/m2. 
Alternatively lopinavir / ritonavir (Kaletra) may be considered. There is limited data 
on the use of NNRTIs in young children with high viral loads. Sine mid-2001 
nevirapine has been used in the Western Cape mother-to-child-transmission 
intervention programme. The K103N resistance mutation has been reported after 
short-course administration of nevirapine in MTCT intervention programmes21. This 
limits the use of NNRTIs in children recently exposed to nevirapine. 
 
c Efavirenz may be an effective alternative in older children, particularly as the 
median viral load is lower and the improved palatability should influence adherence 
positively. 
  
d Both regimens are compatible with concurrent antituberculosis therapy containing 
rifampicin. 
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Individual drugs 
STAVUDINE (D4T)3,20 
 
Dosage 
Paediatric dose: 1 mg per kg body weight every 12 hours (up to 30 kg) Adolescent / adult 
dose: body weight ≥ 60 kg: 40 mg twice daily; body weight < 60 kg: 30 mg twice daily 
 
Major toxicities 
More common: headache, gastrointestinal disturbances, skin rashes 
Less common: peripheral neuropathy and pancreatitis. Lactic acidosis and severe 
hepatomegaly with steatosis, including fatal cases have been reported. 
Rare: increased liver enzymes 
 
Drug interactions 
Should not be administered in combination with AZT 
 
Special instructions 
Can be administered with food 
Oral solution must be kept refrigerated 
 
 
LAMIVUDINE (3TC)3,20 
 
Dosage 
Paediatric dose: 4 mg per kg body weight twice daily 
Adolescent / adult dose: body weight ≥ 50 kg: 150 mg twice daily; body weight < 50 kg: 2 
mg per kg twice daily 
 
Major toxicities  
More common: headache, fatigue, nausea, diarrhoea, skin rash, abdominal pain 
Less common: pancreatitis, peripheral neuropathy, decreased neutrophil count, increased 
liver enzymes. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases 
have been reported. 
 
Special instructions 
Can be administered with food 
Oral solutions may be stored at room temperature 
 
 
DIDANOSINE (DDI)3,20 
 
Dosage 
Paediatric dose: In combination with other antiretrovirals: 90 mg/m2 every 12 hours. 
Adolescent / adult dose: body weight ≥ 60 kg: 200 mg twice daily. Body weight < 60 kg: 125 
mg twice daily. 
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Major toxicities 
More common: diarrhoea, abdominal pain, nausea, vomiting 
Less common: peripheral neuropathy (dose related), electrolyte disturbances and 
hyperuricaemia. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases 
have been reported. 
Rare: pancreatitis, increased liver enzymes, retinal depigmentation. 
 
Special instructions 
Food decreases absorption; administer ddI on an empty stomach (one hour before or two 
hours after a meal). 
Oral solution: keep refrigerated; admixture stable for 30 days. 
 
ZIDOVUDINE (AZT)3,20 
 
Dosage 
Paediatric usual dose: 160 mg/m2 every eight hours 
Adolescent / adult dose: 200 mg three times a day or 300 mg twice daily. 
 
Major toxicities 
More common: haematologic toxicity, including granulocytopaenia and anaemia, headache 
Less common: myopathy, myositis, liver toxicity 
Unusual: lactic acidosis and sever hepatomegaly with steatosis, including fatal cases have 
been reported 
 
Special instructions 
Can be administered with food 
Decrease dosage in patients with severe renal failure 
Reduced dosage may be indicated in patients with substantial hepatic dysfunction 
 
 
RITONAVIR (RIT)3,20 
 
Dosage 
Paediatric dose: 400 – 450 mg/m2 every 12 hours. To minimise nausea and vomiting, 
commence therapy at 250 mg/m2 every 12 hours and increase stepwise to full dose over 5 
days as tolerated. 
Adolescent / adult dose: 600 mg twice daily. To minimise nausea and vomiting, commence at 
300 mg twice daily and increase stepwise to full dose over 5 days as tolerated. 
 
Major toxicities 
More common: nausea, vomiting, diarrhoea, headache, abdominal pain, anorexia 
Less common: circumoral parathesis, increased liver enzymes 
Rare: spontaneous bleeding in haemophiliacs, pancreatitis, increased levels of triglycerides 
and cholesterol, hyperglycaemia, ketoacidotis, diabetes, and hepatitis 
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Special instructions 
Administration with food increases absorption 
Oral solution should be refrigerated 
To improve tolerance: mix oral solution with milk, chocolate milk, or vanilla or chocolate 
pudding or ice cream. Coat the mouth with peanut butter before administration. 
 
LOPINAVIR / RITONAVIR (KALETRA) 
 
Dosage 
Paediatric dose: 
 
Six months to 12 years of age (without nevirapine of efavirenz) 
7 to < 15 kg 12 mg per kg lopinavir / 3 mg per kg ritonavir twice daily with 
food 
15 to 50 kg 10 mg per kg lopinavir / 2.5 mg per kg ritonavir twice daily 
with food 
> 50 kg 400 mg lopinavir / 100 mg ritonavir (three capsules or 5 mL) 
twice daily with food (same as adult dose) 
 
OR 
 
230 mg per m2 lopinavir / 57.5 mg per m2 ritonavir twice daily with food, up to a maximum 
of 400 mg lopinavir / 100 mg ritonavir 
 
Adolescent / adult dose: 400 mg lopinavir / 100 mg ritonavir (three capsules or 5 ml) twice 
daily with food. 
Major toxicities 
More common: diarrhoea, headache, asthenia, nausea and vomiting. Increased in blood lipids 
(cholesterol and triglycerides), and rash in patients on Kaletra and other antiretroviral drugs. 
Rare: Spontaneous bleeding in haemophiliacs, pancreatitis, hyperglycaemia, ketoacidosis, 
diabetes, hepatitis 
Drug interactions 
Lopinavir / ritonavir is extensively metabolized by hepatic cytochrome P450 3A (CYP3A). 
There could potentially be multiple drug interactions. 
Efavirenz and nevirapine induce the metabolism of lopinavir and decrease plasma 
concentrations. A dose increase of lopinavir / ritonavir is recommended.  
 
EFAVIRENZ (EFV)3,20 
 
Dosage 
Paediatric dose: Administered once daily - body weight 10 – 15 kg: 200 mg; 15 – 20 kg: 250 
mg; 20 – 25 kg: 300 mg; 25 – 32.5 kg: 350 mg; 32.5 – 40 kg: 400 mg; > 40 kg: 600 mg 
Adolescent / adult dose: 600 mg once daily 
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Major toxicities 
More common: skin rash, CNS problems primarily in adults (somnolence, insomnia, 
abnormal dreams, confusion, impaired concentration, agitation. Hallucinations, euphoria), 
increased liver enzymes 
 
Special instructions 
Efavirenz can be taken with or without food. Bedtime dosing is recommended. 
Capsules may be opened but the granules have peppery taste 
 
 
Monitoring (Appendix 4) 
 
Viral load:   Baseline then yearly 
1. Laboratory 
   Store EDTA plasma (250µl x 2 aliquots) in between i.e. 6mo,  
18mo, etc. 
CD4+ count:   Baseline and 6-monthly 
FBC:    Baseline, 1 month, 3 month, then 3- to 6-monthly 
LFTs:   Baseline, 1 month, 3 months, then 3- to 6-monthly 
Fasting lipids:  Baseline, then 6- to 12-monthly 
Amylase:  6-monthly 
Fasting glucose: Baseline and 6-monthly 
Vitamin A:  Baseline and 1 year 
Plasma: Store baseline heparinised plasma (5 aliquots plus a balance tube) 
 
Follow-up appointments: 2 weeks, 1 month, monthly until 6 months, then 1 to 3 monthly 
2. Clinical 
 
At each visit the datasheet should be completed (Appendix 7). The clinical team will review 
datasheets and clinical progress of each child at regular meetings. At yearly intervals a 
detailed evaluation will be completed (Appendix 12).  
 
All unused medication must be brought to each clinic visit. Adherence will be monitored by 
checking quantities of used / unused medication at each visit.  An adherence questionnaire 
will be completed periodically (Appendix 8). 
3. Adherence 
 
 
Adverse events22 
 
Adverse events will be managed according to guidelines established by the United States 
Public Health Service and the Infectious Diseases Society of America.22 The severity of 
adverse events have been graded according to an internationally accepted system (Appendix 
9).  
 
 
Principles of managing adverse events 
1. Try to establish whether the adverse event is due to antiretroviral agents, or other 
medication. 
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2. Continue therapy in the presence of non-life-threatening toxicities. Attempts should 
be made to continue antiretroviral therapy at effective doses except in the presence of 
severe (grade 4) or life-threatening toxicities, in which circumstances therapy should 
be stopped. Severe and possibly rapidly fatal complications including pancreatitis, 
hepatic failure or severe skin rashes including Stevens-Johnson syndrome require 
discontinuation of the most suspect medication and often, discontinuation of all 
medication temporarily. Lower-grade toxicities (grades 1 and 2) should prompt 
increased and more frequent observation, monitoring and evaluation. 
3. If there is a need to discontinue antiretroviral therapy for an extended period, it is 
advisable to discontinue all antiretrovirals rather than continuing with one or two 
agents alone. 
  
All severe adverse (grade 4) or life-threatening events should be documented (Appendix 10). 
 
 
Antiretroviral therapy and anti-tuberculous therapy23-25 
 
Many patients in sub-Saharan Africa who are candidates for antiretroviral therapy will have 
active tuberculosis. Tuberculosis is a leading cause of death among HIV-infected individuals. 
Because of the risk of drug interactions between the PI class of antiretrovirals and rifampicin 
(in general, serum protease inhibitor levels are lowered substantially and rifampicin levels 
increased 2 – 3 times the usual concentration), concerns have been raised about the optimal 
therapy for both tuberculosis and HIV infection. An alternative to rifampicin is rifabutin. This 
drug is not readily obtainable locally and is expensive. Important treatment issues to address 
in patients co-infected with tuberculosis and HIV infection and treated with rifampicin-based 
anti-tuberculous treatment regimens are when to start antiretroviral therapy and which drugs 
to use. 
 
 
Guiding principles 
1. Anti-tuberculous therapy should be commenced as soon as the diagnosis of active 
tuberculosis is made irrespective of whether a patient is being treated with 
antiretrovirals. 
2. The first-line antiretroviral treatment regimens in this programme are compatible with 
rifampicin-based anti-tuberculosis regimens.  
3. In children on anti-tuberculosis treatment at the time of recruitment to the programme, 
and who are not at risk of progression of their HIV infection, antiretroviral therapy 
should be delayed until the intensive phase of anti-tuberculosis therapy in complete 
(generally the first 2 months of anti-tuberculosis therapy). This simplifies 
management and minimises toxicity. 
4. In children on anti-tuberculosis treatment at the time of recruitment to the programme, 
and who are at risk of progression of their HIV infection (immunological category III 
or extrapulmonary tuberculosis), antiretroviral therapy should be started as soon as 
possible. 
5. For children who develop tuberculosis while on antiretroviral therapy, options 
include:- 
a. Continue antiretroviral therapy if compatible with anti-tuberculosis therapy. 
b. Discontinue all antiretrovirals during the intensive phase of anti-tuberculosis 
therapy. Reintroduce antiretrovirals during the maintenance phase. 
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c. If antiretroviral therapy is not compatible with anti-tuberculosis therapy, 
discontinue all antiretrovirals during the intensive phase of anti-tuberculosis 
therapy. Recommence antiretroviral therapy during the maintenance phase of 
therapy and use a non-rifampicin-based regimen during the maintenance 
phase. 
 
The treatment of tuberculosis and HIV infection together is problematic. The above 
guidelines may assist in the managing of most patients. However, decisions may be difficult 
and should be individualised where exceptional clinical circumstances exist.  
 
 
Pneumocystis Carinii Pneumonitis (PCP) prophylaxis 
 
Children will be managed according to established PCP prophylaxis guidelines.  
 
Summary of guidelines used by the Infectious Diseases Service, Red Cross Children's 
 
 
1. PCP prophylaxis should be administered to all children born to HIV seropositive mothers, 
from the age of 4-6 weeks. 
2. PCP prophylaxis should be reviewed at the age of 3-4 months if HIV PCR testing is 
available. Prophylaxis must be continued if the HIV PCR is positive and discontinued if 
negative. If PCR testing is unavailable or the result indeterminate, then PCP prophylaxis 
should be continued until the diagnosis of HIV infection has been disproved. 
3. Children with category B and C clinical disease should receive lifelong PCP prophylaxis.  
4. Children with category A clinical disease may discontinue prophylaxis after 12 months of 
age. PCP prophylaxis should be reintroduced with disease progreesion. 
5. TMP-SMX chemoprophylaxis regimen 
 
 
Weight (kg) Total daily dose 
< 5.0 5 ml+ 
5.0 - 9.9 7.5 ml+ 
10.0 - 14.9 10 ml+ 
15 - 21.9 15 ml+ or 1.5 tablets* 
≥ 22 20 ml+ or 2 tablets* 
+ Paediatric suspension, *Single-strength TMP-SMX tablets 
 
TMP-SMX should be administered 3 times per week, on alternative days (e.g. Monday, 
Wednesday, Friday) or on consecutive days (e.g. Monday, Tuesday, Wednesday). Daily 
TMP-SMX should be administered in 2 divided doses. Where this is impractical, a single 
dose may be administered. 
 
6. If TMP-SMX cannot be tolerated dapsone or aerosolised pentamidine may be used. 
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Discontinuation of PCP prophylaxis  
For children treated with antiretroviral therapy, PCP prophylaxis can be discontinued when 
the CD4+ percentage is consistently above 20% (i.e. a CD4+ percentage > 20% on two 
independent assessments at least 6 months apart). This is the guideline currently used by the 
Special Infectious Diseases Service, Children's Memorial Hospital, Chicago (R Yogev, 
personal communication).  
 
 
Indications for changing antiretroviral therapy3,23 
 
Despite a good clinical and immunological response in children on highly active 
antiretroviral therapy, selection of resistant viral strains is likely to occur in the absence of 
complete viral suppression. However, many paediatricians delay changing therapy if there is 
no signs of clinical or immunological progression. Decisions to change antiretroviral therapy 
will depend on clinical and immunological criteria. Currently, because of limited resources 
viral load will be performed at baseline and then at yearly intervals. The initial viral load will 
be used to select initial antiretroviral therapy. Annual viral load evaluations will primarily be 
used to assess the effectiveness of antiretroviral therapy. If increased funding is obtained viral 
loads will be determined more frequently (e.g. 6 monthly) and the results used to determine 
when to change antiretroviral therapy. in the management of the patients.  
 
 
Clinical considerations 
Clinical signs of response to antiretroviral therapy include improvement in growth in children 
who previously failed to grow, improvement in neurological signs or neurodevelopment, and 
decreased frequency of infections (bacterial infections, thrush, and / or other opportunistic 
infections). The following clinical features warrant consideration of a change in antiretroviral 
therapy. 
 
1. Progressive cognitive and / or developmental deterioration or development of 
encephalopathy (Appendix 6). 
2. Growth failure.  
3. Disease progression i.e. advancement from one clinical category to another (Appendix 
1). 
4. Recurrences of infections such as oral candidiasis refractory to treatment. 
 
 
Immunological considerations 
Before considering changing antiretroviral therapy because of a decline in CD4+ count, a 
minimum of one repeated measurement of CD4+ values should be obtained at least 1 week 
after the initial test. 
 
The following immunological features warrant consideration of a change in antiretroviral 
therapy. 
 
1. A return of CD4+ count / percentage to or below pre-therapy baseline. 
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2. Immunological deterioration i.e. advancement from one immunologuical category to 
another (Appendix 1).19   
  
 
Second line therapy 
 
The following general principles should be considered when choosing a new antiretrovoiral 
regimen in children who have received previous treatment. 
 
1. When therapy is changed because of toxicity or intolerance, agents with different 
toxicity and side effect profiles should be selected. In the event of drug intolerance, 
change of a single drug in a multidrug regimen and in certain circumstances, dose 
reduction are permissible. 
2. When changing therapy because of treatment failure, adherence to therapy should be 
assessed as a potential cause of failure. 
3. If the patient is adherent to the regimen, assume the development of resistance and, if 
possible, change to at least two new antiretroviral agents. The new regimen should 
include at least three drugs. 
4. When considering changing to a new regimen, all other medication should be 
reviewed for possible drug interactions. 
5. When considering changing therapy because of disease progression in a patient with 
advanced disease, the patient’s quality of life should be considered. 
 
 
Suggested second line antiretroviral regimens 
Failed previous regimen New regimen 
d4T/3TC plus Ritonavir AZT/ddI plus EFV or NEL 
d4T plus 3TC plus EFV AZT plus ddI plus Ritonavir 
d4T plus ddI plus EFV  AZT plus 3TC plus Ritonavir 
 
 
Treatment of infected parents 
 
(This section has not been included) 
 
 
CAPACITY BUILDING 
 
For the past two years the Infectious Disease Clinic at Red Cross Children's Hospital has 
participated in a mentoring programme whereby doctors from community clinics in the Cape 
Metropolitan Region (estimated population: 3.15 million) attend the clinic over 4-week 
cycles and learn about the management of HIV-infected children. Doctors at the clinic have 
for the past 2 years been involved with the 'roll-out' of the mother-to-child-transmission 
intervention programme of the Western Cape Government,  educating nurses, doctors and 
clinic managers throughout the Western Cape Province about the intervention programme 
and paediatric HIV infection. The programme is based on short-course nevirapine therapy 
coupled with the provision of milk powder to babies of HIV-exposed women for the first 6 
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months of life. It currently covers between 60 and 70% of pregnant women in the province. 
By the end of 2002 the programme is scheduled to include about 95% of all pregnancies in 
the province. 
 
There are few doctors employed in state institutions in South Africa with experience of 
managing HIV-infected people on antiretroviral therapy. Thus one of the medium term 
objectives of our proposed programme is to create a centre of excellence for the management 
of HIV-infected children and to use the skills and experience gained from the programme to 
educate doctors and other health care professionals throughout the province about 
antiretroviral therapy in children. This will be done through a mentoring system and regular 
workshops. This should facilitate the establishment of antiretroviral treatment programmes 
throughout the province, when therapy becomes more accessible.      
 
 
STATISTICAL CONSIDERATIONS 
 
All data collected as part of this treatment programme will be entered into  Epi Info and 
Access databases anonymously. The data will be analysed using conventional descriptive and 
comparative statistical methods. Statistical packages that will be used in the analysis includes 
Epi Info 2000, Division of Surveillance and Epidemiology, CDC, Atlanta, Georgia and 
Statistica, Statsoft, Inc, Tulsa, OK, USA.  
 
 
ETHICAL CONSIDERATIONS  
 
The Chief Director and the Medical Superintendent of Red Cross Children's Hospital have 
given permission for the establishment of this treatment programme. Although ethical 
approval is not required to initiate antiretroviral treatment, all documents will be forwarded to 
the Research Ethics  Committee, Faculty of Health Sciences, University of Cape Town for 
approval of the research components of the programme i.e. data collection and analysis.  
 
Parallel research projects dealing with the neurodevelopmental evaluation of children on 
antiretroviral therapy, immunological reconstitution of children on antiretroviral therapy and 
detailed psychosocial descriptions of families at different stages of HIV infection including 
those on effective treatment (antiretroviral therapy) will be submitted separately to the 
Research Ethics Committee for consideration. These projects are currently under 
development.  
 
All families who commit themselves to the programme will be asked to complete the consent 
process. 
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APPENDICES 
 
Note
• Appendix 6: Developmental assessment 
: The following appendices have not been included in order to abridge the 
document: 
• Appendix 9: Grading of adverse drug reactions for children > 3 months of age 
• Appendix 10: Severe or life-threatening adverse event report form  
• Appendix 11: World Health Organisation guidelines for the diagnosis of pulmonary 
tuberculosis in children (modified)29 
• Appendix 13: WHO clinical staging system for HIV infection (adults) 
• Appendix 14 – Information brocuhure for people commencing antiretroviral therapy 
• Appendix 15: Adherence questionnaire (adults on antiretroviral therapy)  
 
 
APPENDIX 1: CDC CLINICAL AND IMMUNOLOGICAL CLASSIFICATION FOR 
CHILDREN WITH HIV INFECTION19 
 
Clinical classification 
 
 
Category N: Not symptomatic 
Children who have no symptoms or signs considered to be the result of HIV infection or who 
have only one of the conditions listed in Category A. 
 
 
Category A: Mildly symptomatic 
Children with two or more of the following features but none of the conditions in category B 
or C. 
 
Features:  lymphadenopathy (at more than two sites); hepatomegaly; splenomegaly; 
dermatitis; parotitis; recurrent or persistent upper respiratory infection, sinusitis or otits media 
 
 
Category B: Moderately symptomatic 
Anaemia (< 8 gm/dl), neutropaenia (<1000/mm3), or thrombocytopaenia (< 100 000/mm3) 
persisting ≥ 30 days. 
Bacterial meningitis, pneumonia, or sepsis (single episode). 
Candidiasis, oropharyngeal, persisting (> 2 months) in children > 6 months of age. 
Cardiomyopathy. 
Cytomegalovirus infection, with onset before 1 month of age. 
Diarrhoea, recurrent or chronic. 
Hepatitis. 
Herpes simplex virus (HSV) stomatitis, recurrent (≥ episodes within 1 year). 
HSV bronchitis, pneumonitis, or oesophagitis with onset before the age of 1 year. 
Herpes zoster involving at least two distinct episodes or more than one dermatome. 
Leiomyosarcoma. 
Lymphoid interstitial pneumonitis or pulmonary lymphoid hyperplasia complex. 
Nephropathy. 
Nocardiosis. 
Persistent fever (lasting > 1 month). 
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Toxoplasmosis, onset before 1 month of age. 
Varicella, disseminated (complicated chickenpox). 
 
 
Category C: Severely symptomatic 
Serious bacterial infections, multiple or recurrent. 
Candidiasis, oesophageal or pulmonary. 
Cryptococcosis, extrapulmonary. 
Cryptosporidiosis or isosporiasis with diarrhoea persisting > 1 month. 
Cytomegalovirus disease with onset of symptoms at age > 1 month (at a site other than liver, 
spleen, or lymph nodes). 
Encephalopathy (at least one of the following progressive findings present for at least 2 
months in the absence of a concurrent illness other than HIV infection that could explain the 
findings): a) failure to attain or loss of developmental milestones or loss of intellectual 
ability, verified by standard developmental scale or neuropsychological tests; b) impaired 
brain growth or acquired microcephaly demonstrated by head circumference measurements 
or brain atrophy demonstrated by computerized tomography or MRI; c) acquired symmetric 
motor deficit manifested by two or more of the following: paresis, pathologic reflexes, ataxia, 
or gait disturbance. 
Kaposi’s sarcoma. 
Lymphoma, primary, in brain. 
Lymphoma, small, noncleaved cell (Burkitt’s), or immunoblastic or large cell lymphoma of 
B-cell or unknown immunologic phenotype. 
Mycobacterium tuberculosis, disseminated or extrapulmonary. 
Mycobacterium avium complex, or Mycobacterium kansasii, disseminated. 
Pneumocystis carinii pneumonia. 
Progressive multifocal leukoencephalopathy 
Salmonella (nontyphoid) septicaemia, recurrent. 
Toxoplasmosis of the brain with onset at > 1 month. 
 
Wasting syndrome in the absence of a concurrent illness other than HIV infection that could 
explain the following findings: a) persistent weight loss > 10% of baseline OR b) downward 
crossing of at least two of the following percentile lines on the weight-for-age chart (e.g. 
95th, 75th, 50th, 25th, 5th) in a child ≥ 1 year of age OR c) < 5th percentile on weight-for-
height chart on two consecutive measurements, ≥ 30 days apart PLUS a) chronic diarrhoea 
(i.e. at least two loose stools per day for ≥ 30 days) OR b) documented fever (for ≥ 30 days, 
intermittent or constant).  
 
Immunological classification 
 
Immunologic 
category 
Age of child 
< 12 months 1-5 years 6-12 years 
µL                 (%) µL                 (%) µL                 (%) 
1: No evidence of 
suppression 
≥1500            (≥25) ≥1000            (≥25) ≥500             (≥25) 
2: Evidence of 
moderate 
suppression 
750- 
1499          (15-24) 
500- 
999            (15-24) 
200- 
499            (15-24) 
3: severe 
suppression 
<750              (<15) <500              (<15) <200              (<15) 
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APPENDIX 2: SCREENING QUESTIONNAIRE 
 
Date of completion:            /          /          
 
 (dd/mm/yyyy)                              
Name of patient:          
 
Folder number:      
 
Date of birth:           /          /          
 
 (dd/mm/yyyy)                          
Diagnosis of HIV infectionb:        
 
Clinical classificationc:     
 
Immunological classificationc:     
 
Name of parent or caregiver (if parent is not caregiver):     
 
Why are parents not the caregiver?:        
 
Address:           
            
            
         
 
Contact number:       
 
Relation to patient:      
  
Is caregiver prepared to commit to long-term antiretroviral therapy:   
 
Does caregiver have a permanent address in Cape Town for longer than 3 months:  
 
Is caregiver prepared to complete a detailed questionnaire and serial evaluations:   
  
Is caregiver prepared to comply with adherence monitoring:    
 
Is parent with HIV infection prepared to receive antiretroviral therapy, if indicated:  
 
Has child been attending the IDC regularly (at least the last 3 appointments):   
 
Is child taking his / her medication regularly:    
 
Decision of panel:          
 
If accepted onto programme registration number (for data collection):    
 
Notes 
a) Doctor must present a summary of the clinical history of patient 
b) The CDC's paediatric HIV infection diagnosis guidelines will be followed i.e. evidence of HIV 
exposure and a positive HIV PCR result if age < 18 months and two positive HIV ELISA results 
if age > 18 months.19 
c) According to CDC classification system (Appendix 1).19
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APPENDIX 3: CONSENT PROCEDURE 
 
Antiretroviral therapy for HIV-infected children 
 
Assigned registration number:      
 
In rich countries antiretroviral therapy is considered routine treatment for people with HIV infection. 
Antiretroviral therapy has revolutionised the lives of many HIV-infected adults and children. The benefits to 
HIV-infected children include decreased risk for death, improved growth and fewer infections such as 
discharging ears, pneumonia, TB and diarrhoea. Some children who developed HIV infection soon after 
birth are living to beyond the age of fifteen years and remain healthy, because they are being treated with 
antiretroviral therapy.  
 
Doctors at the Infectious Diseases Clinic, Red Cross Children's Hospital are involved in establishing a long-
term treatment programme for HIV-infected children and their caregivers. This is not a research project but 
rather one of many responses to the uncontrolled HIV epidemic that has inflicted tremendous suffering on 
the South African population. The aim of the programme is to provide optimal medical treatment i.e. 
antiretroviral therapy to as many HIV-infected children and their caregivers as is possible. The success and 
sustainability of the programme is dependant on the ability to continue to attract local and international 
funds. As part of the programme we will be documenting the medical progress of the children as well as the 
problems of treating HIV-infected children with antiretroviral drugs in South Africa. This is important as the 
information will allow us to adapt the programme to suite the treatment needs of HIV-infected South 
Africans. All information will be entered into a database and analysed anonymously. This information will 
be communicated to the academic community at conferences and via publications in peer-review journals. 
Blood will be collected periodically to monitor the effects of treatment, including CD4+ count, viral load 
and other immunological markers. 
 
If you decide that your child should not participate in this programme, it will not affect the way we 
treat your child. S/he will continue to receive the same standard of care that s/he presently 
experiences. 
 
Consent 
 
I understand the above information as explained to me by:    and am prepared 
to have my child (NAME):     participate in this antiretroviral therapy 
programme. I understand that strict adherence is needed for continuation of antiretroviral therapy. 
The programme is dependant on financial donations and a time may come when antiretroviral 
therapy may be discontinued because of a lack of resources. Should antiretrovirals be discontinued 
my child will continue to attend the infectious diseases clinic and receive medical treatment. 
 
NAME:           
 
RELATION TO CHILD:         
 
SIGNATURE:            
 
DATE:           /          /          
 
 (dd/mm/yyyy)                           
WITNESSES:           
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BYLAE 3: TOESTEMMINGS PROCEDURE 
 
Anitretroviral therapy for HIV- infected children 
Registrasie nommer:_______________________________ 
 
In bevoorregde lande is ART ‘n roetine behandeling vir mense wat met die HIV besmet is. ART het die 
lewens van kinders en grootmense hervorm. Voordele van hierdie behandeling vir kinders wat met die HI 
Virus besmet is sluit in vermindering van die risiko van vroeer sterfte, verbeterde groei en ontwikkeling plus 
vermindering van infeksies soos,  oor infeksies, long ontsteking, TB en diarree. Somige kinders wat die HIV 
infeksie ontwikkel gou na geborte, lewe nou tot die ouderdom van 15 jaar en bly gesond omdat hulle met 
ART behandel is. 
 
Geneeshers by die Besmetlikheid Siektes Klinik by Rooi Kruis Kinder Hospitaal, is betrokke by die 
ontwikkeling van ‘n lang termyn behandelings program vir kinders wat met HIV besmet is en hul oppassers. 
Hierdie is nie ‘n narvorsings projek nie maar een van die reaksies tot die onbeheerde HIV epidemie wat Suid 
Afrika op die oomblik laat ondergaan. Die doel van die program is om gunstige sorg te verskaf, d.i. om ART 
behandeling vir so veel moontlik HIV besmette kinders en hul oppassers toe te dien. Die sukses van die 
program is afhanklik van die vermoe om aanhoudend binnelands en buitelandse vondse aan te trek. As deel 
van hierdie progam sal ons die mediese verloop van al die kinders dokumenteer asook die probleme wat 
hierdie kinders op die program ondervind. Dit is belangrike informasie en  dit sal ons die nodige inligting 
gee om hierdie program to ontwikkel en die behandeling behoftes aan te pas vir ander HIV besmette kinders 
in SA. Alle informasie sal op ‘n database ingeskryf word en sal naamloos ontleed word. Hierdie informasie 
sal versprei word deur die akademiese gemeentskap by konferensies en inskrywings in medise joernale. 
Bloed sal periodies van kinders geneem word om die uitwerking van die behandeling te monitor insluitend 
CD4+ telings, virus vrag en ander immun merker. 
 
As u besluit dat u nie u kind in hierdie program will inskryf nie, sal dit nie die huidige manier van sy 
behandeling beinvloed nie. Hy/Sy sal nog steeds dieselfde hoe standard van sorg kry. 
 
Toestemming 
 
Ek verstaan die bogenoemde informasie soos aan my verduidelik deur______________________ en ek 
is bereid om my kind (naam)_______________________________ in hierdie program te laat deel 
neem. Ek verstaan dat ek streng moet aankleef soos benodig vir aanhoudende ART behandeling. 
Hierdie progam is afhanklik van geldelike donasies en daarvoor mag die program skelik stop omdat 
die donasies nie voorkomend is nie. Sou dit gebeur sal my kind nog steeds die Besmetlikheid Siektes 
Klinik  bywoon en huidige medise behandeling ontvang. 
 
 
Naam: ______________________________________________________________ 
 
Verwantskap tot kind: _________________________________________________ 
 
Handtekening: _______________________________________________________ 
 
Datum:           /          /          
 
 (dd/mm/yyyy)                           
Getuie: ______________________________________________________________ 
               
               ______________________________________________________________ 
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I-APPENDIX 3: INDLELA YOKUNIKA ISIVUMELWANO 
 
Unyango ngamachiza alwa intsholongwane kaGawulayo (HIV)  kubantwana   abanayo.        
Inombolo yobhaliso enikeziweyo:______________________________________ 
 
Kumazwe atyebileyo unyango ngamachiza okulwa intsholongwane kaGawulayo luqatshelwe njengonyango 
olunokulandelwa ngabantu abosuleleke yile ntsholongwane. Olu nyango ngamachiza seluvuselele ubomi 
babantu abadala nabantwana abaninzi abosuleleke yile ntsholongwane. Inzuzo kubantwana 
abanentshlongwane kaGawulayo ibandakanya ukucutha amathuba okusweleka, ukukhula ngokufanelekiyo 
kunye nokosuleleka okumbalwa zizifo ezinjengokuphuma ubofu ngeendlebe, inyumoniya, isifo sephepha 
(TB) kunye norhudo. Abantwana abafunyenwe yile ntsholongwane kaGawulayo emva kokuzalwa bayaphila 
de bagqithe kwiminyaka elishumi elinesihlanu kwaye babe besaphile kakuhle ngokwase mpilweni, kuba 
benyangwa ngala machiza.  
           
Oogqirha kwiKliniki yezifo ezosulelayo, eRed Cross Children’s Hospital bazibandakanye nokumisela 
inkqubo ende yonyango lwabantwana abanale ntsholongwane kunye nabantu ababakhathalelayo. Olu 
asilophando oluzakuphela kwangoku koko yenye yeendlela zokusabela kwisihelegu sentsholongwane 
kaGawulayo engalawulekiyo nethe yalulwamvila lwentlupheko kuluntu lwaseMzantsi Afrika. Iinjongo zale 
nkqubo kukunika unyango olufikelelekayo, oko kukuthi, ukunika abantwana abanale ntsholongwane 
nabagcini babo amachiza nonyango olufanelekileyo kangangoko. Impumelelo nokuqhubela phambili kwale 
nkqubo kuxhomekeke ekukwazini ukutsala abanokunikezela ngemali balapha eMzantsi Afrika nabamazwe 
ngamazwe. Indima yale nkqubo iyakuba kukwenza amaxwebhu olwazi ngenkqubela phambili yabantwana 
kunye neengxaki abathi babenazo ekunyangeni abantwana abanale ntsholongwane ngala machiza eMzantsi 
Afrika. Lo nto ibalulekile njengoko ulwazi luya kusivumela ukuba simisele le nkqubo ukuze unyango 
luhambelane neemfuno zabantu abanentsholongwane kaGawulayo eMzantsi Afrika. Lonke ulwazi 
luyakugcinwa kwaye luhlalutywe ngokungasebenzisi gama lamntu. Olu lwazi luyakunikwa  i inzululwazi 
nenkcuba-buchopho ukuba zilusebenzise kwiinkomfa nakupapasho. Igazi liyakumana litsalwa ukujonga 
ukusebenza kwalamachiza, okubandakanya i-CD4 count, ubuninzi bentsholongwane egazini   kunye nezinye 
iimpawu ezilwa nosuleleko.   
 
Ukuba ugqiba ukuba umntwana wakho angayithabathi  inxaxheba kule nkqubo, lo nto ayisayi kuchaphazela 
indlela ebenyangwa ngayo lo mntwana wakho. Uyakuqhubeka efumana ukhathalelo olufanelekileyo 
alufumanayo ngoku.  
 
Isivumelwano 
 
Ndiyaluqonda olu lwazi lungentla njengoko lucaciswe ngu:______________________________ kwaye 
ndikulungele ukunikezela ngomntwana wam (IGAMA):______________________________________ 
ukuba athabathe inxaxheba kolu nyango ngamachiza okulwa intsholongwane kaGawulayo. Le nkqubo 
ixhomekeke kwiimali ezisisipho  kwaye lingafika ixesha lokungaqhubekeli phambili ngenxa yemali 
engekhoyo. Ukuba angangabikho la machiza, ndiyakuqhubekeka ndimsa umntwana wam kwikliniki yezifo 
ezosulelayo, ukuba afumane unyango. 
 
IGAMA:____________________________________________________________________________ 
 
UZALWANO NOMNTWANA _________________________________________________________ 
 
USAYINO:__________________________________________________________________________ 
 
UMHLA:____/____/______ (umhla/inyanga/unyaka) 
 
AMANGQINA:______________________________________________________________________ 
 
                           ______________________________________________________________________ 
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APPENDIX 4: SUMMARY CLINICAL AND BLOOD COLLECTION INSTRUCTIONS FOR 
CHILDREN 
 
CLINICAL 
 
 Initial assessment (complete Appendix 5) 
 Mantoux testing 
- before enrolling children on treatment programme 
- read horizontal diameter in mm 
 Neurodevelopmental follow-up (complete Appendix 6) 
- baseline, and 6 month and 1 year after starting ARV 
 Follow-up assessment (complete Appendix 7 at each clinic visit) 
- 2 weeks and 1 month after starting ARV 
- then monthly to 6 months 
- then 1-3 monthly 
 Adherence questionnaire (complete Appendix 8) 
- 3, 6 and 12 months after starting ARV  
 Detailed yearly evaluation (complete Appendix 12) 
 
BLOOD-TAKING AND LABORATORY ISSUES 
 
1. Viral load: Place 1.5 mL blood into an EDTA tube (Purple top) and mix well  
 Sampling: baseline then 6-monthly 
 Immunology laboratory: 
Send baseline and yearly samples to virology for viral load 
Store 2 x 250 µL aliquots of EDTA plasma @ -70°C at 6 mo, 18 mo, ..  
2. CD4+ count: Place 1.0 mL blood into an EDTA tube (purple top) and mix well 
 Sampling: baseline, then 6-monthly 
3. FBC + diff: Place 1.0 mL blood into an EDTA tube (purple top) and mix well 
 Sampling: baseline, 1 month, 3 months, then 3-6 monthly 
4. Chemistry: Place 1.0 mL blood into a heparin tube (green top) and mix well 
 Liver function tests to minimise costs only request 
- total bilirubin 
- conjugated bilirubin if total bilirubin is elevated 
- aspartate transferase (AST) 
- γ-gluteryl transferase (GGT) 
Sampling: baseline, 1 month, 3 months, then 3-6 monthly (yearly samples important) 
 Pancreatic amylase 
 Sampling: 6-monthly 
5. Fasting lipids: Place 1.5 mL blood into EDTA tube (purple top) and mix  well 
Sampling; baseline, then 6 and 12 months 
On a separate chemistry request form write: Attention Professor Marais, Lipid Lab, 5th floor SAMIOT Building, Medical 
School. Mark: ARV Paediatric study and indicate whether baseline, 6-month or 12-month sample. Request: Fasting lipids 
(cholesterol, triglycerides and GGE (gradient gel electrophoresis) 
6. Vitamin A and RBP: Place 2.5 mL blood into special heparin tube covered with tin foil 
 Sampling: baseline and 1 year 
 Immunology laboratory 
  Prepare aliquots for vitamin A and RBP (500µl and 250µL) and store 
7. Vaccine titres: Place 3 ml blood into clotted tube (red top) 
 Sampling: baseline and 1 year 
 Immunology laboratory 
  Save 5 x 300µL aliquots of serum and a balance tube and store at -70°C 
7. Fasting blood glucose: 1.0 mL blood in grey top tube  
 Sampling: 6-monthly  
 
LABELLING OF SAMPLES 
On microbiology  form for viral load requests write: HUSGD - Family clinic (this will ensure that it is costed to the correct 
account. 
CD4 counts/vitamin A/RBP/vaccine titres write: ARV study, if registration number available please include 
For ease of blood taking: do FBC, LFTs and baseline vaccine titres at the same time as screening CD4+ count.  
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APPENDIX 5: INITIAL ASSESSMENT - PAGE 1 
 
I BIOGRAPHICAL / SOCIAL PROFILE 
 
Registration number (assigned to patient):     
 
Date of completion:           /          /          
 
 (dd/mm/yyyy)                 
PRIMARY CAREGIVER 
 
Mother 
 
Age (years): Primary caregiver:           1. yes                    2. no 
HIV status 1. unknown 2. positive 3. negative 
 
Relationship status 1. single 2. partner 3. married Duration (2/3): 
Are you married to the child's father?                    1. yes                   2. no  
 
Education (level attained): 
 
Are you employed? 1. yes 2. no Nature of work: 
 
Does the child's father help with money? 1. yes 2. no 
 
Does anyone else help financially?  1. yes 2. no 
Who? 1. your parent 2. other family 3. another partner 
4. your sibling 5. friend 6. other, specify: 
 
Do you receive a grant? 1. yes 2. no 
Child support grant Care dependency grant Disability grant (self) 
 
Is other parent living with the family? 1. yes 2. no 
If not: 1. left due to pregnancy 2. left due to HIV diagnosis 3. died 
4. other 5. specify: 
 
 
Father 
 
Age (years): Primary caregiver:           1. yes                    2. no 
HIV status 1. unknown 2. positive 3. negative 
 
Relationship status 1. single 2. partner 3. married Duration (2/3): 
Are you married to the child's mother?                    1. yes                   2. no  
 
If caregiver is not the 
mother, has: 
1. she died 2. abandoned child 3.other, specify: 
 
Education (level attained): 
 
Are you employed? 1. yes 2. no Nature of work: 
 
Does the child's mother help with money? 1. yes 2. no 
 
Does anyone else help financially?  1. yes 2. no 
Who? 1. your parent 2. other family 3. another partner 
4. your sibling 5. friend 6. other, specify: 
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APPENDIX 5: INITIAL ASSESSMENT - PAGE 2 
 
Do you receive a grant? 1. yes 2. no 
Child support grant Care dependency grant Disability grant (self) 
 
Is other parent living with the family? 1. yes 2. no 
If not: 1. died 2. left due to HIV diagnosis 
4. other 5. specify: 
 
Primary caregiver who is not a parent 
 
Age (years): Primary caregiver:           1. Yes                    2. no 
 
Relation to child? 1. Maternal grandmother 
2. Paternal grandmother 3. Aunt 
4. Other Specify: 
 
HIV status 1. unknown 2. positive 3. negative 
 
Relationship status 1. single 2. partner 3. married Duration (2/3): 
 
If caregiver is not the 
mother, has: 
1. she died 2. abandoned child 3.other, specify: 
 
Education (level attained): 
 
Are you employed? 1. yes 2. no Nature of work: 
 
Does the child's mother help with money? 1. yes 2. no 
 
Does anyone else help financially?  1. yes 2. no 
Who? 1. child's father 2. other family 3. your partner 
4. your sibling 5. friend 6. other, specify: 
 
Do you receive a grant? 1. yes 2. no 
Child support grant Care dependency grant 
Foster child grant Disability grant (self) 
 
Housing information 
 
Suburb of residence: 
 
Type of dwelling: 1. formal 2. informal 3. other 
Serviced (water): 1. yes 2. no 
Serviced (electricity): 1. yes 2. no 
  
Access to a functioning refrigerator: 1. yes 2. no 
 
Who owns the home: 
 
Support system (HIV- infected parent) 
 
Does someone help you when you are ill: 1. yes 2. no 
  
Who: 1. other parent 2. another partner 3. your parent 
4. your sibling 5. other family 6. other (specify): 
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Disclosure information (HIV-infected parent) 
 
Is child’s other parent aware of your HIV status: 1. yes 2. no 
 
Is child’s other parent aware of child’s HIV status: 1. yes 2. no 
 
Is other parent’s HIV status known: 1. yes 2. no 
 
Is your mother alive: 1. yes 2. no 
Does she know your and your child’s status: 1. yes 2. no 
Is she supportive:   1. yes 2. no 
 
Where does she live (suburb):  
 
 
II. ASSESSMENT OF CHILD 
  
Date of Birth:           /          /          
 
 (dd/mm/yyyy)     Sex:   M      F        
Age at registration (months):    
 
Perinatal / early infancy history 
 
Gestational age at birth weeks 
Birth weight                                                          grams 
 
MTCT intervention 1. yes 2. no 
Details of programme: 
Early infant feeding Breast only Formula only Mixed 
 
Immunization during the first 2 years of life 
 
BCG Polio drops DPT Hib Hepatitis B Measles 
      
      
      
      
 
Developmental milestones (Appendix 8) 
 
PARAMETER FUNCTIONING AGE IN MONTHS 
Gross motor  
Fine motor  
Hearing / speech  
Personal / social  
DQ*  
*Developmental quotient (DQ) = [functioning age / chronological age] X 100 
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Previous hospital admissions in the last 2 years  
 
Date Where Duration (days) Diagnosis 
    
    
    
    
    
 
Previous tuberculosis 
 
Previously treated for tuberculosis? 1. yes 2. no 
 
Date Where Duration (months) Strength of 
diagnosis• 
    
    
    
    
 
• World Health organisation classification: 1 = definite, 2 = probable, 3 = definite (Appendix 11).29  
 
Clinical features 
 
Growth and nutrition (current) 
 
Body mass (kg): Percentile: Z score: 
Length (cm): Percentile: Z score: 
BMI (W/H2): Percentile: Z score: 
W/H z score: Head circum (cm): Percentile: 
MUAC (cm): Percentile: Z score: 
Peripheral oedema? 1. yes 2. no 
 
Recent body mass recorded in the clinic recorded at least 30 days prior to the current date 
 
Date when mass recorded: Age (months): 
Body mass (kg): Percentile: Z score: 
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Clinical features and complications of HIV infection (current) 
 
Generalised lymphadenopathy 1. yes 2. no 
Hepatomegaly 1. yes 2. no 
Splenomegaly 1. yes 2. no 
Dermatitis 
     Active papular urticaria 
 
1. yes 
 
2. no 
     Active eczema 1. yes 2. no 
     Active impetigo 1. yes 2. no 
     Active molluscum contagiosum 1. yes 2. no 
     Active other 1. yes 2. no 
     Inactive / evidence of old lesions 1. yes 2. no 
Digital clubbing 1. yes 2. no 
Parotitis 1. yes 2. no 
Oral candidiasis (≥ 2 months) 1. yes 2. no 
Chronic otitis media (≥ 30 days) 1. yes 2. no 
Chronic diarrhoea (≥ 30 days) 1. yes 2. no 
Chronic lung disease♣ (unspecified) 1. yes 2. no 
Lymphoid interstitial pneumonitis 1. yes 2. no 
HIV encephalopathy (criteria) 
     1. DQ < 75% or regression 
 
1. yes 
 
2. no 
     2. Microcephaly 1. yes 2. no 
     3. Motor deficit 1. yes 2. no 
HIV encephalopathy present (at least 2 criteria)  1. yes 2. no 
Cardiomyopathy 1. yes 2. no 
Nephropathy 1. yes 2. no 
Other (specify): 
 
 
♣ Clinical and / or radiological features persisting for ≥ 6 weeks  
 
CDC clinical classification (Appendix 1): 
 
 
Laboratory findings 
 
Mantoux: 
 
Viral load (copies / mL)  
Log10 viral load  
CD4+ count (x 109/L)  
CD4+ count (percentage)  
 
CDC immunological classification (Appendix 1): 
 
Haematology results Interpretation  
(↑, N, ↓) 
Grading if Abn.  
(Appendix 6) 
Hb (g/dL)    
MCV (fL) 
   
WCC (x 109/L)    
Neutrophils (x 109/L)    
PLT count (x 109/L)    
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Chemistry results Interpretation  
(↑, N, ↓) 
Grading if Abn.  
(Appendix 6) 
Bilirubin (µmol/L)    
Conjugated bilirubin 
(µmol/L)  
   
Aspartate transferase 
(U/L) 
   
γ-glutamyl 
transferase (U/L) 
   
Pancreatic amylase 
(U/L) 
   
Cholesterol (mmol/L)    
 
 
III INITIAL THERAPY 
 
Antiretroviral therapy 
 
Drug Dosing instruction 
  
  
  
  
 
 
Other medication 
 
Drug Dosing instruction 
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Name 
DOB 
Folder number 
Registration number 
 
Drugs       Status at start of ARV treatment  
1.       Clinical cat: 
2.       Immune cat 
3.      
4.     
5.     
6.     
 
Visit Date Mass Length HC MUAC Comments 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
 
SERIOUS OR SEVERE ADVERSE EVENTS / SERIOUS ILLNESSES 
 
1. 
2. 
3. 
4. 
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Registration number:   Start of ARV (date):     
 
Medicine Dose Times / day Date  
commenced 
Date stopped / 
changed 
1.     
2.     
3.     
4.     
5.     
 
Medicine Adherence Wk 0 Wk 4 Wk 8 Wk 12 Wk 16 
 Dispensed (ml or tabs): 
Expected usage: 
Actual usage: 
% Adherence: 
     
 Dispensed (ml or tabs): 
Expected usage: 
Actual usage: 
% Adherence: 
     
 Dispensed (ml or tabs): 
Expected usage: 
Actual usage: 
% Adherence: 
     
Medicine Adherence Wk 20 Wk 24 Wk 28 Wk 32 Wk 36 
 Dispensed (ml or tabs): 
Expected usage: 
Actual usage: 
% Adherence: 
     
 Dispensed (ml or tabs): 
Expected usage: 
Actual usage: 
% Adherence: 
     
 Dispensed (ml or tabs: 
Expected usage: 
Actual usage: 
% Adherence: 
     
Medicine Adherence Wk 40 Wk 44 Wk 48 Wk 52  
 Dispensed (ml or tabs): 
Expected usage: 
Actual usage: 
% Adherence: 
     
 Dispensed (ml or tabs): 
Expected usage: 
Actual usage: 
% Adherence: 
     
 Dispensed (ml or tabs): 
Expected usage: 
Actual usage: 
% Adherence: 
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Registration number:  Start of ARV (date):     
 
Symptom, sign, 
illness1 or adverse 
event 
Onset date Resolution date 
(leave blank if 
continuing) 
Intensity 
1=mild / grade 1 
2=moderate / grade 
2 
3=severe / grade 3 
4=very severe / 
grade 4 
Relationship to ARV 
1=certain,  
2=probable,  
3=possible, 4=not 
likely,  
5 = unrelated 
Action taken 
regarding ARV 
1=none, 2=dose 
reduced 
3=interrupted, 
4=discontinued, 
5=dose increased 
Treatment required 
(yes / no) 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
1Minor illnesses include: upper respiratory infection, oral thrush, otitis media, impetigo, diarrhoea requiring ambulatory treatment 
 Major illnesses include: TB, pneumonia (radiologically proven), pneumonia (clinical diagnosis), bacteremia/septicaemia, urinary infection, diarrhoea requiring 
hospitalisation, meningitis  
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Registration number:   Start of ARV (date):     
 
Visit Viral 
load 
(copies / 
mL) 
Log10 
viral 
load 
CD4+ 
count     
(x 109/L) 
CD4+ 
percent 
Hb 
(g/dL) 
MCV 
(fL) 
Neutro-
phils      
(x 
109/L) 
PLT 
(x 109/L) 
Total 
bilirubin 
(µmol/L) 
Conj. 
Bilirubin 
(µmol/L) 
AST 
(U/L) 
γGT 
(U/L) 
Amylase 
(U/L) 
Choles-
terol 
(mmol/L) 
Blood 
sugar 
(mmol/L) 
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Note to the interviewer 
WORDS IN ITALIC ARE INSTRUCTIONS TO THE INTERVIEWER 
WORDS IN NORMAL FONT ARE TO BE READ IN INTERVIEW 
 
This script is to be used with the Adherence Data Collection sheet. When placed side by side, 
questions correspond to answer blocks in the data collection sheet. 
Circle appropriate answer of fill in tables according to the numbering key provided. 
 
The interviewee should be the person actually
 
 primarily responsible for giving the 
medication. In order to establish who this is in a non-judgemental way it is necessary to read 
the introductory remarks to the interviewee BEFORE asking about who actually gives the 
medication, (PART A, question 1). If the interviewee is not the one who actually gives the 
medication, except under exceptional circumstances, it is best to stop the interview at this 
point and make arrangements for the person primarily responsible for giving the medications 
to come in at the next visit. 
Older children may take responsibility for their medication themselves. The wording of 
questions should then be changed appropriately (e.g. take medicines instead of give 
medicines, omit "CHILD'S NAME"
 
, etc).  
 
Hallo. I am ……….. We're trying to find out how people are managing with giving the 
antiretroviral medicines to their children. So, I'd like to ask you some questions about how 
you are giving the medicines to (CHILD'S NAME) at home.. 
 
We know that there are many different medicines that you need to give at different times 
during the day. This can be difficult to do for many reasons. Some people find it hard to 
remember to give medicines, some may not be at home at the right time and forget to carry 
their medicines with them, some are confused about the instructions for so many medicines, 
some children refuse to take the medicines or spit them out, and sometimes people just feel 
like having a break from the hard work of sticking to the medicines. 
 
It's important for us to know what you are actually doing at home, so that we can find ways to 
make the medicines easier to give and help all our patients to be able to use them. So don't 
worry about telling us that you are not giving the medicines. We want to know what is really 
happening, not what you think we want to hear. Your answers will not affect your access to 
antiretroviral medicines in any way. 
 
All the information you provide is confidential. It will not be given to your relatives or 
friends, to anybody outside this clinic, to the government or to anyone else. You do not have 
to answer a particular question if you don't want to, and you are free to stop this interview at 
any time if you don't want to carry on. Do you have any questions before we start? 
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ADHERENCE QUESTIONNAIRE: STANDARDISED SCRIPT 
 
PART A 
 
The first thing we need to do is to find out who exactly gives the medicines at home: 
 
1. Who is the person mainly responsible for giving the medicines to (CHILD’S NAME
 
)? 
(For the interview to be worthwhile, this should be the interviewee. If not, except under 
exceptional circumstances, it is best to stop the questionnaire at this point and make 
arrangements for the person primarily responsible for giving the medications to come in at 
the next visit.) 
 
2. What is your relationship to (CHILD’S NAME
 
)? 
Now we need to make sure that we are both talking about the same medicines. 
 
Medicines that directly fight HIV, the virus that causes AIDS, are called ‘antiretrovirals’. 
There may be some other medicines as well as the antiretrovirals that you are giving 
(CHILD’S NAME
 
) . All the medicines are important, but for now I am only asking you about 
the medicines that directly fight HIV, the antiretrovirals. 
3. (a) Can you tell me what medicines you are supposed to be giving (CHILD’S NAME
(Subjects can: name the drug, list its characteristics (the pink medicine) or identify special 
labelling features. Naming the drug correctly in ANY of these ways will score a ‘1’ in the 
adherence table.) 
) to 
fight HIV?  
 
3. (b) For each drug mentioned: How many times a day are you supposed to give (drug name 
or characteristics as mentioned above)? Don’t tell me how many spoons or how many pills 
you are supposed to give, just how many times a day? 
 
If all drugs not mentioned, then you can prompt: 
3. (c) Are there any other medicines to fight HIV that you are supposed to be giving  
 
(CHILD’S NAME
Repeat Q 3(b) above 
) ? 
 
Subject is specifically questioned about prescribed medicines not yet mentioned at this point: 
 
3. (d) Are you supposed  to be giving (drug name and characteristics e.g.) ? 
Repeat Q 3 (b) above. 
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ADHERENCE QUESTIONNAIRE: STANDARDISED SCRIPT - CONTINUED 
 
PART A – CONTINUED 
 
5. Now for (drug name and characteristics) it looks to me like this medicine needs to be 
given ….. times each day. 
(State the correct number of doses, not the number mentioned in (4) above). 
 
5. (a) Think about yesterday. Did you give it all …. Times, or did you miss a dose? If so, how 
many doses did you miss? 
 
5. (b) Think about the day before yesterday. That would have been ………. Did you give it 
all …. times, or did you miss a dose? If so, how many doses did you miss? 
 
5. (c ) Try to think back just one more day.  That would have been…….. Did you give it all 
………. times, or did you miss a dose? If so, how many doses did you miss? 
 
Repeat Q 5 for each drug. 
 
6. Some people find that they forget to give the HIV medicines on the weekend days. Did you 
miss out on giving any of the medicines last weekend? 
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ADHERENCE QUESTIONNAIRE: DATA COLLECTION SHEET 
 
PART A 
 
 
 
 
 
 
Question 1 
 
Name the person answering questionnaire and primarily responsible for giving ARVs: 
 
 
Question 2 
 
1. child 
2. biological mother 
3. biological father 
4. grandmother 
5. other relative (specify)       
6. other (specify)        
 
Questions 3 – 5: medication table 
 
Special notes: 
1First 3 columns to be filled in by pharmacist before interview 
Expected doses = number of doses per 24 hour period, not number of pills/teaspoons 
 
2Identification 
1 – Medicine name or description volunteered without 
prompt  
2 – Medicine name or description volunteered with 
prompt 
3 – Acknowledged medicine when reminded 
4 – Did not show any knowledge of medicine 
3Doses missed    
0 – if no doses missed 
1 – missed one dose     
2 – missed all doses 
 
 
 
Complete before interview Complete during interview 
Drug name1 Description1 
(Colour; special 
identifying labels) 
Expected 
doses1 
Identification by 
patient2 
Reported 
prescribed 
doses 
Doses missed3 
Yester-
day 
2 days 
ago 
3 days 
ago 
        
        
        
        
        
 
Question 6 
 
Yes No Don’t know  
Child’s Name: 
Reg number: 
 
Date of questionnaire:
 
 Weeks on ART:   12     24       48  
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ADHERENCE QUESTIONNAIRE: STANDARDISED SCRIPT 
 
PART B 
 
1. Since your last visit, have you used any special aids to help you remember to give the medicines or done 
anything to make it easier to give the medicine? 
 
I am going to read you a list of some of the things that other people do. Please tell me if you have used any 
of these to help you to remember the medicines: (read list)  
Have you done any of these things? 
Have you done anything else to help you with giving the medicines? 
 
2. Now I'd like to ask you about some of the things that make it difficult for you to give the medicines to 
(CHILD'S NAME
 
). 
Do you have problems with giving all of the medicines, some of the medicines, or do you have no problems 
with giving the medicines. 
If none, proceed to question 5. 
If some, proceed to question 4. 
If all, proceed to question 3 and omit question 4. 
 
 
3. (a) I am going to read you a list of the things that other people say make it difficult to give the medicines. 
Please tell me if any of these things make it difficult for you to give ALL the medicines. At this stage, don't 
mention problems that you only have with one or two of them. (Read list opposite page) Are there any other 
reasons why you find it difficult to give the medicines? 
 
3. (b) For each problem identified: Is this a problem occasionally, about half the time, or almost always? 
 
3. (c) (i) Do you experience more difficulty with some of the medicines than with others? 
         (ii) Can you say why you find it more difficult to give ……… ? 
              Would you like me to read the list of reasons for not giving the medicines again? 
         (iii) For each problem identified: Is this a problem occasionally, about half the time, or almost  
         always? 
         (iv) Are there any other medicines that you find particularly difficult to give? 
         (If yes, repeat (iii) to (iv) until subject says none of the rest of the medicines are especially  
         difficult to give)  
 
4 (a) Which medicines do you find difficult to give? 
   (b) I am going to read you a list of some of the things that other people say make it difficult to give  
    some of the  medicines. 
   Please tell me if any of these things make it difficult for you to give (name/characteristics of 1st   
   medicine  identified as a problem) or if there is another reason why it is difficult to give? 
   (c ) Is this a problem occasionally, about half the time, or almost always? 
   (d) Are any of these things I've read out a problem with (name/characteristics of 2nd medicine    
   identified as a problem)? Repeat (c ). (Continue in this way, repeating (d) and (c ) until all medicines  
   identified as problematic have been covered) 
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ADHERENCE QUESTIONNAIRE: DATA COLLECTION SHEET 
 
PART B 
 
Question 1 
 
Circle ALL methods used: 
Special 
labels 
Calendar/
diary 
Alarms/bleepers Activity of daily living triggers (e.g. 
brushing teeth) - specify: 
Treatment partner Disguise taste - specify: Other - specify: 
 
Question 2 
 
All   some  none 
 
Questions 3 & 4 
 
Special notes on filling in table 
1Write in name of medicine  
For each problem: leave blank if not a problem; enter 1 – sometimes; 2 – often; 3 - almost always 
 
Why difficult? All Med 11 Med 21 Med 31 Med 41 
I was away from home      
I was busy with other things      
I just forgot      
There was too much medicine to give      
I was worried about the side effects      
I did not want others to notice me 
giving the medicine 
     
The medicine tastes bad      
My child refused to take the medicine 
or spat it out 
     
There was a change in daily routine      
I felt the medicine might be harmful to 
my child 
     
There are lots of people looking after 
the child and I am not always with 
him/her at the right time 
     
I was ill      
My child was ill      
I felt depressed      
I ran out of medicine      
My child was well      
Other, specify:      
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ADHERENCE QUESTIONNAIRE: STANDARDISED SCRIPT 
 
PART C 
 
1) Do you attend a support group? 
a) Which one? 
b) When was the last time you went to a support group meeting? 
 
2) Do you think the antiretroviral medicines are helping (child's name)? 
 
3) Do you think the antiretroviral medicines make (child's name) sicker? 
 
4)  If you were to stop giving (child's name) the antiretroviral medicines, do you think he/she would get 
sicker? 
 
Thank you for helping us by answering these questions. 
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ADHERENCE QUESTIONNAIRE: DATA COLLECTION SHEET 
 
PART C 
 
Question 1 
 
Yes  No 
 
(a) 
 
Name of support group: 
 
(b) 
 
Less than 2 weeks 
ago 
Within the last 
month 
1-2 months ago More than 2 
months ago 
Never 
 
Question 2 
 
Yes  No  Don't know 
 
Question 3 
 
Yes  No  Don't know 
 
 
Question 4 
 
Yes  No  Don't know 
 
 
Questionnaire completed by: 
 
      
 
Interview conducted in: English Afrikaans Xhosa  Other 
 
Interpreter used  Y / N 
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Registration number (assigned to patient):     
 
Date of completion:           /          /          
 
 (dd/mm/yyyy)                 
 
PRIMARY CAREGIVER 
 
Relation to child 1. mother 2. father 
3. other                        Specify:  
 
HIV status 1. unknown 2. positive 3. negative 
Has your health changed over last year? 1. improved 2. deteriorated 
 
Are you employed? 1. yes 2. no Nature of work: 
 
Does anyone else help financially?  1. yes 2. no 
Who? 1. your parent 2. other family 3. partner 
4. your sibling 5. friend 6. other, specify: 
 
Do you receive a grant? 1. yes 2. no 
Child support grant Care dependency grant 
Foster child grant Disability grant (self) 
 
ASSESSMENT OF CHILD 
  
Date of Birth:           /          /          
 
 (dd/mm/yyyy)     
Age at registration (months):    
 
Developmental milestones (Appendix 8) 
 
PARAMETER FUNCTIONING AGE IN MONTHS 
Gross motor  
Fine motor  
Hearing / speech  
Personal / social  
DQ*  
*Developmental quotient (DQ) = [functioning age / chronological age] X 100 
 
Previous hospital admissions in the last 2 years  
 
Date Where Duration (days) Diagnosis 
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Previous tuberculosis 
 
Previously treated for tuberculosis? 1. yes 2. no 
 
Date Where Duration (months) Strength of 
diagnosis• 
    
    
    
    
• World Health organisation classification: 1 = definite, 2 = probable, 3 = definite (Appendix 11).29  
 
Clinical features 
 
Growth and nutrition (current) 
 
Body mass (kg): Percentile: Z score: 
Length (cm): Percentile: Z score: 
BMI (W/H2): Percentile: Z score: 
W/H z score: Head circum (cm): Percentile: 
MUAC (cm): Percentile: Z score: 
Peripheral oedema? 1. yes 2. no 
 
Clinical features and complications of HIV infection (current) 
 
Generalised lymphadenopathy 1. yes 2. no 
Hepatomegaly 1. yes 2. no 
Splenomegaly 1. yes 2. no 
Dermatitis 
     Active papular urticaria 
 
1. yes 
 
2. no 
     Active eczema 1. yes 2. no 
     Active impetigo 1. yes 2. no 
     Active molluscum contagiosum 1. yes 2. no 
     Active other 1. yes 2. no 
     Inactive / evidence of old lesions 1. yes 2. no 
Digital clubbing 1. yes 2. no 
Parotitis 1. yes 2. no 
Oral candidiasis (≥ 2 months) 1. yes 2. no 
Chronic otitis media (≥ 30 days) 1. yes 2. no 
Chronic diarrhoea (≥ 30 days) 1. yes 2. no 
Chronic lung disease♣ (unspecified) 1. yes 2. no 
Lymphoid interstitial pneumonitis 1. yes 2. no 
HIV encephalopathy (criteria) 
     1. DQ < 75% or regression 
 
1. yes 
 
2. no 
     2. Microcephaly 1. yes 2. no 
     3. Motor deficit 1. yes 2. no 
HIV encephalopathy present (at least 2 criteria)  1. yes 2. no 
Cardiomyopathy 1. yes 2. no 
Nephropathy 1. yes 2. no 
Other (specify): 
 
 
♣ Clinical and / or radiological features persisting for ≥ 6 weeks  
 
CDC clinical classification (Appendix 1): 
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Laboratory findings 
 
Viral load (copies / mL)  
Log10 viral load  
CD4+ count (x 109/L)  
CD4+ count (percentage)  
 
CDC immunological classification (Appendix 1): 
 
Haematology results Interpretation  
(↑, N, ↓) 
Grading if Abn.  
(Appendix 6) 
Hb (g/dL)    
MCV (fL)    
WCC (x 109/L)    
Neutrophils (x 109/L)    
PLT count (x 109/L)    
 
Chemistry results Interpretation  
(↑, N, ↓) 
Grading if Abn.  
(Appendix 6) 
Bilirubin (µmol/L)    
Conjugated bilirubin (µmol/L)     
Aspartate transferase (U/L)    
γ-glutamyl transferase (U/L)    
Pancreatic amylase (U/L)    
Cholesterol (mmol/L)    
 
INITIAL THERAPY 
 
Antiretroviral therapy 
 
Drug Dosing instruction 
  
  
  
  
 
Other medication 
 
Drug Dosing instruction 
  
  
  
  
 
 139 
 
ANNEXURE B: OFFICIAL LETTER OF ETHICAL APPROVAL FROM UNIVERSITY 
OF CAPE TOWN FACULTY OF HEALTH SCIENCES RESEARCH ETHICS 
COMMITTEE 
- UNIVER$ITY OF GAPE TOWN
Research Ethics Committee
E52 Room ?4,Old lloin Buildirg Groote
Schuur HosPitol, Observotory, 7925
Queries: Lomees Emjedi
Tel : (021) 406-6338 Fox: 406-6411
E-tnoil : lemjedi@curie.uct.ac.zo
18 July 2OO3
REC REF: 26t120o,2
Dr B Eley
Poediotrics
Red Cross
Dear Dr Eley
ANTTRETROuIML TlERlPl/-€tIDEIJI.ES FOR THE TREATIIENT OF A COI|oRT OF |{IV-XIfECTED
CI{IDREN AND THEIR II\I3ECTED PARENT5 AT RED CROSS CHIIDRENS I{OSflITAL
Thank you for your leffer fo the Research Ethics Commitfee doted 13 'fuly 20O3'
rt is a plasure to inform you thaf fhe Ethics commiftee has fonnlly apprcrcd the
above-menfioned stuQ on the 16,7u12OO3'
Please qwte the PEC. PEF in all yov cotespondetre'
Yours sincerelY
PROF T. ZABOW
CHAIRPERSON
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General information
You are advised also to read About this journal, which includes other relevant information.
Submission process
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The submitting author takes
responsibility for the article during submission and peer review.
To facilitate rapid publication and to minimize administrative costs, BMC Pediatrics accepts only online submission. The submission process is compatible with
version 3.0 or later of Internet Explorer and Netscape Navigator, and with most other modern web browsers. It can be used from PC, Mac, or Unix platforms.
Files can be submitted as a batch, or one by one. The submission process can be interrupted at any time - when users return to the site, they can carry on
where they left off.
See below for examples of acceptable word processor and graphics file formats. Additional files of any type, such as movies, animations, or original data files,
can also be submitted as part of the publication.
During submission you will be asked to provide a cover letter. Please use this to explain why your manuscript should be published in the journal and to
elaborate on any issues relating to our editorial policies detailed in the instructions for authors.
Assistance with the process of manuscript preparation and submission is available from the customer support team (info@biomedcentral.com).
We also provide a collection of links to useful tools and resources for scientific authors, on our Tools for Authors page.
Publication and peer review processes
Submitted manuscripts will be sent to peer reviewers, unless they are either out of scope or below threshold for the journal, or the presentation or written
English is of an unacceptably low standard. They will generally be reviewed by two experts with the aim of reaching a first decision as soon as possible.
Statistical reviewers are also used where required (for a full list of our statistical advisers, please click here). Reviewers are asked to declare any competing
interests and have to agree to open peer review, which works on two levels: the authors receive the signed report and, if the manuscript is published, the same
report is available to the readers. The pre-publication history (initial submission, reviews and revisions - see, for example, pre-publication history) is posted on
the web with the published article.
Reviewers are asked whether the manuscript is scientifically sound and coherent, how interesting it is and whether the quality of the writing is acceptable.
Where possible, the final decision is made on the basis that the peer reviewers are in accordance with one another, or that at least there is no strong dissenting
view. In cases where there is strong disagreement either among peer reviewers or between the authors and peer reviewers, advice is sought from a member of
the journal's Editorial Board. The journal allows a maximum of two revisions of any manuscript. All appeals should be directed to the Medical Editor. The
ultimate responsibility for editorial decisions lies with the Editor-in-Chief.
Reviewers are also asked to indicate which articles they consider to be especially interesting or significant. These articles may be given greater prominence and
greater external publicity, and the authors may be asked if they would prefer to have the manuscript published in BMC Medicine
Submitted manuscripts will be sent to peer reviewers, unless they are either out of scope or below threshold for the journal, or the presentation or written
English is of an unacceptably low standard. They will generally be reviewed by two experts with the aim of reaching a first decision as soon as possible. A third
reviewer, generally one of the journal's advisers, will be used where necessary. Statistical reviewers are also used where required (for a full list of our statistical
advisers, please click here). In addition, advice on whether the article is of sufficient significance for publication in BMC Medicine will generally be obtained from
a member of the Editorial Board or a researcher of equivalent standing. Reviewers are asked to declare any competing interests and have to agree to open peer
review, which works on two levels: the authors receive the signed report and, if the manuscript is published, the same report is available to the readers. The
pre-publication history (initial submission, reviews and revisions - see, for example, pre-publication history) is posted on the web with the published article.
Reviewers are asked whether the manuscript is scientifically sound and whether it is of sufficient significance for publication in BMC Medicine. They are told that
should the work be sound but of limited significance, the authors will be given the option of publication without further review in one of the BMC subject-specific
journals. In cases where there is strong disagreement either among peer reviewers or between the authors and peer reviewers, advice is sought from a member
of the journal's Editorial Board. The journal allows a maximum of two revisions of any manuscript. All appeals should be directed to the Medical Editor. The
ultimate responsibility for editorial decisions lies with the Editor-in-Chief.
Once an article is accepted, it is published in BMC Pediatrics immediately as a provisional PDF file. The paper will subsequently be published in both fully
browseable web form, and as a formatted PDF. The article will then be available through BMC Pediatrics, BioMed Central and PubMed Central, and will also be
included in PubMed.
BMC Pediatrics | Instructions for authors
http://www.biomedcentral.com/bmcpediatr/ifora/&print=yes&print=yes[4/20/2010 8:59:37 AM]
Authors will be able to check the progress of their paper through the submission system at any time by logging into My BioMed Central , their personalized
section of the site.
Article-processing charges 
BMC Pediatrics levies an article-processing charge for every accepted article, to cover the costs incurred by open access publication. In 2010 the article-
processing charge is £1125/US$1735/€1285. Generally, if the submitting author's institution is a BioMed Central member the cost of the article processing
charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are supporter members of BioMed Central,
however, a discounted article processing charge is payable by the author. Please click here to check if your institution is a BioMed Central member. We routinely
waive charges for authors from low-income countries. For further details, see more information about article-processing charges.
Editorial policies
Any manuscripts, or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not
have already been published in any journal or other citable form, although it may have been deposited on a preprint server. The journal is willing to consider
peer-reviewing manuscripts that are translations of articles originally published in another language. In this case, the consent of the journal in which the article
was originally published must be obtained and the fact that the article has already been published must be made clear on submission and stated in the abstract.
Further information on duplicate/overlapping publications can be found here. Authors are required to ensure that no material submitted as part of a manuscript
infringes existing copyrights, or the rights of a third party. Authors who publish in BMC Pediatrics retain copyright to their work (more information).
Correspondence concerning articles published in BMC Pediatrics is encouraged through the online comment system.
Submission of a manuscript to BMC Pediatrics implies that all authors have read and agreed to its content, and that any experimental research that is reported
in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the
Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the
Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Informed consent must
also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework, e.g. if
the severity of the experimental procedure is not justified by the value of the knowledge gained.
BMC Pediatrics 's publisher, BioMed Central, has a legal responsibility to ensure that its journals do not publish material that infringes copyright, or that includes
libellous or defamatory content. If, on review, your manuscript is perceived to contain potentially libellous content the journal Editors, with assistance from the
publisher if required, will work with authors to ensure an appropriate outcome is reached.
Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in parentheses in the Methods section.
We ask authors of BMC Pediatrics papers to complete a declaration of competing interests, which should be provided as a separate section of the manuscript, to
follow the Acknowledgements. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.
Much has been written about competing interests (or conflict of interest, as other journals call it) within scientific research, but the following articles provide
some background:
R Smith: Beyond conflict of interest. BMJ 1998, 317 :291-292 
R Smith: Making progress with competing interests. BMJ 2002, 325 :1375-1376 
CD DeAngelis, PB Fontanarosa, A Flanagin: Reporting financial conflicts of interest and relationships between investigators and research
sponsors. JAMA 2001, 286 :89-9 
K Morin, H Rakatansky, FA Riddick Jr, LJ Morse, JM O'Bannon 3rd, MS Goldrich, P Ray, M Weiss, RM Sade, MA Spillman: Managing conflicts of interest
in the conduct of clinical trials. JAMA 2002, 287 :78-84
For all articles that include information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must also
be mailed or faxed to the editorial staff. The manuscript should also include a statement to this effect in the Acknowledgements section, as follows: "Written
consent for publication was obtained from the patient or their relative."
BMC Pediatrics supports initiatives to improve the performance and reporting of clinical trials, part of which includes prospective registering and numbering of
trials. The International Committee of Medical Journal Editors (ICMJE) defines a clinical trial as any research study that prospectively assigns human subjects to
one or more health related interventions to evaluate the effects on health outcomes. Authors of protocols or reports of such clinical trials, where the primary
purpose of the research is to understand the causes, development and effects of disease, or to improve preventative, diagnostic or therapeutic interventions,
must register their trial prior to submission in a suitable publicly accessible registry. Registries which meet the requirements of the ICMJE include WHO Primary
Registries. The trial registration number should be included as the last line of the abstract of the manuscript.
BMC Pediatrics also supports initiatives aimed at improving the reporting of biomedical research. Checklists have been developed for a number of study designs,
including randomized controlled trials (CONSORT), systematic reviews (PRISMA), meta-analyses of observational studies (MOOSE), diagnostic accuracy studies
(STARD) and qualitative studies (RATS). We recommend authors refer to the EQUATOR network website for further information on the available reporting
guidelines for health research, and the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research where applicable. Authors are
requested to make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these studies.
For authors of systematic reviews, a supplementary file, linked from the Methods section, should reproduce all details concerning the search strategy. For an
example of how a search strategy should be presented, see the Cochrane Reviewers' Handbook.
Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines
for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to
any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications
companies.
The involvement of medical writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source
of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications.
If medical writers are not listed among the authors, it is important that their role be acknowledged explicitly. We suggest wording such as 'We thank Jane Doe
who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.'.
Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the
editorial office.
Submission of a manuscript to BMC Pediatrics implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be
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freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be
deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence
information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the
article.
Nucleotide sequences 
Nucleotide sequences can be deposited with the DNA Data Bank of Japan (DDBJ), European Molecular Biology Laboratory (EMBL/EBI) Nucleotide Sequence
Database, or GenBank (National Center for Biotechnology Information).
Protein sequences 
Protein sequences can be deposited with SwissProt or the Protein Information Resource (PIR).
Structures 
Protein structures can be deposited with one of the members of the Worldwide Protein Data Bank. Nucleic Acids structures can be deposited with the Nucleic
Acid Database at Rutgers. Crystal structures of organic compounds can be deposited with the Cambridge Crystallographic Data Centre.
Chemical structures and assays 
Structures of chemical substances can be deposited with PubChem Substance. Bioactivity screens of chemical substances can be deposited with PubChem
BioAssay.
Microarray data 
Where appropriate, authors should adhere to the standards proposed by the Microarray Gene Expression Data Society and must deposit microarray data in one
of the public repositories, such as ArrayExpress, Gene Expression Omnibus (GEO) or the Center for Information Biology Gene Expression Database (CIBEX).
Computional modeling 
We encourage authors to prepare models of biochemical reaction networks using the Systems Biology Markup Language and to deposit the model with the
BioModels database, as well as submitting it as an additional file with the manuscript.
Plasmids 
We encourage authors to deposit copies of their plasmids as DNA or bacterial stocks with Addgene, a non-profit repository, or PlasmID, the Plasmid Information
Database at Harvard.
BioMed Central is a member of the Committee on Publication Ethics (COPE). Authors who have appealed against a rejection but remain concerned about the
editorial process can refer their case to COPE. For more information, visit www.publicationethics.org.
BioMed Central endorses the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions.
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Preparing main manuscript text
File formats 
The following word processor file formats are acceptable for the main manuscript document:
Microsoft Word (version 2 and above)
Rich text format (RTF)
Portable document format (PDF)
TeX/LaTeX (use BioMed Central's TeX template)
DeVice Independent format (DVI)
Publicon Document (NB)
Users of other word processing packages should save or convert their files to RTF before uploading. Many free tools are available which ease this process.
TeX/LaTeX users: We recommend using BioMed Central's TeX template and BibTeX stylefile. If you use this standard format, you can submit your manuscript in
TeX format (after you submit your TEX file, you will be prompted to submit your BBL file). If you have used another template for your manuscript, or if you do
not wish to use BibTeX, then please submit your manuscript as a DVI file. We do not recommend converting to RTF.
Note that figures must be submitted as separate image files, not as part of the submitted DOC/ PDF/TEX/DVI file.
Article types 
When submitting your manuscript, you will be asked to assign one of the following types to your article:
Research article
Case report
Database
Debate
Software
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Study protocol
Technical advance
Please read the descriptions of each of the article types, choose which is appropriate for your article and structure it accordingly. If in doubt, your manuscript
should be classified as a Research article, the structure for which is described below.
Manuscript sections for Research articles 
Manuscripts for Research articles submitted to BMC Pediatrics should be divided into the following sections:
Title page
Abstract
Background
Methods
Results
Discussion
Conclusions
List of abbreviations used (if any)
Competing interests
Authors' contributions
Authors' information (if any)
Acknowledgements
References
Figure legends (if any)
Tables and captions (if any)
Description of additional data files (if any)
You can download a template (compatible with Mac and Windows Word 97/98/2000/2003/2007) for your article. For instructions on use, see below.
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets
and include the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-
Prot:Q96KQ7, PIR:S66116].
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ ), GenBank at the NCBI
(GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).
Title page 
This should list the title of the article. The title should include the study design, for example:
A versus B in the treatment of C: a randomized controlled trial
X is a risk factor for Y: a case control study
The full names, institutional addresses, and e-mail addresses for all authors must be included on the title page. The corresponding author should also be
indicated.
Abstract 
The abstract of the manuscript should not exceed 350 words and must be structured into separate sections: Background, the context and purpose of the
study; Methods, how the study was performed and statistical tests used; Results, the main findings; Conclusions, brief summary and potential implications.
Please minimize the use of abbreviations and do not cite references in the abstract; Trial registration, if your research article reports the results of a
controlled health care intervention, please list your trial registry, along with the unique identifying number, e.g. Trial registration: Current Controlled Trials
ISRCTN73824458. Please note that there should be no space between the letters and numbers of your trial registration number.
Background 
The background section should be written from the standpoint of researchers without specialist knowledge in that area and must clearly state - and, if helpful,
illustrate - the background to the research and its aims. Reports of clinical research should, where appropriate, include a summary of a search of the literature
to indicate why this study was necessary and what it aimed to contribute to the field. The section should end with a very brief statement of what is being
reported in the article.
Methods 
This should include the design of the study, the setting, the type of participants or materials involved, a clear description of all interventions and comparisons,
and the type of analysis used, including a power calculation if appropriate.
Results and Discussion 
The Results and Discussion may be combined into a single section or presented separately. Results of statistical analysis should include, where appropriate,
relative and absolute risks or risk reductions, and confidence intervals. The results and discussion sections may also be broken into subsections with short,
informative headings.
Conclusions 
This should state clearly the main conclusions of the research and give a clear explanation of their importance and relevance. Summary illustrations may be
included.
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List of abbreviations 
If abbreviations are used in the text, either they should be defined in the text where first used, or a list of abbreviations can be provided, which should precede
the competing interests and authors' contributions.
Competing interests 
A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with
other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them
embarrassment were they to become public after the publication of the manuscript.
Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles.
Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.
When completing your declaration, please consider the following questions:
Financial competing interests
In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from
the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)?
If so, please specify.
Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in
the future? If so, please specify.
Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or
salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
Do you have any other financial competing interests? If so, please specify.
Non-financial competing interests
Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation
to this manuscript? If so, please specify.
If you are unsure as to whether you or one of your co-authors has a competing interest, please discuss it with the editorial office.
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual contributions of authors to the manuscript should be specified in this section.
An "author" is generally considered to be someone who has made substantive intellectual contributions to a published study. To qualify as an author one should
1) have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) have been involved in drafting
the manuscript or revising it critically for important intellectual content; and 3) have given final approval of the version to be published. Each author should
have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of funding, collection of data, or general
supervision of the research group, alone, does not justify authorship.
We suggest the following kind of format (please use initials to refer to each author's contribution): AB carried out the molecular genetic studies, participated in
the sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES participated in the design
of the study and performed the statistical analysis. FG conceived of the study, and participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
All contributors who do not meet the criteria for authorship should be listed in an acknowledgements section. Examples of those who might be acknowledged
include a person who provided purely technical help, writing assistance, or a department chair who provided only general support.
Authors' information 
You may choose to use this section to include any relevant information about the author(s) that may aid the reader’s interpretation of the article, and
understand the standpoint of the author(s). This may include details about the authors' qualifications, current positions they hold at institutions or societies, or
any other relevant background information. Please refer to authors using their initials. Note this section should not be used to describe any competing interests.
Acknowledgements 
Please acknowledge anyone who contributed towards the study by making substantial contributions to conception, design, acquisition of data, or analysis and
interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the
criteria for authorship. Please also include their source(s) of funding. Please also acknowledge anyone who contributed materials essential for the study.
The role of a medical writer must be included in the acknowledgements section, including their source(s) of funding.
Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements.
Please list the source(s) of funding for the study, for each author, and for the manuscript preparation in the acknowledgements section. Authors must describe
the role of the funding body, if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision
to submit the manuscript for publication.
References 
All references must be numbered consecutively, in square brackets, in the order in which they are cited in the text, followed by any in tables or legends.
Reference citations should not appear in titles or headings. Each reference must have an individual reference number. Please avoid excessive referencing. If
automatic numbering systems are used, the reference numbers must be finalized and the bibliography must be fully formatted before submission.
Only articles and abstracts that have been published or are in press, or are available through public e-print/preprint servers, may be cited; unpublished
abstracts, unpublished data and personal communications should not be included in the reference list, but may be included in the text and referred to as
"unpublished data", "unpublished observations", or "personal communications" giving the names of the involved researchers. Notes/footnotes are not allowed.
Obtaining permission to quote personal communications and unpublished data from the cited author(s) is the responsibility of the author. Journal abbreviations
follow Index Medicus/MEDLINE. Citations in the reference list should contain all named authors, regardless of how many there are.
BMC Pediatrics | Instructions for authors
http://www.biomedcentral.com/bmcpediatr/ifora/&print=yes&print=yes[4/20/2010 8:59:37 AM]
Examples of the BMC Pediatrics reference style are shown below. Please take care to follow the reference style precisely; references not in the correct style may
be retyped, necessitating tedious proofreading.
Links 
Web links and URLs should be included in the reference list. They should be provided in full, including both the title of the site and the URL, in the following
format: The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do]
BMC Pediatrics reference style
Style files are available for use with popular bibliographic management software:
BibTeX
EndNote style file
Reference Manager
Article within a journal 
1. Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional motifs. Nat Genet 1996, 13:266-267.
Article within a journal supplement 
2. Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: Analysis and assessment of ab initio three-dimensional prediction, secondary structure, and
contacts prediction. Proteins 1999, 43(Suppl 3):149-170.
In press article 
3. Kharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. Eur Respir J, in press.
Published abstract 
4. Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: Mesenchymal cells, stromal derived factor-1 and rheumatoid arthritis
[abstract]. Arthritis Rheum 1999, 42:s250.
Article within conference proceedings 
5. Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Edited by
Smith Y. Stoneham: Butterworth-Heinemann; 1996:16-27.
Book chapter, or article within a book 
6. Schnepf E: From prey via endosymbiont to plastids: comparative studies in dinoflagellates. In Origins of Plastids. Volume 2. 2nd edition. Edited by
Lewin RA. New York: Chapman and Hall; 1993:53-76.
Whole issue of journal 
7. Ponder B, Johnston S, Chodosh L (Eds): Innovative oncology. In Breast Cancer Res 1998, 10:1-72.
Whole conference proceedings 
8. Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Stoneham: Butterworth-Heinemann; 1996.
Complete book 
9. Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970.
Monograph or book in a series 
10. Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells and Tissues. Edited by Harris TJR. New York: Academic Press; 1995:54-
56. [Stoner G (Series Editor): Methods and Perspectives in Cell Biology, vol 1.]
Book with institutional author 
11. Advisory Committee on Genetic Modification: Annual Report. London; 1999.
PhD thesis 
12. Kohavi R: Wrappers for performance enhancement and oblivious decision graphs. PhD thesis. Stanford University, Computer Science Department;
1995.
Link / URL 
13. The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do]
Microsoft Word template 
Although we can accept manuscripts prepared as Microsoft Word, RTF or PDF files, we have designed a Microsoft Word template that can be used to generate a
standard style and format for your article. It can be used if you have not yet started to write your paper, or if it is already written and needs to be put into BMC
Pediatrics style.
Download the template (Mac and Windows compatible Word 1998/2000) from our site, and save it to your hard drive. Double click the template to open it.
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How to use the BMC Pediatrics template 
The template consists of a standard set of headings that make up a BMC Pediatrics Research article manuscript, along with dummy fragments of body text.
Follow these steps to create your manuscript in the standard format:
Replace the dummy text for Title, Author details, Institutional affiliations, and the other sections of the manuscript with your own text (either by entering
the text directly or by cutting and pasting from your own manuscript document).
If there are sections which you do not need, delete them (but check the rest of the Instructions for Authors to see which sections are compulsory).
If you need an additional copy of a heading (e.g. for additional figure legends) just copy and paste.
For the references, you may either manually enter the references using the reference style given, or use bibliographic software to insert them
automatically. We provide style files for EndNote and Reference Manager.
For extra convenience, you can use the template as one of your standard Word templates. To do this, put a copy of the template file in Word's 'Templates'
folder, normally C:\Program Files\Microsoft Office\Templates on a PC. The next time you create a new document in Word using the File menu, the template will
appear as one of the available choices for a new document.
return to  top
Preparing illustrations and figures
Figures should be provided as separate files. Each figure should comprise only a single file. There is no charge for the use of color.
Please read our figure preparation guidelines for detailed instructions on maximising the quality of your figures,
Formats 
The following file formats can be accepted:
EPS (preferred format for diagrams)
PDF (also especially suitable for diagrams)
PNG (preferred format for photos or images)
Microsoft Word (figures must be a single page)
PowerPoint (figures must be a single page)
TIFF
JPEG
BMP
CDX (ChemDraw)
TGF (ISIS/Draw)
Figure legends 
The legends should be included in the main manuscript text file immediately following the references, rather than being a part of the figure file. For each figure,
the following information should be provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15
words); detailed legend, up to 300 words.
Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures or tables that have
previously been published elsewhere.
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Preparing tables
Each table should be numbered in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also have a title that summarizes the whole table,
maximum 15 words. Detailed legends may then follow, but should be concise.
Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in portrait format (note that tables on a
landscape page must be reformatted onto a portrait page or submitted as additional files). These will be typeset and displayed in the final published form of the
article. Such tables should be formatted using the 'Table object' in a word processing program to ensure that columns of data are kept aligned when the file is
sent electronically for review; this will not always be the case if columns are generated by simply using tabs to separate text. Commas should not be used to
indicate numerical values. Color and shading should not be used.
Larger datasets can be uploaded separately as additional files. Additional files will not be displayed in the final, published form of the article, but a link will be
provided to the files as supplied by the author.
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls) or comma separated values (.csv). As with all files, please use the
standard file extensions.
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Preparing additional files
Although BMC Pediatrics does not restrict the length and quantity of data in a paper, there may still be occasions where an author wishes to provide data sets,
tables, movie files, or other information as additional information. These files can be uploaded using the 'Additional Material files' button in the manuscript
submission process.
The maximum file size for additional files is 20 MB each, and files will be virus-scanned on submission.
Any additional files will be linked into the final published article in the form supplied by the author, but will not be displayed within the paper. They will be made
available in exactly the same form as originally provided.
If additional material is provided, please list the following information in a separate section of the manuscript text, immediately following the tables (if any):
File name
File format (including name and a URL of an appropriate viewer if format is unusual)
Title of data
Description of data
Additional datafiles should be referenced explicitly by file name within the body of the article, e.g. 'See additional file 1: Movie1 for the original data used to
perform this analysis'.
Formats and uploading 
Ideally, file formats for additional files should not be platform-specific, and should be viewable using free or widely available tools. The following are examples of
suitable formats.
Additional documentation
PDF (Adobe Acrobat)
Animations
SWF (Shockwave Flash)
Movies
MOV (QuickTime)
MPG (MPEG)
Tabular data
XLS (Excel spreadsheet)
CSV (Comma separated values)
As with figure files, files should be given the standard file extensions. This is especially important for Macintosh users, since the Mac OS does not enforce the use
of standard extensions. Please also make sure that each additional file is a single table, figure or movie (please do not upload linked worksheets or PDF files
larger than one sheet).
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that they will be browsable from within the full text HTML version of the article.
In order to do this, please follow these instructions:
1. Create a folder containing a starting file called index.html (or index.htm) in the root
2. Put all files necessary for viewing the mini-website within the folder, or sub-folders
3. Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or
"C:\Documents and Settings\username\My Documents\mini-website\images\picture.jpg") and no link is longer than 255 characters
4. Access the index.html file and browse around the mini-website, to ensure that the most commonly used browsers (Internet Explorer and Firefox) are able
to view all parts of the mini-website without problems, it is ideal to check this on a different machine
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is in the root of the ZIP, and that the file has .zip extension,
then submit as an additional file with your article
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Style and language
General 
Currently, BMC Pediatrics can only accept manuscripts written in English. Spelling should be US English or British English, but not a mixture.
Gene names should be in italic, but protein products should be in plain type.
There is no explicit limit on the length of articles submitted, but authors are encouraged to be concise. There is no restriction on the number of figures, tables or
additional files that can be included with each article online. Figures and tables should be sequentially referenced. Authors should include all relevant supporting
data with each article.
BMC Pediatrics will not edit submitted manuscripts for style or language; reviewers may advise rejection of a manuscript if it is compromised by grammatical
errors. Authors are advised to write clearly and simply, and to have their article checked by colleagues before submission. In-house copyediting will be minimal.
Non-native speakers of English may choose to make use of a copyediting service.
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, please visit our page on "Writing titles and abstracts for scientific articles" 
Tim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript. MedBioWorld also provides a list of resources for science writing.
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Abbreviations should be used as sparingly as possible. They can be defined when first used or a list of abbreviations can be provided preceding the
acknowledgements and references.
Typography 
Please use double line spacing.
Type the text unjustified, without hyphenating words at line breaks.
Use hard returns only to end headings and paragraphs, not to rearrange lines.
Capitalize only the first word, and proper nouns, in the title.
All pages should be numbered.
Use the BMC Pediatrics reference format.
Footnotes to text should not be used.
Greek and other special characters may be included. If you are unable to reproduce a particular special character, please type out the name of the symbol
in full. 
Please ensure that all special characters used are embedded in the text, otherwise they will be lost during conversion to PDF.
Units 
SI Units should be used throughout (liter and molar are permitted, however).
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ANNEXURE D: CHOICE OF MEDICATION RETURN (MR) ADHERENCE MEASURE 
The protocol stated that MR adherence data would be examined to determine the best composite 
measure of adherence for all three drugs over the year.  The guiding principles for selecting the 
best composite MR adherence measure were (i) ability to predict viral suppression and (ii) 
clinical relevance, simplicity and explicability.  The following approaches to calculating such a 
composite measure were explored: 
(i) Mean monthly adherence:  For each month for which medications were returned, the sum of 
the percentage adherence for all drugs was divided by the number of ART drugs prescribed (3) to 
determine mean adherence for that month.  Association of mean monthly adherence and viral 
suupression was examined using an adjusted robust longitudinal logistic regression model 
clustered on patient.  
(ii) Minimum monthly adherence for any drug:  The association between the lowest percentage 
adherence for any drug during each month for which medications were returned and viral 
suppression was examined using an adjusted robust longitudinal logistic regression model 
clustered on patient.  
(iii) Mean annual adherence: The sum of all mean monthly adherence measures (as calculated in 
(i) above) was divided by the total number of months for which medications were returned to 
obtain a mean annual adherence.  Association with viral suppression was examined using logistic 
regression. 
 
 152 
 
Results of univariate associations of each of the potential adherence measures with viral 
suppression are shown below.  For each measure of adherence , cut-offs of ≥90% or ≥95% for 
“good adherence” were examined, however results using the threshold of ≥95% are shown for 
mean annual adherence only by way of example, as this threshold performed worse in terms of 
predicting viral suppression for all potential measures of adherence. 
 
Table 7: Univariate associations between different composite measures of MR adherence 
and viral load <400 copies/ml after 1 year on ART 
Adherence measure Unadjusted OR 95%CI 
Mean annual MR adherence ≥ 90% 10.30 1.92 – 55.67 
Mean annual MR adherence ≥ 95% 2.56 0.97 – 6.72 
Mean monthly MR adherence ≥ 90% (clustered on patient) 2.24 1.33 – 3.76 
Minimum monthly adherence ≥ 90% (clustered on patient) 1.54 0.84 – 2.84 
 
Mean annual MR adherence ≥90% was selected as the best composite measure of adherence.  
Not only did this measure demonstrate the greatest magnitude of effect in terms of viral 
suppression, it is also the simplest and easiest to explain and understand clinically. 
